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General Introduction
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8 Chapter 1
RHEUMATOID ARTHRITIS
Although records of diseases with features mimicking those of rheumatoid arthritis have been 
around as early as the prehistoric ages, the term rheumatoid arthritis has been introduced around 
the middle of the 19th century. Initially starting as an ill-defi ned and rather underrated clinical 
image, it took until the 20th century during which it established its status as a full-grown disease.1 
Especially in the last few decades, the scientifi c progresses went rapidly and many new insights 
have been gained in aspects of its etiology and pathophysiology.2 
Nowadays rheumatoid arthritis (RA) is a disease that is recognized as a major infl ammatory 
arthritis of the joints that, can be found in approximately 1% of the population worldwide. Th e 
infl ammation is characterized by a symmetric and poly-articular distribution that primarily 
aff ects the synovium of the small joints of hands and feet and can lead to subsequent local-
ized joint destruction. It is considered to have an autoimmune origin because of the presence of 
self-reactive antibodies, such as anti-citrullinated protein antibodies (ACPA), thereby refl ecting 
the complexity of the disease (Figure 1).3,4 If left  unattended or not properly treated, RA can 
lead to increased disability or even invalidity of patients in their normal daily functions, thereby 
reducing the quality of life. For society, this can ultimately lead to enormous costs in healthcare 
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Inflammation Autoantibodies Arthritis    
Figure 1. Overview of the complex nature of RA. FcγR: Fc-γ receptor; MΦ: macrophage; TACT: activated T-cell; 
TREG: regulatory T-cell; HLA: human leukocyte antigen; TH: helper T-cell; ACPA: anti-citrullinated protein 
antibodies; UA: undiff erentiated arthritis; RA: rheumatoid arthritis; ACR: American College of Rheumatology. 
Adapted from Scott et al4
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CLASSIFICATION AND DEVELOPMENT OF RA
In order to achieve early recognition of patients at risk, the 1987 American College of Rheu-
matism (ACR) classifi cation criteria for RA10 and more recently the revised 2010 classifi cation 
criteria for RA, a joint initiative of the ACR and th e EUropean League Against Rheumatism 
(EULAR),11 have been developed (Figure 2). Th ese sets of classifi cation criteria, although not 
devised as diagnostic criteria, have been and will be frequently used to identify RA patients, both 
with established RA (1987 ACR) and with the intention of indentifying patients in a very early 
stage of RA (2010 ACR/EULAR). 
RA can develop from undiff erentiated arthritis (UA), which is defi ned as having a form of 
arthritis not fulfi lling the criteria for RA or for any other rheumatologic disease. From the Leiden 
Early Arthritis Clinic (EAC), a prospective inception cohort, it is known that about 40% of the 
patients, initially diagnosed with UA, will eventually progress to RA (Figure 3).12,13
RA is characterized by an insidious onset combined with slow or rapid progression and fre-
quently a severe outcome (Figure 3).14 Cumulative evidence, indicating that a delay in treatment 
leads to worse outcome,15 together with the increased availability and performance of newer and 
more aggressive treatments,16-19 make it exceptionally valuable to aim for early intervention of 
patients diagnosed with RA. Application of these modern treatments however should be done 
with caution to prevent overtreatment of less severe patients and associated detrimental short 
and long-term side eff ects.20-23 
PREDICTION OF DISEASE OUTCOME IN RA
Th e ultimate goal in the treatment of RA patients would be the ability to predict the individual 
patients’ chance of developing RA and the disease course of RA and subsequently apply a per-
1. Morning stiffness (at least 1h)
2. Arthritis of three or more joint areas
3. Arthritis of hand joints (≥1 swollen joints)
4. Symmetrical arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes (erosions)
1.  Joint involvement (0–5)
•   One medium-to-large joint (0)
•   Two to ten medium-to-large joints (1)
•   One to three small joints (large joints not counted) (2)
•   Four to ten small joints (large joints not counted) (3)
•   More than ten joints (at least one small joint) (5)
2.  Serology (0–3)
•   Negative RF and negative ACPA (0)
•   Low positive RF or low positive ACPA (2)
•   High positive RF or high positive ACPA (3)
3.  Acute-phase reactants (0–1)
•   Normal CRP and normal ESR (0)
•   Abnormal CRP or abnormal ESR (1)
4.  Duration of symptoms (0–1)
•   Less than 6 weeks (0)




Points are shown in parentheses. Cutpoint for rheumatoid arthritis
6 points or more. Patients can also be classified as having rheumatoid
arthritis if they have: (a) typical erosions; (b) long-standing disease




Four of these seven criteria must be present. Criteria 1–4 must have been
present for at least 6 weeks
Figure 2. Overview of the 1987 ACR and the 2010 ACR/EULAR criteria. Adapted from Scott et al4
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sonalized treatment.24 However, the amount of people aff ected and the course of severity of the 
disease as described by epidemiological data, show that both on a population level as well as on 
the level of the individual patient the disease varies in outcome and presentation. Evidence sug-
gests that environmental, genetic as well as serologic factors infl uence not only the development 
of RA but also its severity, either resulting in persistent disease or, preferably, remission (Figure 
3). However, the precise contribution of these factors for the diff erent disease outcomes has yet to 
be unraveled.25 Together with already known factors, newer risk factors yet to be discovered may 
lead to the identifi cation of new pathways, and may ultimately contribute to the development of 
patient tailored treatment therapies.26-28 
Th e role of genetics 
Numerous eff orts to better understand and further defi ne the role of genetics in the develop-
ment and disease course of RA have resulted in enormous progression during the last decade.29,30 
Analyzing variations in genetic constitution between patients and healthy controls has led the 
way to the discovery of specifi c genetic variants that show an association with a higher risk on de-
veloping RA. To determine these new genetic variants, referred to as so-called single nucleotide 
polymorphisms (SNPs), two diff erent methods have been used for genotyping. Th e fi rst method 
is the candidate gene approach, implicating that based on a priori knowledge of disturbances 
in function or homology to other diseases, the corresponding genetic regions are selectively 
targeted for analysis. Th e second method is the genome wide association study (GWAS) that is 
an unbiased approach that scans the whole genome. Until now this has resulted in the identifi ca-
tion of over thirty genetic regions that associated with development of RA.31-40 In contrast to the 
susceptibility to RA however, the infl uence of genetics on the severity of the disease course in RA 
remains (fairly) unknown, since only relatively few studies have thus far shown an association 
between a genetic variant and the disease course.41-44 Moreover, these studies are all single data 
and were not replicated to confi rm their fi ndings, thereby leaving questions about the role of 
genetics on the severity of RA largely unanswered.
Th e role of serology
Serology comprises a second group of factors that are in the center of attention, both for further 












Figure 3. Model of the factors involved in the development and outcome of RA. UA: undiff erentiated arthritis; 
RA: rheumatoid arthritis; G: genes; E: environment
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representing several pathways that are involved the pathophysiological processes underlying RA 
and its phenotypical appearance, can be measured in the serum of RA patients.45
One of the key elements of RA is infl ammation. In the clinic, infl ammation of the joints is 
objectifi ed by quantifying the joint swelling of patients using a swollen joint count (SJC). Th e 
SJC is correlated with the serum levels of systemic infl ammatory markers such as the erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) that refl ect infl ammatory burden in RA.46 
Other serum markers may represent more localized infl ammatory processes with pro-infl amma-
tory and regulatory functions in the rheumatic joint. As schematically presented in Figure 4, 
markers like interleukins (ILs), tumor necrosis factor (TNF) and interferon gamma (IFN-γ), 
so-called cytokines, refl ect the interplay between the cells of the immune system involved in the 
localized infl ammation of the joint space, and the cellular composition of the cells that produce 
them, e.g. B- and T-lymphocytes cells, macrophages and fi broblast like synoviocytes.47-50 Th ese 
factors and their corresponding cellular components are known not only to initiate disease pro-
cesses, but also to maintain the infl ammatory reaction. Subsequently, this may cause disturbances 
in the homeostasis of cartilage and bone that can ultimately result in joint damage.50 
A special element of serology is formed by the presence of autoantibodies. Although the exact 
mechanisms are still unclear, the scientifi c view on the pathophysiological basis for RA has 
changed enormously since the concept of “immune hyper-reactivity” emerged in the mid-20th 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Figure 4. Schematic overview of the infl ammatory processes in the rheumatic joint. T: T-lymphocyte; B: 
B-lymphocyte; Syn: synoviocyte; FDC: follicular dendritic cell; GC: germinal center; APC: antigen presenting 
cell. Adapted from Marston et al50
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century. Refl ecting its status of a disease with an autoimmune origin, the classical rheumatoid 
factor (RF) and the more recently discovered antibodies directed against anti-citrullinated 
proteins (ACPA)51 can be detected in the serum of patients (Figure 5). Th e presence of both is 
associated with an aggressive and destructive disease course.3,52 
Taken together, serological factors are thus involved in the various pathophysiological pro-
cesses that take place in RA and as such would represent possible targets for developing newer 
treatment therapies. In addition, they can be used for predicting the development as well as 
disease outcomes of RA. Th e degree in which these factors are in fact useful as a marker have 
been the subject of discussion, and has led to the development of a set of criteria that has to be 
fulfi lled for a factor to be regarded as a real ‘biomarker’.53 
Th e role of environmental factors
In addition to genetic factors and serology, a third group of factors shown to associate with the 
development and disease course of RA are environmental factors. Several environmental factors 
have suggested potential candidates to infl uence RA.54 Th us far, smoking is regarded as the most 
important environmental risk factor in the ACPA-positive subset of RA patients.55-57 However, 
for other environmental risk factors, like alcohol, socioeconomic status and region of birth, the 
eff ect on RA is less well defi ned. In addition, also infectious agents could have a possible role in 
the activation of immune responses as observed in RA.58
Explanatory properties of predictive factors 
Th us, although in the last decade clearly huge progress has been made with the identifi cation 
of numerous genetic, serological and environmental factors that show an association with the 
development and severity of RA, together they do not completely explain the development and 






























Figure 5. Th e process of citrullination. Citrullination is an enzymatic conversion that results in the loss of one 
positive charge for every arginine residue converted to a neutral citrulline, by deimination of peptidylarginine 
to peptidylcitrulline by the enzyme peptidyl arginine deiminase (PAD). Th e change in charge causes changes 
in intra- and intermolecular interactions, which could lead to altered protein folding, enhanced degradation by 
proteases, and exposure of cryptic epitopes. Adapted from Klareskog et al51 
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For the severity of RA, the exact contribution of genetics is not defi ned yet. In summary, the 
complexity of RA is illustrated by the observed interplay between several factors and the limited 
explained variance of the risk factors that are known thus far. 
OUTCOME MEASURES
In order to identify new risk factors, diff erent outcome measures can be used for evaluating the 
predictive performance for the development and disease course of RA. 
For predicting outcome in UA, fulfi llment of the criteria for RA can be determined. Other 
outcome measures that are frequently used are the initiation of therapy and the development of 
persistent disease.11
For investigating the severity of the disease course of RA, also various outcome measures 
thus have far been used. Th ese concern “clinical factors” that are used to assess the reaction to 
treatment like disease activity score (DAS), health assessment questionnaire (HAQ) and joint 
swelling,60 or laboratory measures like CRP and ESR. An objective measure for evaluating the 
course of RA is the development and progression of radiographic joint damage in the hands 
and feet. Th is can be measured by validated methods and is associated with infl ammation and 
disability.61,62 Other outcome measures that are used (less frequently) are also the achievement of 
remission and, although somewhat controversial, repair of erosions.
Radiographic joint damage
For assessing the amount of joint destruction that is visible on radiographs several methods exist. 
Compared to the Larsen and the Ratingen scoring methods, the Sharp/van der Heijde method is 
considered as the most sensitive method for measuring joint destruction.63 In an observational 
cohort study scoring is done chronologically, thus with known time order.64 Th e Sharp/van der 
Heijde score consists of a measure for cartilage degradation, the joint space narrowing (JSN), and 
a component refl ecting the amount of bone degradation, the erosion score (ES). Taken together, 
they are referred to as the total Sharp/van der Heijde score (SHS), which will be used as the main 
outcome measure in this thesis.65 
Evaluation of radiographic data is in literature frequently performed in a cross-sectional way, 
on single time points. Van der Helm-van Mil et al point out that ideally, joint damage is measured 
repeatedly over time as this may lead to a more precise estimation of an individual’s progression 
rate.62
Achievement of (clinical) remission
A second outcome measure to evaluate the eff ect of risk factors on the outcome of RA is the 
achievement of remission. Remission as a clinical endpoint in studies has been used since many 
years.66,67 Th e achievement of remission is self-evidently the most favorable and desired disease 
outcome,68 but only ~10-15% of patients were observed to reach this goal.69 Although diff erent 
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defi nitions have been used over the years, to achieve disease-modifying antirheumatic drugs 
(DMARD)-free remission as it is has been used in this thesis, a patient has to fulfi ll three criteria: 
1) no current use of DMARDs, 2) no swollen joints, and 3) classifi cation as DMARD-free remis-
sion by the patient’s rheumatologist.69
Repair of joint erosions
A somewhat controversial and less well documented outcome measure is the occurrence of 
repair of bone erosions. Th ese sites of repair are characterized by the formation of new bone 
leading to a reduction in the magnitude of the previously developed sites of erosion (Figure 6).70 
Th e characteristics of repair as well as the factors responsible for this shift  in balance from bone 
degradation to bone formation however are not clear yet. Identifying these factors could help 
both in elucidating the causal pathophysiological mechanisms of RA and developing treatment 
targets for inducing the mechanisms of repair of erosions. 
OUTLINE OF THIS THESIS
Risk prediction in RA i s in the center of attention, with the development of personalized medi-
cine as the fi nal endpoint. Especially during the last decade, enormous advances in this fi eld have 
been achieved, but mainly in identifying risk factors for the risk prediction of RA susceptibility. 
Risk factors for the outcome of RA, however, have thus far been scarcely explored.
Th e aim of this thesis was to study the risk prediction in RA, with the main focus on the 
disease outcome of RA and to lesser extent the development of RA from UA. For this purpose, 
longitudinal radiograph data from RA patients that were enrolled in the Leiden Early Arthritis 
Cohort between 1993 and 2006,12 an inception cohort that has been up and running for a period 
2007 
2010 
Figure 6. Example of repair of joint erosions. Th e arrows indicate sites of erosions in the year 2007 in the upper 
panel. Subsequently, in 2010 shown in the lower panel, these sites have been the subject of new bone formation, 
so-called repair
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of 17 years, were collected and scored using the Sharp/van der Heijde method. Together with 
other outcome measures, these data were subsequently used for risk estimation. 
In the fi rst part, in chapter 2 of this thesis, a detailed explanation how to analyze longitudinal 
radiological data is provided. It describes and compares diff erent statistical methods of analysis 
and their advantages and disadvantages given the presence of repeated measurements. Detailed 
information is given about the development of the model referred to as the repeated measurement 
analysis (RMA). Th is model is one of the cornerstones in this thesis and forms the statistical basis 
for the risk estimation of the diff erent risk factors for radiographic progression of joint damage. 
In Part II of this thesis, we studied in more detail the relationship between serum markers and 
both the chances for a patient to develop RA and a subsequent worse outcome of RA. Th e mark-
ers we studied in this thesis all refl ect a certain part in the chain of infl ammatory processes that 
take place in the rheumatic joint as described in the introduction. 
In the last decade, next to the older RF test, a new test against a collection of citrullinated 
proteins was developed, e.g. anti-CCP1, and improved to a second generation test that is widely 
used nowadays, anti-CCP2. Th e last few years also the third generation anti-CCP(3) test was de-
veloped as well as a test specifi cally directed against modifi ed citrullinated vimentin (anti-MCV), 
for which performances similar to anti-CCP2 were reported.71,72 Th us far, the performance for 
these autoantibodies was not subjected to a head-to-head comparison and the additive eff ect for 
each of these autoantibodies has not been subjected to a thorough investigation. In chapter 3, we 
compared all four autoantibodies, RF, anti-CCP2, anti-CCP3 and anti-MCV, for their usefulness 
in predicting RA development and looked at the predictive abilities for the rate of joint dam-
age and the achievement of DMARD-free remission. Also the cumulative eff ect of performing 
multiple autoantibody tests was studied.
With the development of the revised 2010 criteria not only the aspect of presence or absence of 
ACPA was given weight in the prediction of RA development, but also higher autoantibody levels 
of RF and/or ACPA were valued more predictive in the classifi cation of RA during the process 
of its development.11,73 Although it has been shown that higher levels of RF and ACPA autoan-
tibodies show a higher specifi city than lower levels respectively, so does ACPA-positivity.74-76 
Th e question therefore arises, what is the value of incorporating RF-levels in the new criteria 
compared to ACPA-positivity, especially since in the new criteria RF and ACPA are regarded as 
equally predictive.11 In an eff ort to improve the new criteria, in chapter 4 we studied the value of 
higher levels of RF, defi ned as a cut-off  level of 50 U/ml as used in literature,74,75 and three times 
the cut-off  for antibody positivity (3xULN) according to the defi nition in the new criteria,11 and 
compared the results for multiple outcome measures with those obtained for ACPA-positivity.
Important factors in the infl ammatory processes that take place in RA, as indicated in the in-
troduction, are cytokines. In chapter 5 the association of serum levels of one of these cytokines, 
CXCL13, and erosiveness was studied. CXCL13, also known as B lymphocyte chemo-attractant 
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(BLC) or B cell-attracting chemokine 1 (BCA-1), selectively attracts B lymphocytes,77 and may 
play an important role in the process of bone remodeling through the interaction with its re-
ceptor CXCR5 that is also found on human osteoblasts.78-81 Th e initial association between this 
serum marker and the amount of bone loss was predicted using an artifi cial computer model that 
mimics the processes in the joint of an RA-patient. 
Th e last few years, genetic polymorphisms have been a focus of attention for establishing risk 
profi les in RA. New genetic regions have been identifi ed to play a role in -primarily- the develop-
ment of RA. Especially the use of whole genome scans has resulted in these multiple new targets. 
In part III, we report our fi ndings for a selection of these factors. 
Recently, several new polymorphisms were identifi ed in a genetic region that is close to tumor 
necrosis factor α-induced protein 3 (TNFAIP3), involved in regulating TNF-receptor-mediated 
signaling eff ects.82 In the ACPA-positive subgroup of patients, these polymorphisms have been 
observed to associate with a higher susceptibility for RA.36 Hypothetically, these polymorphisms 
could associate with the severity of RA as well, but thus far this question has not been answered. 
In chapter 6, we studied if these polymorphisms, initially identifi ed as risk factors for RA suscep-
tibility, show an association with radiographic progression of joint damage in RA patients as well.
Similarly, in chapter 7, 6 SNPs that were recently identifi ed in a genome wide association study 
to associate with the development of RA, were studied for an association with the outcome of RA. 
Th ese polymorphisms are located in several genes, e.g. CD40, KIF5A-PIP4KC, CDK6, CCL21, 
PRKCQ and MMEL1-TNFRSF14, that have functions that are not only restricted to the immune 
systems response, but also are involved in regulation of the cell cycle progression.37 
Th e third polymorphism studied for a possible association with the rate of joint destruction 
is located in the region of the protein tyrosine phosphatase non-receptor 22 (PTPN22). Th is 
region encodes a negative regulator of T-cell activation, and has been observed to be a risk factor 
for RA susceptibility in the ACPA-positive subgroup of patients.83 Although this polymorphism 
was studied for an association with the outcome of RA several times, no consistent results were 
observed, possibly due to diff erences in methods of measurement and analysis. In chapter 8, we 
tried to clarify the role of PTPN22 in the disease outcome of RA, using sensitive methods for 
scoring and analysis in two large cohorts of RA patients, both in the total group of patients and 
in the ACPA-positive subgroup. 
Th e classic image of RA has been marked as a slow developing disease, and as such would provide 
opportunities by identifying RA patients as soon as possible for initiating treatment promptly. 
Years of experience in the treatment of RA patients have led to the hypothetical existence of 
a “golden” three month period for treating patients, the so-called window of opportunity.84 
Although it is a common rationale that increased symptom duration, e.g. a delay in visiting a 
rheumatologist and subsequent treatment, leads to a worse outcome of RA, the exact properties 
in terms of outcome measures and patient characteristics have not been studied in great detail 
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thus far. In chapter 9 of part IV, we study the eff ect of symptom duration on the rate of joint 
destruction and the achievement of DMARD-free remission. In addition, since both patients 
and general practitioners can contribute to the total duration of the delay, we quantifi ed these 
delays and studied various characteristics, among which ACPA, if associating with these delays. 
In addition to the presence of ACPA also the number of ACPA isotypes has been observed to 
associate with radiographic joint damage.85 Th erefore, the eff ect of the autoantibody response 
was studied for an association with the delay in ACPA-positive RA patients as well (chapter 10). 
In part V of this thesis, we will address diff erent clinical subphenotypes of RA. To identify factors 
that can be useful in the prediction of a disease, analysis of subphenotypes and extreme pheno-
types can be valuable in addition to “more standard” cohort analyses. Although the number of 
patients representing the groups of the sub- and extreme phenotypes in general results in a lower 
number of patients available for analysis, it has been shown that these types of studies in fact can 
be informative.86,87
Reciprocal to the accumulation of joint erosions, is the occurrence of repair of joint erosions. 
Although joint damage was previously thought to be permanent, in the last few years the general 
state of mind shift ed towards acknowledging that repair does exist.88 Clinically, next to early 
treatment of patients to prevent the occurrence of bone damage, achieving repair of damage once 
it has developed would be an additional attainable goal. To reach this goal, understanding the 
pathophysiological mechanisms underlying the processes of repair are of great interest. Although 
the processes involved in bone homeostasis are complicated, in chapter 11 we studied the occur-
rence of repair in a fi rst step of characterizing this phenomenon.
In RA, the typical course of the disease is characterized by the occurrence of infl ammation 
and subsequent development of joint erosions. Although the classic dogma is that infl ammation 
causes damage directly, progressing insights indicate that the relation between infl ammation and 
joint damage might not be that straight forward and might have diff erent causal pathways.89 In 
chapter 12, we studied the relation between infl ammation, measured by the cumulative amount 
of joint swelling over a period of 5 years, and the degree of erosiveness that accumulated over this 
same period. In concordance with the extreme phenotype approach, patients from the extreme 
groups of joint swelling and erosiveness were studied and their characteristics compared to 
achieve more insight in the association between clinical infl ammation and subsequent damage 
to the bones of RA patients.  
 
In chapter 13 (part VI) of this thesis, the 1987 ACR and the 2010 ACR/EULAR criteria for 
RA were subjected to a head-to-head comparison. Th e older 1987 criteria have already been 
established and incorporated in clinical practice by rheumatologists. Th e recently revised 2010 
ACR/EULAR criteria however, have thus far not been subjected to a thorough evaluation of its 
applicability in clinical rheumatologic practice. We studied the performance of the new 2010 
criteria for predicting development of RA, as well as the use of MTX or any DMARDs during the 
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fi rst year and disease persistency over 5 years and compared it to the performance of the 1987 
criteria. 
Subsequently, in chapter 14, a 2010 update of the achievements in prediction making using the 
Leiden EAC is given. In particular the discoveries from the last decade and their implications in 
explaining the variance, not only for development of RA from UA but also for the outcome of RA 
in terms of the long term progression in radiological damage have been studied, the latter thus 
far not reported in literature yet.
Finally, in chapter 15, all results of this thesis will be summarized and the implications for pre-
dicting the development and outcome of RA will be discussed.
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Th e fi eld of genetics is reaching phenotypic disease aspects. Within rheumatoid arthritis (RA), 
progression of joint destruction is an important phenotypic feature. Genetic factors oft en have 
small eff ect sizes, making avoidance of phenotypic misclassifi cation and discerning true eff ects 
from noise challenging. Assembling radiological measurements repeatedly in time harbors a 
smaller risk of misclassifi cation than single measurements. Given serial measurements, diff er-
ent methods of analysis can be applied. Th is study evaluates diff erent statistical methodology to 
analyze longitudinal data and its eff ect on the power of such a study.
Methods
Kruskal-Wallis, Linear Regression and Repeated Measurements Analysis (RMA) were studied, 
both cross-sectionally (testing for diff erences in joint destruction at individual time points) 
and longitudinally (testing for diff erences in progression rates). Of these tests, only RMA takes 
advantage of within-patient correlations in serial radiological measurements. Data of 602 early 
RA patients included in an inception cohort with yearly radiographs and 7-years follow-up were 
assessed. Genetic data of HLA-DRB1 Shared-Epitope alleles and rs675520 (TNFAIP3-OLIG3) 
were used as example.
Results 
From all methods studied, cross-sectional and longitudinal RMA were most powerful. For 
example analyses using longitudinal RMA in the current data set yielded powers >95%, even 
in presence of missing radiographs. In particular in the presence of small eff ect sizes RMA was 
more powerful than linear regression. Th e preciseness increased with a higher number of avail-
able measurements per patient. 
Conclusion 
A repeated measurement analysis on subsequent radiographs provides the most powerful meth-
odology to analyze longitudinal data.
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INTRODUCTION
In medicine more than 600 genome wide association studies have been published; oft en revealing 
inconsistent fi ndings.1 Now the fi eld of genetics is moving from qualitative traits (disease yes/no) 
to phenotypic disease aspects and disease outcomes, which are oft en quantitative traits. Correct 
determination of the phenotype is of most importance here. Within rheumatoid arthritis (RA), 
progression of joint destruction is a relevant outcome measure, refl ecting the cumulative burden 
of infl ammation over time. Th e severity of joint destruction is highly variable between patients. 
Th us far, little is known about the pathophysiology of this diff erence. In addition, several clinical 
and serological risk factors for a severe rate of joint destruction have been identifi ed, but the 
variation explained by these factors is low (R2 0.36).2-4 Prediction models based on these variables 
could classify only ~50% of RA patients.2,5,6 In order to increase the understanding of the mecha-
nisms underlying joint destruction, additional risk factors need to be identifi ed. Th us far, few 
identifi ed genetic factors for joint destruction are replicated. Th e absence of replication can have 
several causes. Obviously, it may be due to false-positive results in the initial study. Secondly, the 
replication study could have been underpowered. It is challenging to obtain long-term radio-
logical data of a large number of patients. Finally, diff erences between studies may occur when 
diff erent radiological measures are studied or when diff erent methods of analyses are applied. 
Since the eff ect sizes of genetic markers in complex diseases are oft en moderate to small, both 
sensitive measurements of joint destruction and powerful methods of analysis are necessary to 
prevent false negative fi ndings.
It is discussed elsewhere that the use of a continuous method to measure the degree of joint 
damage is more sensitive and discriminative than usage of categorical measures such as the 
presence of erosions.7 In addition it has been shown that serial measures in time per patient 
give a more accurate and precise estimation of the rate of joint destruction compared to single 
measurements. Th erefore, whenever possible, RA patients are preferably studied prospectively 
and have radiographs made at subsequent time-points.7 In the presence of serial quantitative 
measurements, diff erent statistical methods for analysis are available and applied. Th e level of 
joint destruction can be compared between groups at individual time-points, with and without 
taking radiological data on other time-points into consideration. Alternatively, the progression 
over all time-points can be compared in one test. An additional challenge in analyzing longitu-
dinal radiological data is how to deal with missing radiographs. Th erefore, we aimed to compare 
currently used statistical methodology to analyze continuous data on joint destruction over 
time. Th e main outcome measure evaluated was the power. We therefore evaluated the power of 
analyses performed with diff erent statistical methods on the same patients and genetic data. First 
the power of these methods was evaluated using data of genetic variants known to associate with 
joint destruction. Second, we compared the ability of the diff erent methods to deal with missing 
radiological data, as well as the eff ect of the number of available radiographs on the power of the 
study.




Radiological data were used of 602 RA patients (according to the 1987 ACR-criteria) that were 
included in the Leiden Early Arthritis Clinic cohort (EAC) in 1993-2006.8 Median symptom 
duration at inclusion was 0.36 years. At baseline, the mean age was 56.1±15.8 years, 78% was 
female and 54% was ACPA-positive. Yearly follow-up data over 7-years was used. Radiographs of 
hands and feet were scored chronologically according to the Sharp-van der Heijde method (SHS) 
by an experienced reader.9-11 409 radiographs belonging to 60 randomly selected RA patients 
were rescored. Th e intraclass correlation coeffi  cient was 0.91 for all scored radiographs, and 
0.97 for the radiographic progression rate. Treatment strategies changed in time.8,12 Patients in-
cluded in 1993-1995 were initially treated with analgesics and subsequently with chloroquine or 
salazopyrin. From 1996-1998 chloroquine or salazopyrin was promptly started. From 1999-2006 
patients were readily treated with methotrexate or salazopyrin. Twenty-eight of the 602 patients 
received anti-TNF treatment somewhere during the seven follow-up years. Th e frequency of 
anti-TNF users was equally distributed between periods of inclusion (3.3%, 4.7% and 4.7% 
respectively).
Methods to analyze joint destruction
Th e HLA-DRB1 Shared-Epitope (SE) alleles and rs675520 (TNFAIP3-OLIG3) are associated with 
joint destruction.13-16 To compare diff erent statistical methods, these two genetic variants were 
studied as example (Figure 1). Th ree statistical methods were studied, representing the major 
methods for analyses. Other not-applied methods are more or less similar to the methods applied 
here. 
Figure 1. Sharp-van der Heijde scores during 7-years of follow-up for RA patients with 0, 1 or 2 HLA-SE alleles 
and with absence, presence or double presence of the minor allele of TNFAIP-OLIG3 rs675520. Presented are 
the geometric means of the SHS
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Cross-sectional methods studied, comparing destruction levels at individual time-points, were 
the Kruskal-Wallis test, linear regression analysis (LRcs) and repeated measurement analysis 
(RMAcs). Th e Kruskal-Wallis and LRcs was performed on each time-point with SHS score as 
dependent variable ignoring the data of other time-points. For RMAcs, a multivariate normal 
regression analysis was used with time as categorical variable.17 Th e RMAcs tested diff erences 
between SHS levels at each time-point taking radiological data on previous time-points into 
consideration.
Th e evaluated longitudinal methods, testing for diff erences in progression rates over time, 
were Kruskal-Wallis, longitudinal linear regression analysis (LRlong) and repeated measurements 
analysis (RMAlong). Here the Kruskal-Wallis test compared subtractions of SHS between baselines 
and the 7-years time-points and therefore data of only two measurements could be used. LRlong 
compared regression coeffi  cients which are based on all available measurements, assuming them 
to be independent. RMAlong evaluated the progression rates over time considering the correla-
tion between the measurements at all time-points within one subject. In order to have optimal 
comparisons of the tests, no adjustments were made in the LRs, and RMAs.
Since SHS were positively skewed, radiological scores were log-transformed to approximate 
normal distribution before performing any of the LRs and the RMAs. Analyses were performed 
using SPSS version 16.0 (SPSS Inc., Chicago, IL).18
Repeated measurement analysis
Detailed information on the used RMAs, a multivariate normal regression analysis, is provided 
in Box I, supplementary data. Th is analysis uses all available radiological measurements and 
has great fl exibility to model time eff ects. It takes advantage of within patients’ correlations and 
can handle missing data provided that the reason for missingness can be determined from the 
observed data (an assumption called missingness at random).17,19
Th e within-patient correlation of serial measurements is quantifi ed by a covariance matrix. 
To determine the best-fi tting covariance matrix the matrices available in SPSS were considered, 
using the Akaike information criteria as measure of goodness of fi t. Th e heterogeneous fi rst 
order autoregressive (ARH1) matrix was our fi nal choice. It assumes a stronger correlation for 
measurements taken in a short period than taken over a longer period in time.
Power of diff erent methods
It was hypothesized that the diff erent methods will yield diff erences in power. To study this, 
the power to detect an association between the two genetic variants and joint destruction over 
7-years was determined; both for the cross-sectional and longitudinal methods. For the Kruskal-
Wallis, Quanto version 1.2.420 was used on the present data assuming that the eff ect of HLA-SE 
and rs675520 increased with respectively 1.3 and 1.2 times per year. Th e power of LR and RMA 
were computed by simulating the RMA model. Th e baseline characteristics of the patients, the 
sample size and parameter values were sampled such that they correspond to the original EAC 
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data. In order to also study the impact of missingness to the power, the percentage of missing 
radiographs was varied from 0 to almost 90% for the last visit. For the remaining visits, missing-
ness was created with the same percentage as in the original dataset. More detailed description 
on the power analyses are described in the supplement. Power analyses were performed using R 
statistical soft ware.21
Eff ect of number of radiological measurements
Th e number of measurements available per subject can diff er between diff erent study designs. 
Here we studied the infl uence of the number of measurements per subject on the preciseness 
of the estimation expressed as the 95% confi dence interval (95%CI) of the eff ect size. To this 
end 107 patients with complete yearly follow-up over 7-years were studied. By simulation an 
increasing number of radiographs were left  out between baseline and the 7-years time-point. In 
this way analyses were repeated with a lower number of radiological measurements per patient. 
Analyses were done on HLA-SE and joint destruction analyzed with both LRlong and RMAlong.
Missing radiological data in relation to diff erent methods
Th e presence of missing data in longitudinal cohort studies is inevitable. Exclusion of the patients 
with missing data will generate bias in case missingness is related to the outcome of interest.22 
From the methods evaluated here, RMA is able to deal with missing data provided that the miss-
ingness is ‘at random’ or ‘completely at random’ and that the correlation structure (expressed 
by the covariance matrix) of the patients with missing data is comparable to that of patients 
with complete radiological data. Th erefore the characteristics of missing radiological data in the 
studied cohort were evaluated.
RESULTS
Methods to analyze joint destruction
Th e cross-sectional and longitudinal methods of analysis were compared using radiological data of 
RA patients with diff erent numbers of HLA-SE alleles. Th e various methods all resulted in signifi -
cant outcomes at individual time-points (cross-sectional analyses) as well as on progression over 
time (longitudinal methods). Th e width of the 95%CI diff ered between the methods (see Table I).
Power and preciseness of diff erent methods
Th e power to detect an association of HLA-SE with levels of joint destruction at the individual 
time-points from baseline till 7-years with Kruskal-Wallis in the present dataset were 0.52, 0.37, 
0.40, 0.34, 0.36, 0.41, 0.48, 0.47. For rs675520, the power were 0.53, 0.31, 0.29, 0.22, 0.21, 0.19, 
0.20, 0.18 from baseline till 7-years. Comparing diff erences in SHS between baseline and 7-years 
with Kruskal-Wallis had a power of 0.92 and 0.25 for HLA-SE and rs675520 respectively. Th e 
eff ect of missingness on the power of LR and RMA, both cross-sectional and longitudinal, are 
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illustrated by a simulation for diff erent frequencies of missingness in Figure 2. Th e power to 
detect a diff erence in the cross-sectional analyses of HLA-SE groups was approximately 100% 
if the data at 7-years were complete. With increasing missingness the power of LRcs diminished 
to <80%, whereas the power of RMAcs remained >95%, even in case of a large percentage of 
missingness (Figure 2A). Although the power to detect a diff erence was lower in the analysis 
of rs675520, again it was observed that the power of RMAcs remained higher than of LRcs. Also 
for the longitudinal analyses, RMA had a higher power compared to LR (Figure 2B), for both 
HLA-SE and rs675520.
Eff ect of number of radiological measurements
With an increasing number of available radiographs the 95%CI of the estimation of the progres-
sion rate decreased, indicating a more precise estimation in the presence of more measurements 
per subject (see Figure 3). 
Missing radiological data
Th ree major causes were identifi ed that together accounted for >90% of all missing follow-up 
data: sustained DMARD-free remission (n=64), death (n=74), and not having complete follow-
up data because of recent inclusion. Patients without sustained DMARD-free remission had 
a 2.35 (95%CI 1.83-3.19 p<0.001, RMAlong) times larger increase in SHS per 7-years. Patients 
had a constant 2.09 (95%CI 1.65-2.65 p<0.001, RMAlong) times larger joint damage over 7-years 
compared to those who stayed alive. For both reasons of missing data the missingness related to 
the outcome (missingness at random).
Figure 2. Power to detect diff erences in joint destruction with (A) cross-sectional and (B) longitudinal methods 
(LR and RMA) for diff erent percentages of missing radiographs at the last time-point. Depicted is the power 
(y-axis) to detect an association between two diff erent genetic variants, HLA-SE and TNFAIP-OLIG3 (rs675520) 
and the rate of joint destruction in the present RA patients at the 7-years time-point.24 Th e power was calculated 
(A) cross-sectional with linear regression (LR) and repeated measurement analysis (RMA) at 7-years and (B) 
longitudinally with LR and RMA over 7-years with diff erent percentages of missing radiographs at the 7-year 
time-point (x-axis)
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DISCUSSION
Th e fi eld of genetics is moving from disease susceptibility studies to studies addressing disease 
outcomes. Since genetic risk factors generally have small eff ect sizes, it is crucial to measure 
the outcome sensitively and to apply powerful statistical methodology. Given the presence of 
repeated radiologic measurements in time, diff erent statistical tests can be used. We aimed to 
derive optimal statistical methodology. We considered commonly used methods but did not 
intend to give a complete overview of all possible statistical methods. We observed that, among 
the methods tested, a RMA is most powerful and least susceptible to bias. Th e increased power is 
the result of taking advantage of the high within-patient correlation in repeated measurements. 
We also observed that eff ect estimates were more precise in the presence of a higher number of 
measurements, an eff ect which is not specifi c for RMA. A RMA can compare absolute diff erences 
in SHS levels at a single time-point and rates of progression over time; the choice between these 
two may depend on whether one is interested in identifying associations with the level of joint 
destruction at a specifi c time-point or in identifying associations with the speed of progression 
of radiological joint damage over time.
We considered commonly used methods but did not intend to give a complete overview of all 
possible statistical methods. Advantages and disadvantages of the methods studied are presented 
in Table II. Advantageous of RMA is that all patients, also those who had missing radiographs, 
are included. Th is is done assuming that missing radiological scores can be estimated using avail-
able measurements and complete datasets of patients with similar characteristics, a situation 
called ‘missingness at random’. Identifi ed causes for missing radiographs in the present study 
Figure 3. Width of 95% confi dence interval (95%CI) for diff erent number of measurement over 7-years of 
follow-up for (A) Linear regression analysis and (B) Repeated measurement analysis. Depicted is the 95%CI 
width (y-axis) of the analyses of the association between HLA-SE and joint destruction. Th e analysis was 
performed on 107 patients with complete follow-up yearly over 7-years. First only baseline and 7-years data was 
used, additional time-points were added to test the eff ect of the number of measurement used over the same 
time-period. A) Th e width of the 95%CI analyzing HLA-SE with LRlong demonstrates the advantage of adding 
more measurements to the analyses. B) Th e width of the 95%CI analyzing HLA-SE with RMAlong demonstrates 
the advantage of more measurements plus taking the correlation into account
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were assumed to be missing at random, a requirement for adequate handling of missing data 
by the RMA. Th e RMA takes into account the uncertainty of the estimation for patients with 
missing radiographs. In other words, patients with complete datasets are weighted more heavily 
in the analysis than patients with missing radiographs. Th e RMA is the only studied method that 
did not exclude patient with missing data, which prevents certain bias. 
Another, simple and frequently used method to deal with missing radiographs is a completers 
only analysis. Here all patients with missing observations are excluded. Th is is used when com-
paring diff erences in SHS between 7-years and baseline with Kruskal-Wallis tests and can lead to 
confl icting results at diff erent time-points. An alternative is the last-observation-carried forward 
approach; this uses the last observation for every subsequent missing. Both methods can create 
bias since we observed that patients that are more inclined to have missing radiographs have 
relatively severe or relative mild joint destruction.23
Th e longitudinal LR studied compared the regression coeffi  cients of SHS with time between 
groups. An advantage of LR above Kruskal-Wallis is that it gives an eff ect size and allows ad-
justment of correction variables. A drawback of LR is that it ignores the correlation between 
serial measurements; accounting for this would have resulted in a smaller standard error and 
therefore a more sensitive analysis. An alternative LR analysis over time is a two-step approach;24 
fi rst a regression coeffi  cient of SHS over time for each individual is estimated, which are then 
compared between groups. Although this method takes into account the correlation of the serial 
measurements within one subject, it ignores the standard error of these individual coeffi  cients. 
Th erefore, standard errors obtained with this approach are generally too small, introducing the 
risk of false-positive fi ndings.
Th e RMA used in this manuscript is a multivariate normal regression analysis.17 An alterna-
tive statistical method to analyze repetitive measurements is Generalized Estimating Equations 
(GEE),25 which is occasionally used in clinical trials.26,27 Advantages of GEE are that the data do 
not have to be normally distributed and the correlation structure does not have to fi t the data. A 
disadvantage of GEE is that it assumes that missingness is ‘completely at random’, which is oft en 
not the case.28 An extension of GEE, GEE with inverse probability weights,29,30 can deal with miss-
ing data that is not completely at random, but this extension is not readily available in standard 
soft ware packages. Since for GEE the correlation structure does not have to fi t the data, GEE is 
oft en less precise than a multivariate normal regression. Since in the present cohort missingness 
was not ‘completely at random’, we preferred multivariate normal regression over GEE.
In the present study, no adjustments were made in the LRs and RMAs in order to increase 
the comparability of the tests. However, in studies evaluating associations with risk factors, it 
will be relevant to adjust for factors that interfere with or modify levels of joint damage, such as 
treatment. Adjustments generally result in a more precise estimation since the residual variance 
is decreased.
In conclusion, identifi cation of new risk factors for RA severity is important. Genetic risk 
factors generally have moderate to small eff ect sizes. Th erefore it is important to diff erentiate true 
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eff ects from noise and to have powerful methods of analysis. Th e present study demonstrated 
that a repeated measurement analysis on subsequent radiographs provides a sensitive method to 
analyze associations with joint destruction over time in longitudinal cohort studies.
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SUPPLEMENTARY DATA
Methods of power calculations
To show the power loss in detecting genetic eff ects when the within-patient correlation is ig-
nored, we simulated data from the RMA (I) and (II) for the longitudinal and cross-sectional 
analyses, respectively. In the following section we will discuss the simulation setup in terms of 
the RMA (I).
First the RMA (I) is fi tted to the EAC data in order to obtain estimates for the regression 
coeffi  cients (namely intercept, β_j, γ and δ) and the variance components Σ. Th en baseline char-
acteristics for 602 patients are simulated based on the EAC patients’ information. In particular, 
regarding sex 68% are women and 32% men and their age has been simulated from a normal 
distribution with mean 56 and standard deviation 16. In addition, the patients were assumed 
to have enrolled at diff erent inclusion periods, i.e., 18% in the fi rst, 35% in the second and 13% 
in the third. Regarding the genotypic information, genotypes have been simulated such that 
the minor allele frequency equals 0.41 and 0.37 (similar to the HLA-SE and TNFAIP-OLIG3 in 
the EAC study). Finally, 8 yearly measurements are assumed to have been scheduled for all the 
patients. Using the baseline characteristics longitudinal responses Yij are simulated under model 
(I). To induce missingness at the last visit we randomly deleted 0-85% of the recorded values. Th e 
simulation of the longitudinal responses (for each missingness percentage) has been repeated 
2000 times. In each of the 2000 simulated datasets both the RMA model (I) and LRlong are fi tted 
and for each model we counted the number of times (out of the 2000) that the null hypothesis 
δ = 0 is rejected. Th ereby we compute the power to detect a genetic eff ect with eff ect size equal 
to that estimated for the EAC patients for diff erent missingness percentages at the last visit. Th e 
same procedure is followed when model (II) is considered.
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BOX I: Formula of RMA’s
General formula of multivariate normal regression:
 Yij = intercept + β1xij1 + …. + βPxijP + εij,   i = 1, …, n, j = 1, …, T
 Yij= outcome from patient i at time-point j.
 βp = coeffi  cient of P
 P = covariate / interfering variables
  εi = error terms, we assumed a multivariate normal distribution with mean vector zero and variance-
covariance matrix Σ.
Here, the outcome is written as a linear function of a set of P covariates xijp
So the RMAlong concerns the following formula:
 Yij = intercept + β_j *[timeij=tj] + γ*risk factori+ δ*timeij*risk factori + εij, (I)I = 1, …, 602, j = 1, …, 8
 γ = the main group eff ect not changing over time
 δ = the diff erence in increase of the outcome per year.
 timeij=tj, time as factor, this allows the mean increase in response to diminish over time.20,21
For the RMAcs the risk factor was entered with an interaction of time as categorical variable:
  Yij = intercept + β_j *[timeij=tj] + γ*risk factori+ δj*[timeij=tj]* risk factori + εij, (II)i = 1, …, 602, j = 1, 
…, 8
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PART II
Serology in risk prediction of 
RA development and severity
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Autoantibodies such as rheumatoid factor (RF) and the second generation anti-cyclic-citrulli-
nated-peptide autoantibodies (anti-CCP2) are frequently measured in clinical practice because 
of their association with disease outcome in undiff erentiated arthritis (UA) and rheumatoid ar-
thritis (RA). Recently two new tests were developed: anti-CCP3 and anti-modifi ed-citrullinated-
vimentin autoantibodies (anti-MCV). To facilitate the decision of which autoantibody to test in 
daily practice, this study evaluates aforementioned autoantibodies and combinations of them for 
predicting three outcome measures: progression from UA to RA, the rate of joint destruction and 
achieving sustained DMARD-free remission in RA.
Methods
625 UA patients were studied for the progression to RA aft er 1 year. 687 RA patients were studied 
for achieving sustained DMARD-free remission and the rate of joint destruction during a median 
follow-up of 5 years. Positive predictive values (PPVs) for RA development and the associations 
with the disease course in RA were compared for single tests (anti-CCP2, anti-CCP3, anti-MCV, 
RF) and for combinations.
Results
Using a single test in UA patients revealed that anti-CCP2 tended to have the highest PPV for 
RA development (67.1%), but the 95% confi dence intervals of the other tests overlapped. Using 
a single test in RA, all tests showed comparable associations with the rate of joint destruction 
and achievement of remission. In ACPA-positive and ACPA-negative RA, RF-presence did not 
associate with more joint destruction. For all outcome measures, combining two autoantibody 
tests did not increase the predictive accuracy compared to performing one test. 
Conclusion
For clinical practice, a single autoantibody test is suffi  cient for risk estimation in UA and RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is considered to have an autoimmune origin because of the presence 
of self-reactive autoantibodies. In addition to rheumatoid factor (RF), to date the only serologic 
measure included in the 1987 American College of Rheumatology criteria for RA, in recent years 
several other autoantibodies have been described.1 Th e discovery of anti-citrullinated protein 
autoantibodies (ACPA) has led to the development of various new tests for autoantibodies in RA. 
Th e fi rst generation anti-cyclic-citrullinated-peptide (anti-CCP) test, directed against a synthetic 
citrullinated peptide, revealed a higher specifi city than RF (91-96% vs. 74-91%).2-6 Subsequently, 
a commercially available second generation anti-CCP test (anti-CCP2) was developed, showing 
an even better specifi city (90-97%).3-8 RF and anti-CCP2 autoantibodies can also be present in 
the preclinical phase and are associated with future RA development.9,10 Consequently, tests for 
anti-CCP2 and RF are nowadays widespread used as diagnostic tools in clinical practice.
Recently two other serological tests emerged, anti-CCP3 and anti-MCV. Th e anti-CCP3 test 
has been reported to have sensitivities and specifi cities comparable to anti-CCP2 (69-83% and 
93-95% respectively).8,11 Th e second novel autoantibody test targets modifi ed citrullinated vi-
mentin (MCV). Th is test has its origin in the older anti-Sa autoantibody test that has been shown 
to target citrullinated vimentin.12 Compared to anti-CCP2, studies reported somewhat lower 
specifi cities and higher sensitivities for anti-MCV (79-92% and 70-84%).3-5,13 
Th e aforementioned data were obtained by case-control studies comparing RA patients with 
non-RA patients or healthy individuals and the resulting test characteristics quantify the propor-
tion of patients that are identifi ed as positive by the test (sensitivity) or the proportion of healthy 
individuals that are identifi ed as negative (specifi city). As such, these measures, as well as the 
likelihood ratio of a test, provide information on the quality of the test. In clinical practice, 
the value of determining ACPA or RF relates to their ability to predict the disease course. Th e 
chance for an individual patient to have a certain disease course is expressed by the positive 
predictive value (PPV) and negative predictive value (NPV). A clinical state in which knowledge 
on the presence of RF and ACPA can be particularly helpful is undiff erentiated arthritis (UA). 
In this subgroup of early arthritis patients no diagnosis can be established according to existing 
classifi cation criteria and the presence of RF or anti-CCP2 indicates an increased risk for RA 
development.14,15 Th us far the PPV and NPV for the risk to develop RA in UA have not been 
studied for anti-CCP3 and anti-MCV and the four autoantibodies have not been subjected to 
a head-to-head comparison. Furthermore, the additive value of testing several combinations of 
autoantibodies for the prediction of RA development in individual UA patients has not been 
addressed. Th erefore, the fi rst aim of this study is to compare anti-CCP2, anti-CCP3, anti-MCV 
and RF in the prediction of the RA development in patients with UA and to explore whether 
testing combinations of autoantibodies increases the predictive accuracy.
RF and anti-CCP2 are not only important predictors for RA development, but are also some 
of the most potent predictors for the outcome of RA, as measured by the rate of radiological 
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joint destruction.16-18 Th us far, only one study compared radiological progression for anti-MCV 
and anti-CCP2 in 273 RA patients and provided suggestive evidence that anti-MCV is a better 
predictor than anti-CCP2.19 Th e eff ect of testing combinations of all four autoantibodies however 
was not studied. Th us, the second aim of the present study is to compare anti-CCP2, anti-CCP3, 
anti-MCV and RF in the prediction of the rate of joint destruction and to explore whether com-
binations of autoantibodies can increase the predictive ability, taking advantage of a longitudinal 
cohort of 687 RA patients with a median follow-up of 5 years. 
A second disease outcome of RA is the achievement of remission that with the introduction 
of new aggressive treatment modalities has increasingly become an attainable goal. We chose a 
strict defi nition and defi ned sustained disease-modifying antirheumatic drugs (DMARD)-free 
remission as the persistent absence of synovitis for at least 1 year aft er cessation of DMARD-
therapy.20 Since the predictive value of the four autoantibodies in relation to remission is scarcely 
explored, the present study compares the four tests for their ability to predict sustained DMARD-
free remission in RA patients treated with conventional DMARDs.
In summary, to support the choice on which autoantibody to test in daily practice, this study 
uses a large longitudinal cohort to evaluate the value of determining anti-CCP2, anti-CCP3, 
anti-MCV and RF for predicting three outcome measures: progression from UA to RA, the rate 
of joint destruction and the chance of achieving sustained DMARD-free remission in RA. In 
addition, the predictive value of combining several tests is investigated.
PATIENTS AND METHODS
Patients
All patients included in this study are selected from the Leiden Early Arthritis Clinic (EAC) 
cohort that was started in 1993.21 Patients were referred by general practitioners when arthritis 
was suspected. Inclusion took place when arthritis was confi rmed at physical examination and 
symptom duration was less than 2 years. Written informed consent was obtained from all partici-
pants. Th e study was approved by the local Medical Ethical Committee. 
At inclusion, patients were inquired about their joint symptoms and subjected to a physical 
examination. Blood samples were taken for routine diagnostic laboratory screening (including 
IgM-RF) and stored to determine other autoantibodies at a later time. Follow-up visits were 
performed on a yearly basis and included radiographs of hands and feet.
Since the start of the EAC treatment strategies for RA have changed; four diff erent strategies 
were applied depending on the inclusion period. Patients included between 1993 and 1995 were 
treated initially with analgesics and subsequently with chloroquine or salazopyrin if they had 
persistent active disease (delayed treatment).22 From 1996 to 1998 RA patients were promptly 
treated with either chloroquine or salazopyrin (early treatment).21,22 From 1998 to 2002 patients 
were promptly treated with either salazopyrin or methotrexate (early treatment) and patients 
included in 2002 or later were promptly treated with either salazopyrin or methotrexate com-
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bined with treatment adjustments based on the disease activity (early and disease activity based 
treatment). Treatment of UA patients was not protocollized. 
UA was defi ned as not fulfi lling one of the existing classifi cation criteria for rheumatologic 
diagnoses two weeks aft er the fi rst presentation.23 Th us other rheumatic diseases like Sjögren’s 
syndrom, psoriatic arthritis, spondylarthropathies, etc. that were established at baseline were 
excluded (Figure 1). 625 patients with UA, consecutively included between 1993 and 2006, were 
studied. Aft er 1 year of follow-up, 201 patients (32.2%) had progressed to RA, fulfi lling the 1987 
ACR criteria for RA. In addition, 687 patients with RA included between 1993 and 2006 were 
studied for their disease outcome; 486 patients fulfi lled the ACR criteria for RA already at inclu-
sion and 201 patients were initially diagnosed with UA and developed RA within the fi rst year 
of follow-up (Figure 1). 
Leiden  
EAC 
Diagnosis at  
2 weeks 
RA 
N = 486 
UA 
N = 625 
Other diagnoses 
N ≥ 1100 
RA 
N = 687 
RA 
N = 201 
Other diagnosis  
N = 424 
Diagnosis at  
1 year 
 Median follow-up 5 years 
Figure 1. Flowchart of the study. From the 687 RA patients, 579 had radiographic data available and for 635 
patients information on sustained DMARD-free remission was obtained. From all UA patients RF, anti-CCP2, 
anti-CCP3 and anti-MCV were determined in 623, 624, 597 and 597 patients respectively. From all RA patients 
with radiographs available RF, anti-CCP2, anti-CCP3 and anti-MCV were determined in 572, 565, 544 and 544 
patients respectively. From all RA patients with data on sustained DMARD-free remission, RF, anti-CCP2, anti-
CCP3 and anti-MCV were determined in 615, 603, 579 and 579 patients respectively
Autoantibodies
IgM–RF was determined by enzyme-linked immunosorbent assay (ELISA). Anti-CCP2 auto-
antibodies (total IgG) were measured by ELISA (Immunoscan RA Mark 2; Euro-Diagnostica, 
Arnhem, Th e Netherlands). Th e cutoff  level for anti-CCP2 autoantibody-positivity was set at 25 
arbitrary units, according to the manufacturer’s instructions. Anti-CCP3 autoantibodies (IgA 
and IgG subforms) and anti-MCV autoantibodies were measured with ELISA as well (Quanta 
lite CCP 3.1 IgG/IgA, INOVA Diagnostics Inc., San Diego, CA, USA and Orgentec Diagnostika 
GmbH, Mainz, Germany respectively). According to the manuals, the cutoff  level for both tests 
was 20 arbitrary units. Th e numbers of patients in which RF, anti-CCP2, anti-CCP3 and anti-
MCV measurements were performed show some little variation (available data for RF, anti-CCP2, 
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anti-CCP3 and anti-MCV were respectively 665, 653, 629 and 629 out of 687 RA patients and 
623, 624, 597 and 597 out of 625 UA patients). Th is is due to the diff erence in timing of perform-
ing the tests. RF was determined routinely at inclusion whereas the ACPA were determined using 
stored serum samples. Th e recently introduced anti-CCP3 and anti-MCV assays were performed 
on all available sera in 2008, whereas the anti-CCP2 assay was performed earlier. 
Radiographs
Radiographs of hands and feet were taken on consecutive years starting at baseline and were 
scored according to the Sharp-van der Heijde method.24 From all RA patients, 579 had data on 
both autoantibodies and radiographs. To encompass a reliable sample size during follow-up, 
radiographic data were restricted to a maximum of 7 years of follow-up. Th e number of available 
radiographs varied per time-point and declined from 552 at baseline to 478 aft er 1 year, 426, 358, 
299, 270, 207 and 156 aft er 2 till 7 years of follow-up respectively. Due to the study design (an 
inception cohort) not all patients had a similar duration of follow-up (median 5 years). All radio-
graphs were scored by one experienced scorer (ML) who was blinded with respect to the patient’s 
autoantibody status, treatment and other clinical data. Scoring was performed with known time 
order, which is more sensitive to change compared to scoring with unknown time sequence.25 
From the total number of scored radiographs, 499 radiographs were rescored by the same reader, 
consisting of 149 baseline radiographs and 350 radiographs during follow-up belonging to 60 
randomly selected RA patients. Th e intraobserver intraclass correlation coeffi  cients were 0.91 for 
all scored radiographs, 0.84 for baseline radiographs and 0.97 for the radiographic progression 
rate. 
Sustained DMARD-free remission in RA
Remission was defi ned in its most stringent form as the persistent absence of synovitis for at least 
one year aft er cessation of DMARD therapy and the identifi cation of remission by the patient’s 
rheumatologist.26 Th e remission status could be reliably ascertained in 635 RA patients. Most 
patients who achieved remission were followed-up longer than the minimum requirement of 1 
year; the median time of observation aft er discontinuation of DMARDs in the absence of swollen 
joints was 2.5 years. Patients, who had a recurrence of their arthritis aft er discharge, could easily 
return to the Leiden University Medical Center, the only referral center for Rheumatology in a 
health care region of approximately 400.000 inhabitants. Th e frequency of relapse was recorded 
and patients with relapse were included in the non-remission group (n=6).
Statistical analysis
Th e PPV (proportion of UA patients with a positive test that progressed to RA) and the NPV 
(proportion of UA patients that did not develop RA) were determined. 
As radiographic data are not normally distributed, non-parametric Mann-Whitney tests were 
used to compare the Sharp-van der Heijde scores at individual time points for patients with and 
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without autoantibodies or for autoantibody combinations. In addition, to take advantage of the 
prospective character of the data consisting of repeated measurements, and to avoid multiple 
testing by performing statistical tests for each time point, a linear mixed model with an au-
toregressive correlation structure with heterogeneous variances was used. Th is model estimates 
the linear progression rate in radiological joint destruction using normalized, log-transformed 
Sharp-van der Heijde scores, taking missing observations into account. Th is means that it 
compares the progression rates for the diff erent patient groups. In the mixed model analyses, 
corrections were applied for age, gender and inclusion period/treatment strategy. Correction for 
treatment strategy was performed by including the inclusion period in the linear mixed model. 
Th is was done because treatment modalities improved over time and an infl uence of the treatment 
strategy (refl ected by the inclusion period) on the progression of radiographic joint damage was 
observed previously as well as in the present study (data not shown). In addition, the available 
follow-up duration diff ered between patients and therefore the number of radiographs per time 
point declined during follow-up. As the patients with the longest follow-up were included in the 
earliest inclusion period and thus have been treated with the least aggressive treatment strategy, 
correction for inclusion period was performed. In order to prevent overfi tting of the data no 
corrections were applied for other variables. Analysis of sustained DMARD-free remission was 
performed by Cox regression analysis, to take into account the diff erences in follow-up times 
among patients. For patients that achieved remission the dependent variable is the “time-to-
event”, indicating the time until reaching remission. For non-remission patients the time to last 
follow-up was used, with a maximum of 10 years. SPSS version 16.0 (SPSS Inc., Chicago, IL, 
USA) was used. P-values <0.05 were considered signifi cant. All reported p-values are two-sided.
RESULTS
Progression from UA to RA
From the total EAC, consisting of >2,000 patients with early arthritis, UA patients (n=625) were 
selected and studied for progression to RA aft er 1 year of follow-up. At inclusion, the mean age 
was 50.9 (±17.0) years, 371 (59.1%) patients were female and the self-reported symptom duration 
was 5.5 (±8.5) months. Anti-CCP2, anti-CCP3, anti-MCV and RF were present in 149 (23.9%), 
172 (28.7%), 199 (31.7%) and 155 (24.8%) patients respectively. Th e presence of autoantibodies 
overlapped; UA patients who tested positive for anti-CCP2 were also frequently positive for other 
autoantibodies (Figure 2). 
Th e PPV was compared for the four autoantibodies (Table 1). Anti-CCP2 had the highest PPV, 
67.1%, compared to 64.0%, 56.3% and 61.7% for anti-CCP3, anti-MCV and RF respectively. Th e 
NPVs of all four tests were comparable (~80%). Th us, in case one autoantibody test is performed, 
a positive anti-CCP2 test tends to correlate with the highest risk of RA development, but overlap-
ping 95%CI’s hamper a defi nite diff erentiation. 
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Next it was determined whether performing two autoantibody tests results in a better estima-
tion of the risk for RA than performing one test. Since anti-CCP2 and anti-CCP3 are related 
tests and anti-CCP2 positive patients were in 90% also positive for anti-CCP3, the possible 
combinations of anti-MCV, anti-CCP2 and RF were fi rst assessed. Th e proportions of patients 
that developed RA in case of two positive test results (PPV) were: anti-CCP2+/anti-MCV+ 69.9% 
(95%CI 62.1-77.7), anti-CCP2+/RF+ 74.1% (95%CI 65.8-82.3) and anti-MCV+/RF+ 70.6% 
(95%CI 62.1-79.2). Additional analyses using anti-CCP3 instead of anti-CCP2 yielded compa-
rable results (data not shown). Altogether, these data show that when two tests are performed 
none of these combinations is clearly superior to the other. Furthermore, no additive value of 
performing two instead of one autoantibody test could be observed.
When performing a single autoantibody test, no information about the presence or absence 




































































Figure 2. Prevalence of other autoantibodies in case of a positive test result for anti-CCP2, anti-MCV and RF 
for both UA and RA. Figure 2 illustrates the prevalence of other autoantibodies given one positive autoantibody 
test. Th is fi gure is derived using 596 UA and 540 RA patients for whom data on all autoantibodies was present. 
none: no other autoantibodies present
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unmeasured autoantibodies can aff ect the risk for RA. To determine the risk for RA as conferred 
to by the individual autoantibodies or by the number of autoantibodies, the PPVs for progression 
to RA were determined in the group of 596 UA patients for whom information on all three 
autoantibodies was available. Th e diff erence with above mentioned data is that the presence of 
two autoantibodies now indicates that the third is absent, whereas in above mentioned data only 
two tests were performed and the third autoantibody test could be positive as well as negative. 
Th e PPV for RA development in patients without autoantibodies was 18.8% (95%CI 14.7-22.9). 
In the presence of one autoantibody the PPV was 26.5% (95%CI 17.9-35.0) and increased signifi -
cantly to 59.6% (95%CI 45.5-73.6) in the presence of two autoantibodies (Table I, supplementary 
data). Th e PPV was the highest in the presence of 3 autoantibodies (73.3%, 95%CI 64.6-81.9). 
In conclusion, when performing one autoantibody test in clinical practice, none of the four 
tests is clearly superior. Although the presence of 2 autoantibodies signifi cantly increased the 
risk for RA compared to the presence of 1 autoantibody, for clinical use performing two tests 
does not signifi cantly increase the predictive performance compared to performing one test. Th is 
fi nding is likely explained by the presence of other, non-measured autoantibodies that aff ect the 
risk for RA.
Joint destruction in RA
Baseline characteristics of the 579 studied RA patients were: mean age 56.2 (±15.5) years, 405 
patients (69.9%) were female, anti-CCP2, anti-CCP3, anti-MCV and RF were present in 313 
(55.4%), 322 (59.2%), 331 (60.8%) and 334 (58.4%) patients respectively. Anti-CCP2 positive 
patients also tested positive for anti-MCV and RF in 93% and 87% of cases respectively (Figure 2).
First, the association between autoantibody-positivity and rate of joint destruction was as-
sessed when performing only one autoantibody test. For all autoantibody tests (anti-CCP2, anti-
CCP3, anti-MCV and RF) a positive test result was associated with a higher Sharp-van der Heijde 
score at all time points except baseline (M-W, p<0.001) and a higher rate of joint destruction 
over a period of 7 years (mixed model, p<0.001) compared to a negative test result. Figure 3A 
shows that there is no diff erence among the four tests with regard to predictive ability for joint 
destruction. 
Next, it was investigated whether the addition of a second autoantibody test increased the 
predictive value for the rate of joint destruction. As depicted in Figure 3B no diff erences were 
seen between testing positive for anti-CCP2, anti-MCV or RF alone and combinations of these 
autoantibodies. Th ese results indicate that for clinical use, a positive test for one of these auto-
antibodies predicts a severe disease course, and a second or third autoantibody test does not 
increase the predictive accuracy. Testing for anti-CCP3 instead of anti-CCP2 gave comparable 
results (data not shown).
To identify the contribution of the individual autoantibodies to the association with the rate 
of joint destruction, the eff ect of the number of positive autoantibodies (with the known absence 
of the other autoantibodies) was investigated using data on RF, anti-CCP2 and anti-MCV. Th e 
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presence of either 2 or 3 autoantibodies was associated with a higher rate of joint destruction 
compared to 0 or 1 autoantibody (Figure 4A) (mixed model, p <0.001 for both 2 and 3 compared 
to 0 as well as 1 autoantibody). No signifi cant diff erence was observed between the presence of 
2 or 3 autoantibodies or between 0 and 1 autoantibody. It should be noted that the group with 
1 autoantibody consisted almost exclusively of patients that were anti-MCV+ (n=33) or RF+ 
(n=39); only two patients were positive for anti-CCP2 and negative for anti-MCV and RF. 
To more specifi cally investigate the role of RF in relation to ACPA (anti-CCP2, anti-CCP3 
or anti-MCV) and the rate of joint destruction, the additional eff ect of RF in the presence or 
Figure 3. Mean Sharp-van der Heijde scores (±SEM) for the diff erent autoantibody tests (A) and for 
combinations of positive tests (B). Th e number of patients in Figure 3A for anti-CCP2-positive/negative, anti-
CCP3-positive/negative, anti-MCV-positive/negative and RF-positive/negative were respectively 313/252, 
322/222, 331/213 and 334/238. *Mann-Whitney, p<0.001, for comparison of positive with negative test. For 
all four tests the p-value was <0.001 using mixed models. In Figure 3B, for anti-CCP2+, RF+, anti-MCV+, 
anti-CCP2+/RF+, anti-CCP2+/anti-MCV+, anti-MCV+/RF+ and anti-CCP2+/anti-MCV+/RF+ the numbers 
of patients were 313, 334, 331, 271, 283, 259 and 244 respectively
Figure 4. Mean Sharp-van der Heijde scores (±SEM) for the number of positive autoantibody tests (A) and for 
the eff ect of RF in the presence or absence of ACPA (B). In Figure 4A the mean Sharp-van der Heijde scores 
are depicted for the number of positive autoantibody tests (with the other tests negative) studying data on RF, 
anti-CCP2 and anti-MCV (total n=540). Th e numbers of patients positive for 0, 1, 2 or 3 autoantibodies were 
152, 74, 70 and 244 respectively. Comparing 3 with 0, 3 with 1, 2 with 1 and 2 with 0 autoantibodies revealed 
a p<0.05 at all time points except baseline (M-W) and a p<0.001 for the 7 year period (mixed model). In 
Figure 4B the mean Sharp-van der Heijde scores are depicted for the following groups ACPA-RF-, ACPA-RF+, 
ACPA+RF- and ACPA+RF+, the patients numbers per group were 152, 39, 36 and 244. P=0.864 for comparison 
of ACPA-RF- with ACPA-RF+ and p=0.702 for comparison ACPA+RF- and ACPA+RF+ (both mixed model)
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absence of ACPA was determined (Figure 4B). Th is revealed that in the presence of ACPA, but 
also in the absence of ACPA, RF did not signifi cantly contribute to the rate of joint destruction. 
Sustained DMARD-free remission in RA
From a total of 635 RA patients, 78 patients achieved sustained DMARD-free remission aft er 
a median follow-up of 39.5 months. Th ese 78 patients had a mean age of 59.4 (±15.7) years, 57 
(73.1%) were female. Anti-CCP2 autoantibodies were present in 11.8% and anti-CCP3, anti-
MCV autoantibodies and RF in 21.9%, 28.8% and 25.0%. 
Th e four autoantibody tests were compared for their association with the achievement of re-
mission (Figure 5A). Th e Hazard Ratio (HR) of each of the four tests for not achieving sustained 
DMARD-free remission was 11.6 (95%CI 5.8-23.4) for anti-CCP2, 6.0 (95%CI 3.4-10.4) for 
anti-CCP3, 4.9 (95%CI 3.0-8.2) for anti-MCV and 4.7 (95%CI 2.8-8.0) for RF.
Subsequently, the additive value of performing two autoantibody tests compared to one test 
was investigated. Th e HRs were 15.6 (95%CI 6.7-36.4), 14.0 (95%CI 6.4-31.0) and 11.5 (95%CI 
5.4-24.5) for combinations of anti-CCP2 and RF, anti-CCP2 and anti-MCV and anti-MCV and 
RF respectively. Th ese data indicate that to predict the chance on remission, performing two tests 
has no additional value compared to anti-CCP2 alone.
To investigate whether the number of present autoantibodies aff ected the chance of achieving 
sustained DMARD-free remission, the HRs were determined for the presence of 1, 2 or 3 positive 
autoantibodies (with the other autoantibodies known to be absent) using data on anti-CCP2, 
anti-MCV and RF (Figure 5B). Th e HRs for not achieving sustained DMARD-free remission 
were as follows, 3.7 (95%CI 1.1-12.3), 15.5 (95%CI 5.9-41.2) and 17.1 (95%CI 6.8-43.3) for the 
presence of, respectively, 1, 2, and 3 autoantibodies compared to no autoantibodies. Th us, how-
ever the 95%CIs were overlapping, the results suggestively indicate that the more autoantibodies 
are present, the lower the chance is to achieve sustained DMARD-free mission. 
Figure 5. Eff ect of the presence of a positive autoantibody test (A) and the number of autoantibodies on 
sustained DMARD-free remission (B)
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DISCUSSION
Among the autoantibodies tested in RA, only RF and ACPA are considered clinically useful. In 
clinical practice a physician or patient is interested in the chance for the individual to progress to 
RA or not, given a positive or negative test result respectively. Th ese risks are refl ected by the PPV 
and NPV. In addition, in early arthritis the predictive value of these autoantibody tests is valued 
the most in patients in whom at presentation no defi nite diagnosis can be established (UA), as 
only one-third of these patients progresses to RA aft er one year.14 Also in RA, the autoantibody 
tests form one of the most potent predictors to obtain an indication on the severity of the future 
disease course. As such, information on the results of the autoantibody tests can infl uence treat-
ment decision in individual patients with UA and RA.23 Nevertheless, it is thus far unknown 
which test, or which combination of tests, is most powerful in predicting the progression from 
UA to RA and the disease progression in RA and therefore the present study was undertaken. 
To evaluate the prediction from UA to RA using a single test, the PPVs of the four tests were 
compared. Th is revealed that a positive anti-CCP2 test tended to have the highest predictive value 
(PPV 67% compared to 62% and 56% for RF and anti-MCV), but due to overlapping 95%CIs a 
defi nite diff erentiation could not be made. In addition, performing a second test did show a 
tendency for a higher chance on RA development in case both tests were positive (highest risk for 
RA in anti-CCP2+, RF+ patients, PPV 74%), but also here the 95%CIs overlapped. To formally 
conclude whether the PPVs of 67% and 74% are statistically signifi cantly diff erent or not, >1800 
UA patients would be required (using a p-value of 5% and a power of 90%). Based on the present 
data it is concluded that addition of a second test does not result in an increased predictive 
accuracy. Notably, UA patients who tested positive for anti-CCP2 were also frequently positive 
for other autoantibodies (Figure 2). Th us the fi nding of comparable prognostic performances of 
one or two tests is likely due to co-existing presence of autoantibodies that are unmeasured with 
a single test but that do aff ect the risk-estimation for RA. 
Th e development of RA was assessed aft er 1 year of follow-up. Th is time-point was chosen in 
order to have a similar duration of follow-up for all studied patients. However, this may have 
introduced misclassifi cation as patients with UA may have progressed to RA aft er more than 1 
year of follow-up. With all available follow-ups, 25 patients (4.4%) progressed to RA later than 
1 year, indicating that the current PPVs may be marginally underestimated. Since this misclas-
sifi cation is present in the total group of UA patients this does not hamper a comparison of tests. 
Two measures were studied for the severity of the disease course in RA: achieving sustained 
DMARD-free remission and the level of radiological joint destruction during a median follow-
up of 5 years. Although Figure 3A and 5A may lead to the impression that anti-CCP2 positive 
patients have a higher rate of joint destruction and achieve sustained DMARD-free remission 
less frequently than patients positive for the other autoantibodies, these diff erences were not sta-
tistically signifi cant. Similar to the data on RA development, performing a second test appeared 
not to result in a more accurate prediction for the disease outcome in RA. Th is observation, 
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which is in contrast to an earlier report,27 can be explained by the presence of non-measured 
autoantibodies that are associated with a progressive course of RA.To obtain a more detailed 
comprehension of the current results, the contribution of the individual autoantibodies to dis-
ease progression (RA development, joint destruction and achievement of remission) was inves-
tigated. Th is showed that the presence of two autoantibodies indicated a signifi cantly increased 
risk compared to the presence of one autoantibody. However, the group with one autoantibody 
present consisted mostly of anti-MCV or RF-positive patients. Patients that were positive only 
for anti-CCP2 were very rare. Th erefore it cannot be excluded that the increased risk in the 
presence of two compared to one autoantibody is due to the eff ect of anti-CCP2 rather than to 
the eff ect of an additional autoantibody. Nevertheless, in general it was observed that a higher 
number of autoantibodies present resulted in a higher risk for RA or for progressive disease. Th is 
is in line with recent published data showing that a broader autoantibody response associated 
with disease progression.28 
As the association of RF with the presence of RA is primarily explained by its interaction 
with ACPA,29 we investigated whether we could observe a similar eff ect for the progression of 
joint destruction in RA. Intriguingly, the rate of joint destruction both in the ACPA-positive and 
ACPA-negative groups was not aff ected by the presence or absence of RF. Th is fi nding further 
supports the notion that RF does not, by itself, contribute to disease progression. 
In order to get an impression of the eff ect of anti-MCV itself on the rate of joint destruction, 
RA patients that were positive only for anti-MCV (n=33) were studied. Th is revealed that the 
rate of joint destruction was comparable to that of the patients with no autoantibodies (data not 
shown), indicating that anti-MCV alone does not strongly aff ect the level of joint damage in RA.
In conclusion, our results indicate that for risk estimation of the disease course in clinical 
practice, performing a single autoantibody test is suffi  cient, both in UA and RA.
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Recently new classifi cation criteria for Rheumatoid Arthritis (RA) have been devised by method-
ology that used fi rst a quantitative approach (data from databases), then a qualitative approach 
(consensus-based on paper patients) and fi nally a common sense based approach (evaluation 
of the former phases). Now these criteria are being evaluated to assess characteristics of the 
individual items. Th is study analyzed characteristics of the item autoantibodies, in particular RF 
level.
Methods
Th ree separate cohorts with a total of 972 undiff erentiated arthritis patients were studied for RA 
development (according to the 1987 ACR criteria) and arthritis persistency. Positive and negative 
predictive values (PPV, NPV) and likelihood ratios (LR) were compared between diff erent levels 
of RF and the presence of ACPA. A similar comparison was made in 686 RA patients for the 
rate of joint destruction during 7 years of follow-up and achievement of sustained DMARD-free 
remission. Th e variation in RF levels obtained by diff erent measurement methods in the same 
RF-positive sera was explored.
Results
Presence of ACPA had a better balance between LR+/LR- and PPV/NPV than high RF levels for 
RA development. Th e additive value of ACPA assessment aft er high level RF testing was higher 
than vice versa. High level RF was less strongly associated with RA severity than ACPA antibod-
ies. Th e RF level obtained by diff erent methods in the same patients’ sera varied considerably.
Conclusion
Level determination of RF is subject to large variation; high level RF has limited additive prog-
nostic value compared to ACPA positivity. Th us, omitting RF level and using RF presence, ACPA 
presence and ACPA level may improve the 2010 criteria for RA.
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INTRODUCTION
Recently, the American College of Rheumatism (ACR) classifi cation criteria for rheumatoid 
arthritis (RA) dating back from 1987,1 have been subjected to a process of rejuvenation by a joint 
taskforce of both the ACR and the EULAR (European League Against Rheumatism). Th e aim of 
these criteria is to classify RA in an earlier disease stage compared to the 1987 ACR criteria and 
the development of these criteria is an important step forwards. 
Th e development of the 2010 ACR/EULAR criteria comprised three phases. First, a data driven 
phase using data from 3115 patients from Europe and Canada. Next, a phase incorporating the 
expertise of 39 rheumatologists and fi nally a consensus phase by the same group.2-4 It is foreseen 
that in the next years the criteria will be studied in cohorts with diff erent ethnic backgrounds 
and dissimilar healthcare systems in which the pretest probability for RA in new patients visiting 
rheumatologists diff ers. 
Th e 2010 criteria are the fi rst that include anti-citrullinated peptide antibodies (ACPA), in 
addition to RF. Presence of these auto-antibodies can contribute substantially to the classifi cation 
of RA for which ≥6 points are required; presence of ACPA or RF yields 2 points and high levels 
of ACPA or RF yields 3 points. In the data driven phase of the development of the criteria, using 
data of several early arthritis cohorts, ACPA and RF were recognized as a theme in a factor 
analysis. Th en, ACPA and RF were summarized as ‘serology’. Subsequently the importance of se-
rology, independent of other variables, was determined using a multivariate regression analysis. 
It was observed that within the patients with a positive serology, patients with a level higher than 
median received a higher weight than patients with a level lower than median. Aft er the expert-
phase and consensus-phase a high level was redefi ned as ≥ three times the reference value.
Th e present study aimed to provide two main characteristics of the items serology, particularly 
the RF level criterion, in the 2010 ACR/EULAR criteria for RA. Th e fi rst characteristic was the 
discriminative ability of high levels of RF compared to ACPA for early RA. Several studies ob-
served an increased specifi city for RA of a higher RF level compared to RF positivity.5,6 However, 
an increased specifi city for RA has also been observed for presence of ACPA compared to the 
presence of RF.7 Th us far extensive comparisons of the prognostic performance for RA develop-
ment of increased RF levels in comparison to the presence of ACPA, notably anti-CCP antibodies, 
have not been made. In three separate prospective cohorts with undiff erentiated arthritis (UA) 
patients of recent onset from three diff erent countries, RA development was studied in relation 
to baseline RF levels and ACPA. RA was defi ned by the 1987 ACR criteria.1 To verify that the 
results were not diff erent when other outcome measures were used, analyses in UA patients were 
repeated with arthritis persistency as outcome. Furthermore, in RA patients the same analyses 
were performed with the rate of joint destruction and the achievement of sustained disease 
modifying antirheumatic drugs (DMARD)-free remission as outcome.
Th e second characteristic was the capacity of diff erent assays to uniformly defi ne a high RF 
level. Despite the presence of international units for RF, RF level measurement is not adequately 
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standardized between diff erent measurement methods. Subsequent variations in RF levels may 
yield diff erences in classifying or diagnosing RA between laboratories. Th erefore we determined 
the degree of variation in RF levels obtained when the same RF-positive serum samples were 
tested by the methods that are currently most frequently applied (ELISA, nephelometry, turbi-
dimetry). Although older studies evaluated the correlations between results of the Rose-Waaler 
method and ELISA,8 data on a head-to-head comparisons of currently applied methods are to the 
best of our knowledge not available.
PATIENTS A ND METHODS
Patients
Development of RA in UA patients
UA patients of three separate cohorts were studied for RA development, comprising an overall 
total of 972 UA patients (Figure 1). UA was defi ned as not fulfi lling any of the existing classifi ca-
tion criteria for a rheumatic disease diagnosis 2 weeks aft er the fi rst presentation when the results 
of laboratory and radiological examinations were known.9 Patients were followed up for one year, 
where aft er the fi nal diagnosis was established. Patients were categorized as RA (according to the 
1987 ACR criteria)1 or as non-RA (all other diagnoses).
Th e Leiden EAC is a large prospective cohort that started in 1993, which has been described 
previously.10 Patients with confi rmed arthritis were included when the symptom duration was 
less than 2 years. At baseline, blood samples were taken for routine diagnostic laboratory screen-
ing (including testing for IgM-RF) and stored for determining other auto-antibodies later on 
(anti-CCP2). Follow-up visits (including radiographs) were performed yearly. Between 1993 
and 2006, 625 patients were diagnosed with UA at baseline. Almost all patients had a follow-up 
duration longer than one year and 30% of the UA patients had developed RA aft er one year and 
4% later than one year of follow-up.11
Th e Berlin EAC was started in January 2004, and patients were included if they had synovitis in 
at least 2 joints and a duration of symptoms between 4 weeks and 12 months. Th is Berlin cohort 
has been described previously.12 At fi rst presentation, 154 patients had UA. Fulfi llment of the 
1987 ACR criteria1 for RA was assessed aft er 1 year of follow-up. 
Th e third cohort consisted of 193 UA patients from Oslo, Norway, included in the Norwegian 
very early arthritis (NOR-VEAC).13 Th is cohort included patients with at least one swollen joint 
of 16 weeks duration. During the fi rst year patients were seen aft er 3, 6, and 12 months and the 
development of RA was classifi ed aft er one year of follow-up. 
In the fi rst, data driven phase of developing the new 2010 ACR/EULAR criteria, patients from 
the Leiden EAC (n=213) and from the NORVEAC (n=193) were used.3 All studies were approved 
by the local ethics committees. All patients gave their written informed consent.
Michael vd Linden bw.indd   66 01-08-11   16:08
RF level in the 2010 ACR/EULAR criteria for RA 67
Arthritis persistency in UA patients
In order to determine whether results diff ered when another outcome measure was used, analy-
ses were repeated with arthritis persistency as outcome in the Leiden dataset. A generally ac-
cepted defi nition for persistency is lacking and its frequency depends on the observation period. 
We defi ned persistent arthritis as the absence of sustained remission, which was defi ned as the 
absence of swollen joints for at least one year aft er cessation of eventual DMARD therapy. When 
remission was not obtained aft er 5 years of disease, a patient was classifi ed as having persistent 
arthritis. With this defi nition, 61.3% of UA patients had persistent arthritis.
Severity of disease course in RA patients
Patients who fulfi lled the ACR 1987 criteria for RA during the fi rst year and were included in 
the Leiden EAC between 1993 and 2006 were studied. Of the total of 687 RA patients, 486 had 
already fulfi lled the 1987 ACR criteria for RA at baseline and 201 developed RA within the fi rst 
year of follow-up (Figure 1). 
672 RA patients had radiographs of hands and feet taken at baseline and on consecutive years. 
Th ese were scored chronologically by an experienced reader (MPMvdL) according to the Sharp/
van der Heijde method.14 Intraobserver intraclass correlation coeffi  cients (ICC) were 0.91 for 
all radiographs, 0.84 for baseline radiographs, and 0.97 for the radiographic progression rate. 
To encompass a reliable sample size, radiographic follow-up data were restricted to a maximum 
of 7 years (median 5, IQR 2-7). Treatment strategies for RA had changed over time and became 























at 2 weeks 
UA to RA RA 
Figure 1. Flowchart of the cohorts used in this study. Left  Part: Patients initially diagnosed with UA were 
studied for development of RA. For the Berlin data, all of the 154 UA patients had data on RF as well as ACPA. 
Also in the NOR-VEAC, both RF and ACPA were determined in all 193 UA patients. For the Leiden EAC, data 
was available for RF in 623 and for ACPA in 624 out of 625 UA patients. Right Part: In the Leiden EAC, a total 
of 687 patients were diagnosed with RA aft er one year. In these patients 686 had data on radiographic data 
and/or the achievement of sustained DMARD-free remission. RF and ACPA were in measured in 663 and 658 
patients respectively
Michael vd Linden bw.indd   67 01-08-11   16:08
68 Chapter 4
A second outcome measure for the severity of the disease course was the achievement of 
sustained DMARD-free remission. Remission was defi ned in a stringent form as the persistent 
absence of synovitis, e.g. no swollen joints, for at least one year aft er cessation of DMARD therapy 
and the identifi cation of remission by the patient’s rheumatologist.16 Here, corticosteroids (both 
oral and intra-articular) were considered as DMARDs; NSAIDs were allowed. Most patients who 
achieved remission had a follow-up aft er cessation of DMARDS longer than one year. Th e remis-
sion status could be reliably ascertained in 641 RA patients using medical fi les. Th e frequency of 
DMARD-free remission in these RA patients was 12.3%.
Autoantibody testing
In the Leiden EAC, RF was determined by enzyme-linked immunosorbent assay (ELISA) 
(IgM-RF, in-house ELISA),17 using a standard cutoff  value of 5 arbitrary units. Anti-CCP2 auto-
antibodies (total IgG) were measured by ELISA (Immunoscan RA Mark 2; Euro-Diagnostica, 
Arnhem, Th e Netherlands). Th e cutoff  level for anti-CCP2 autoantibody positivity was set at 25 
arbitrary units, according to the manufacturer’s instructions. 
In the Berlin cohort, RF was determined by ELISA (Autostat II, Hycor Biomedical, Edinburgh, 
UK), using a reference value of >24 IU/l Units for a positive test result. Anti-CCP 2 was deter-
mined by ELISA (Immunoscan CCPlus, Euro-Diagnostica, Malmö, Sweden), using a reference 
cutoff  of >25 U/l for autoantibody positivity. 
In the NOR-VEAC, sera frozen at inclusion were used to analyze anti-CCP2 (Inova Inc., San 
Diego, USA) and IgM-RF (in-house ELISA) levels in one batch. Cutoff s used to defi ne a positive 
status were as recommended by the local laboratory: anti-CCP2 25 units/ml and IgM-RF 25 
units/ml. 
Considering the absence of agreement on a uniform defi nition of high level RF, two defi nitions 
of high RF level were evaluated. Th ese were three times the reference cutoff  value, the defi nition 
of a high RF level that is used in the 2010 ACR/EULAR criteria, and a RF level of 50 U/ml (RF50), 
as RF50 is the defi nition of high RF levels used in previous studies on this subject.5,6 
Variation in RF measurements
In order to facilitate laboratories in quality control in the Netherlands, the SKML - section HIM 
(Stichting Kwaliteitsbewaking Medische Laboratoria – section Humoral Immunology) organizes 
external quality assessment schemes for rheumatoid factor testing twice a year. In each scheme 
six patient samples are sent to 78 participating laboratories. Th ese six patient samples consist of 
three RF-negative samples, two RF-positive samples and one standard serum (RELARES). Th is 
is a commercially available standard serum, consisting of pooled serum of RF-positive patients, 
which was previously standardised to correspond with 100 International Units using the Rose-
Waaler agglutination test.18,19 For this paper the results of the spring 2008 scheme are used of 
the two RF-positive patient sera and the standard serum. Th e sera were tested according to local 
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protocols and reported in local units and as a ratio compared to the local cutoff  value by the 
participants. 
Statistical analysis
Development of RA in UA patients
Diff erent test characteristics (sensitivity, specifi city, positive (LR+) and negative (LR-) likelihood 
ratio) were determined. Th e likelihood ratio incorporates both the sensitivity and specifi city of 
the test and provides an estimate of how much a test result will change the odds of having a 
disease. In addition, absolute post test changes on RA aft er 1 year of follow were determined 
(positive predictive value (PPV) and negative predictive value (NPV)). Analyses were performed 
using two descriptions of a high RF level (three times the reference cutoff  level and a RF level 
of 50 U/ml (RF50), and the resulting data were compared with the data for ACPA positivity. RA 
development was analyzed aft er 1 year of follow-up and arthritis persistency was classifi ed aft er 
5 years of follow-up.
Severity of disease course in RA patients
Associations with the rate of joint destruction during 7 years of follow-up were assessed using a 
repeated measurement analysis (RMA) on log-transformed radiological data, because of skew-
ness. Th e RMA is performed using a multivariate normal regression model that, on longitudinal 
data, evaluates the progression rates over time and takes into account the correlation between the 
measurements within one subject. Adjustments were made for age, gender and applied treatment 
strategy as previously described.20 
Analysis of sustained DMARD-free remission was performed by comparing Kaplan Meier 
curves and by Cox regression analysis, correcting for age and gender, taking into account the dif-
ferences in follow-up times among patients. For patients who achieved remission, the dependent 
variable was “time-to-event”, indicating the time until reaching remission. For non-remission 
patients the time to last follow-up was used. 
Variation in RF measurements
To test for correlations between the diff erent methods that are used for measurement of the RF 
level, non-parametric Spearman correlation coeffi  cients (ρ) were determined. 
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used. P-values <0.05 were considered 
signifi cant. All reported p-values are two-sided. 
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RESULTS
Development of RA in UA patients
Baseline characteristics of UA patients included in the three cohorts are presented in Table 1. Th e 
percentages of UA patients that developed RA within the fi rst year were 32%, 48% and 12% in the 
Leiden EAC, Berlin EAC and NOR-VEAC respectively. 
First, the predictive values for high RF levels and presence of ACPA antibodies were deter-
mined for each cohort separately (Table 2). Increasing the cutoff  value for a high RF level yielded 
an increased PPV and decreased NPV. Similarly, the specifi city increased but the sensitivity 
decreased. For example, in the Leiden EAC data, the PPV increased from 62% (RF positivity) 
to 69% (three times the reference value) and 72% (RF50) and the NPV decreased from 78% to 75 
% and 71% respectively. Also, the specifi city increased from 86% (RF positivity) to 93% (three 
times the reference value) and 97% (RF50) but the sensitivity decreased from 48% to 33% and 14% 
respectively. In addition, the LR+ increased at the expense of an increased LR-. Th is indicates 
that the odds on RA increased in case of a high RF level, but that the odds on RA in case of 
the absence of a high RF level increased as well. Th e percentage of UA patients that had a high 
RF level was 15% (three times the reference value) or 6% (RF50) compared to 25% that was RF 
positive. Th e observed eff ects were comparable for all three cohorts (Table 2).
Second, the results for a high RF level were compared to that of ACPA positivity. In all three 
cohorts, the 95% confi dence intervals (95% CI’s) overlapped. Nevertheless the balance between 
PPV (preferably high) and NPV (preferably high) tended to be better for ACPA than for high 
level RF. In addition, the balance between LR+ (preferably high) and LR- (preferably low) was 
better for ACPA presence than for high RF level in all three cohorts. Th ese eff ects were less 
compelling in the NOR-VEAC than in the Berlin EAC and Leiden EAC. However, the fi ndings in 
the NOR-VEAC are more diffi  cult to interpret because of large confi dence intervals. Th ese larger 






Age at inclusion, (yrs) 51.0 (16.9) 51.2 (14.5) 46.1 (14.5)
Female, N (%) 368 (58.9) 110 (71.9) 114 (59.1)
Symptom duration at fi rst presentation, 
days 170 (181) 137.4 (96.1) 35 (30)
Swollen joint count 5.5 (6.0)§ 2.7 (4.5)‡ 3.9 (6.8)£
CRP (mg/l), median (IQR) 17.0 (7.0-43.0)$ 6.2 (2.0-16.8)¥ 14.0 (5.0-32.0)$
RF positive, N (%) 154 (24.7) 79 (51.3) 18 (9.3)
ACPA-positive, N (%) 149 (23.9) 44 (28.6) 19 (9.8)
Values are the mean ± SD except where indicated otherwise. CRP: C-reactive protein; SJC: swollen joint count; 
§44 swollen joint count; ‡28 swollen joint count; £66 swollen joint count; $Used cutoff  for abnormal CRP ≥10 
mg/l; ¥Used cutoff  for abnormal CRP >5 mg/l; RF = rheumatoid factor; ACPA = antibodies to cyclic citrullinated 
peptide
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confi dence intervals may be related to the low percentage of UA patients with a high RF level in 
this very early cohort (3% for three times the reference value and 5% for RF50). When arthritis 
persistency was used as outcome measure instead of RA development comparable observations 
were made (Supplementary Table 1). 
Subsequently, the additive value of performing a second autoantibody test was investigated 
for predicting RA development. In other words, the additive value of performing an ACPA test 
in UA patients without high level RF was determined, as well as the additive value of testing RF 
levels in ACPA negative UA patients. As shown in Table 3, the PPVs and NPVs of performing 
an ACPA test in patients without a high level RF were about twice as large compared to the 
PPVs and NPVs of RF level testing in ACPA negative patients. Th is observation was done for 
diff erent defi nitions of high level RF and in the diff erent cohorts. Th e LR+ for additional ACPA 
testing in patients without a high level RF ranged between 3.6 and 12.4 and the LR- ranged 
between 0.63 and 0.77 in the Leiden and Berlin EACs. RF level testing in ACPA negative patients 
resulted in marginal LR+ and LR- (around 1) in these cohorts. Th is contrast was less evident in 
the NOR-VEAC but also here the number of ACPA negative UA patients that developed RA that 
had high levels of RF was very low (n=1). Overall, for the prediction of RA development in early 
UA patients, performing an ACPA test in addition to a RF level testing seems more valuable than 
determining the RF level aft er assessments on the presence of ACPA antibodies. 
Severity of disease course in RA patients
Th e predictive ability for the severity of RA was assessed and compared for high level RF and 
presence of ACPA. Th e rate of joint destruction for patients with high RF levels (both for RF50 
and three times the reference value) and ACPA positive RA patients are depicted in Figure 2A. To 
compare the eff ect sizes of the three groups, the estimates obtained from the repeated measure-
ment analyses performed on log-transformed data were back-transformed to the original scale. 
Th is yielded a 1.13, 1.05 and 1.04 times greater progression rate per year for the presence of 
ACPA, three times the reference value of RF and RF50 respectively compared its the absence. 
Over a total followup period of seven years this resulted in 2.41 (95%CI 2.06-2.83, p<0.001), 1.45 
(95%CI 1.24-1.70, p<0.001) and 1.29 (95%CI 1.05-1.59, p=0.015) times larger progression rates 
for ACPA, three times the reference value of RF and RF50. 
To further substantiate the fi ndings on RA severity, the analyses were performed with the 
achievement of sustained DMARD-free remission as outcome (Figure 2B). Presence of ACPA or 
high RF levels was associated with a worse disease outcome, refl ected by an increased hazard ratio 
(HR) for not achieving DMARD-remission. Th e observed HRs for not achieving DMARD-free 
remission were respectively 11.3 (95%CI 5.6-22.7, p<0.001), 5.7 (95%CI 2.9-11.4, p<0.001) and 
3.1 (95%CI 1.2-7.6, p=0.016) for ACPA, three times the reference value of RF and RF50. Similar to 
joint destruction, the eff ect sizes for high level RF (RF50 as well as three times the reference value) 
were lower than that for the presence of ACPA antibodies.
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Variation in RF measurements
In order to evaluate whether and to what extent the method of measuring the RF level infl uences 
the test outcomes, the RF levels determined in the same serum samples by diff erent methods 
were studied. Th e serum levels measured are shown in Figure 3A. Large variation in absolute 
levels was observed. In general the highest levels were measured by nephelometry, followed by 
turbidimetry and the lowest levels were measured by ELISA. Th e correlation coeffi  cient between 
the absolute levels determined by nephelometry and ELISA was 0.470 (p=0.007), between neph-
elometry and turbidimetry was 0.531 (p=0.002) and between ELISA and turbidimetry was 0.402 
(p=0.022). Since the two RF-positive sera used contained high RF levels, all of the measurements 
done by nephelometry and turbidimetry had an absolute RF level >50 Units. With ELISA, a 
measurement of <50 Units was found once. Figure 3A illustrates the large variation in measure-
ments that is observed when local units are used. 
Expressing the data as a ratio in relation to the local cutoff  did not improve the variation within 
and between methods (Figure 3B). Th e correlation coeffi  cient between these ratios was 0.288 
(p=0.11) for nephelometry and ELISA, 0.443 (p=0.011) for nephelometry and turbidimetry and 
0.302 (p=0.093) for ELISA and turbidimetry.
To investigate whether expression of RF level in relation to a standard reference serum would 
increase the reproducibility of results between laboratories and between methods, the absolute 
levels of the two patient sera were divided by the RF levels obtained for the standard serum 
(RELARES). Although the variance within the methods decreased, the variability between meth-
Figure 2. Comparison of high level RF and ACPA for outcome of disease severity in RA patients. Association of 
outcome with positive (versus negative) test results for two diff erent high level RF cutoff s and ACPA. (A) Sharp/
van der Heijde scores for radiographic progression over 7 years of followup (mean (±SEM)). (B) Achievement 
of DMARD-free remission. In A, the numbers of patients in each group were as follows: for RF15-positive and 
negative, n=378 and n=271 respectively, for RF50-positive and negative, n=123 and n=526 respectively and for 
ACPA positive and negative, n=342 and n=289 respectively. In B, the numbers of patients in each group were 
as follows: for RF15-positive and negative, n=370 and n=252 respectively, for RF50-positive and negative, n=122 
and n=500 respectively and for ACPA positive and negative, n=336 and n=270 respectively. RF15: three times the 
standard cutoff  of 5.0; RF50: cutoff  of 50.0 U/ml; ACPA: cutoff  of 25.0 arbitrary units
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ods was still considerable (Figure 3C). Here, the correlation coeffi  cients were 0.469 (p=0.008) 
between nephelometry and ELISA, 0.452 (p=0.012) between nephelometry and turbidimetry, 
and 0.537 (p=0.002) between ELISA and turbidimetry. As is shown, this eff ort did not lead 
to harmonization and refl ects the diffi  culty with using standard sera to homogenize RF level 
measurements.
DISCUSSION 
Detailed knowledge of the individual characteristics of the 2010 ACR/EULAR criteria is neces-
sary to optimally use these criteria in daily clinical practice. Th e characteristics of the “low-
positive RF” versus “high-positive RF” seem to hamper uniform application of the 2010 ACR/
EULAR criteria. 
Figure 3. Comparison of RF measurements between diff erent detection methods and diff erent test facilities in 
samples positive for RF. Each dot represents a single measurement for a sample observed in a separate test facility. 
Horizontal bars refl ect the median. (A) Units were measured in U/ml for ELISA, in kU/l for nephelometry and 
in IU/l for turbidimetry. Th e dashed line at 50 units represents the cutoff  value of RF50, the defi nition of a high 
RF level that is used in literature.5,6 (B) Th e number of units determined by each method of measurement 
divided by the corresponding cutoff  value. Th e dashed line at a ratio of 3 represents three times the reference 
cutoff  value, the defi nition of a high RF level that is used in the 2010 ACR/EULAR criteria.4 (C) Th e number 
of units determined for each method of measurement divided by the level obtained for the standard serum 
(RELARES) in the corresponding test facility
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Th e test characteristics and prognostic ability of high RF levels and the presence of ACPA 
were compared in early UA patients. Th e data, originating from three cohorts, revealed that the 
balance between LR+ and LR- as well as between PPV and NPV was more favorable for ACPA 
positivity than for high level RF. Th is fi nding was made with regards to diagnosing RA and hav-
ing persistent arthritis. Th e same observations were done when the severity of the course of RA 
was studied, which substantiated the fi ndings. 
Th e main outcome measure used in the current study was the development of RA by fulfi lling 
the 1987 ACR criteria for RA. An advantage of these criteria is that they could be uniformly 
applied in the diff erent cohorts in Germany, Norway and the Netherlands. In the light of the 
new 2010 ACR/EULAR criteria however, this outcome measure may seem an outdated defi ni-
tion of RA. Obviously, the 2010 ACR/EULAR criteria can not be used for the purpose of the 
present study because of circularity; both the presence of ACPA and RF level are part of these 
criteria. Usage of MTX treatment as outcome measure, such as done when deriving the 2010 
ACR criteria for RA, has limitations as well. UA patients in the Leiden cohort were included since 
1993 and at that time DMARDs were infrequently prescribed in early UA. Hence diff erences in 
MTX prescription are dependent on the inclusion year, impairing fair comparisons. In addition, 
when prescribed, MTX is used for other diagnoses as well, for example psoriatic arthritis. An 
alternative outcome is the expert’s opinion on the presence of RA. However, the expert opinion 
is likely not independent of the 1987 ACR-criteria for RA. Having worked with the 1987-ACR 
criteria for about twenty years, clinicians may, consciously or unconsciously, refer to these crite-
ria in their judgements. In the present study, comparable observations were done when using RA 
development, arthritis persistency or RA severity as outcome, suggesting that the fi ndings are not 
depending on one outcome measure. 
Two defi nitions of high RF levels were studied in three cohorts. Th e defi nitions were RF50, 
the RF level that in previous publications was labeled as high level, and three times the refer-
ence value, the defi nition of high RF included in the 2010 classifi cation criteria for RA. It was 
observed that the post test probabilities (PPV, NPV) varied between the cohorts. For example 
the NPV was the highest in the NOR-VEAC and the lowest in the Berlin EAC. Th ese values are 
infl uenced by diff erent percentages of UA patients that developed RA during the observation 
period (the pretest probability). On the other hand, despite this diff erence, the same tendency in 
the level data with high RF compared to ACPA positivity was seen, strengthening the fi ndings. 
Th e sensitivities and specifi cities for high RF levels diff ered between the cohorts as well. Th is 
may partly be due to the diff erent cutoff  levels used to defi ne RF positivity. Subsequently, RF50 
may be a twofold increase compared to the cutoff  in some cohorts (as was the case in the Berlin 
EAC and the NOR-VEAC) but it may present a tenfold increase when other methods are applied 
(as was the case in the Leiden EAC). Although this argument may apply to a lesser extend to the 
three times the reference value defi nition for high level RF, also here the stringency with which 
the reference value was chosen (manufacturer instructions or according to in house reference 
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groups) aff ect the test characteristics of this variable. Th e diff erences in test characteristics of the 
presence of ACPA were smaller than for RF level.
Another factor that may contribute to diff erences in measured RF levels and diff erences in 
resulting test characteristics are the diff erent techniques that can be used to measure RF. Here 
in all cohorts ELISA’s were used. Generally for each technique, several variants are prevalent, 
among which both in house and commercially available kits. Th e manufacturers of these com-
mercially available tests have not provided a 100% standardization of these kits to a reference kit 
with regards to detection and quantization of RF. Previously International Units/ml have been 
established but this method only yields standardized results in case the Boehringer nephelometer 
is used. Th e prevalent methods also diff er with regard to the origin of the antibodies that are 
directed against RF (human or rabbit) and the isotypes of the antibodies that are tested. Neph-
elometry usually measure complexes of IgM-, IgG- and IgA-RF, whereas ELISAs are specifi cally 
directed against one isotype, for instance IgM-RF. 
Appropriate and uniform application of the RF level criterion of the 2010 criteria for RA re-
quires harmonization of all available RF tests. Eff orts to harmonize RF determinations have been 
done by Dutch and European task forces. In the Netherlands this was done by the development 
of a standard serum consisting of pooled serum of RF-positive patients (RELARES). However, as 
reported, this did not result in better reproducibility between laboratories. Considerable variabil-
ity was still observed, not only between various methods - ELISA, nephelometry and turbidim-
etry - for determining RF, but also within each method for diff erent laboratories. Considering 
the present diffi  culties it is not feasible that worldwide harmonization will be achieved in a short 
term for measuring RF. Th is study did not address the possibility to harmonize anti-CCP level 
measurements. In our experience, harmonizing ACPA measurements may be less complicated 
(data not shown). Th erefore, supposed that a modifi cation of the 2010 ACR/EULAR criteria will 
arise in time, we propose to omit the RF level and use only ACPA, with diff erent weighed scores 
for positivity and level.
In conclusion, defi ning a high level of RF is intricate due to the variation in RF levels obtained 
when diff erent methods are applied. Th is problem hampers uniform application of the 2010 ACR/
EULAR criteria for RA. Th e data of the present study revealed that the overall prognostic ability 
of ACPA positivity outweighs that of high level RF in UA patients. For this reason we suggest 
that in a future modifi cation of the classifi cation criteria for RA the RF level is not incorporated 
in contrast to ACPA determination.
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Identifi  cation of CXCL13 as marker for 
outcome of rheumatoid arthritis using 
an in silico model of the rheumatic joint
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Rheumatoid arthritis (RA) is characterized by infl ammation and destruction of joints. Th e 
amount of damage is highly variable between RA patients. Prediction of the disease severity 
using known clinical and serological risk factors is inaccurate. Here we aimed to identify new 
serological markers for RA severity using an in silico computer model of the rheumatic joint.
Methods
An in silico computer model of a prototypical rheumatic joint predicted candidate markers 
associating with erosiveness. From a broader set of candidate markers, four were progressed 
for validation: Trap5b, NTX, Ang-2 and CXCL13. Serum of 74 RA patients was used to study 
whether radiological joint destruction (total erosion score (ES) and total Sharp/van der Heijde 
score (SHS)) aft er 4-years of disease associated with serum levels at the time of diagnosis. Serum 
marker levels were determined using ELISAs. For confi rmation, baseline serum levels were 
studied for an association with progression of joint damage over seven years of follow-up in a 
cohort of 155 early RA patients. 
Results
Comparison of high and low quartiles of ES and SHS at 4-years showed a diff erence in baseline 
CXCL13 serum level (p=0.011 and p=0.018 respectively). In the confi rmation cohort, elevated 
baseline CXCL13 levels associated with increased rates of joint destruction during 7 years 
follow-up, without (p<0.001) and with (p<0.005) adjustment for CRP levels. Analyzing anti-
CCP2-positive and anti-CCP2-negative RA separately yielded a signifi cant result only in the 
anti-CCP2-negative group (p<0.001).
Conclusion
CXCL13 is a novel serological marker predictive for RA severity. Th is marker was identifi ed with 
the help of an in silico model of the RA joint.
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INTRODUCTION
Th e perspectives of patients with rheumatoid arthritis (RA) have improved by treatment strate-
gies with tight disease control and the availability of new potent biological agents. In order to 
balance the risks of overtreatment, inducing unnecessary costs and toxicity, and undertreatment, 
leading to joint destruction that could have been prevented, it is of utmost importance to be able 
to predict the disease outcome for each patient. At present several markers linked to a severe 
course of RA are extensively reported on, such as multiple swollen joints at disease onset, rela-
tively high baseline C-reactive protein levels, presence of anti-cyclic citrullinated protein (CCP) 
antibodies, rheumatoid factor (RF) and erosions at baseline.1-3 Several attempts have been made 
to derive adequate prediction models or prediction matrices using these risk markers, but in all 
cases only less than 50% of the patients could actually be classifi ed.4-6 Th is indicates that the cur-
rently used risk factors do not allow adequate prediction for individual patients. Th is, together 
with the fact that the severity of the disease course is highly variable between patients, underlines 
the importance to identify new markers for disease outcome in RA.
Th e severity of RA can be measured objectively by levels of joint destruction on radiographs of 
hands and feet using validated scoring methods. It refl ects the cumulative burden of infl amma-
tion over time, and strongly correlates with joint functionality and subsequent disability. Several 
attempts to predict the radiological damage using serological markers have been made in the last 
few years. Examples are OPG, RANKL and MMP3 that are all primarily markers that refl ect joint 
tissue remodeling. Th e baseline OPG/RANKL ratio was observed to be an independent predictor 
for the level of joint destruction later in the disease course.7 Such an association is reported 
for baseline MMP3 levels as well, although its association was dependent on a correlation with 
traditional risk factors such as anti-CCP antibodies.8 Importantly, a recent study indicated that 
these factors insuffi  ciently account for radiological joint damage.9 Th is underlines the value of 
new serological markers.
Th e present study aimed to identify new serological markers that are predictive for the severity 
of the disease course of RA. A computer model representing the biology of the rheumatic joint 
was used to select candidate markers for bone erosiveness. Th ese markers were tested in baseline 
serum of RA patients with 4-years radiological data in order to study for an association in vivo. 
A second cohort of RA patients with long-term follow-up data was used in order to confi rm the 
predictive ability of these markers for the disease outcome of RA, measured by the rate of joint 
destruction as well as the chance of sustained DMARD-free remission. 
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PATIENTS AND METHODS
Identifi cation of markers
In silico model 
An in silico computer model of a prototypical articular joint in a patient with RA was created 
previously (Rheumatoid Arthritis (RA) PhysioLab® platform, Entelos, Foster City, CA, USA).10,11 
Th is RA PhysioLab platform represents the biology behind RA on the level of synovial tissue 
infl ammation, cartilage destruction and bone erosion. Th e model integrates relevant in vitro 
and clinical data into a computer-based platform to reproduce disease characteristics of RA. 
When run, the model simulates disease or biological response to treatment in a prototypical 
joint representative of aff ected joints of RA patients. Th e platform models the life cycle of 
infl ammatory cells, endothelium, synovial fi broblasts, chondrocytes, and bone cells, as well as 
their products and interactions. During simulation experiments with the computer model the 
interplay between these cells and processes result in a reproduction of RA disease characteristics: 
self-perpetuating infl ammation and breakdown of cartilage and bone. Th ese characteristics are 
represented by numerical read-outs in the model that closely resemble accepted read-outs in 
the clinic, such as ACR-response, DAS28 and bone erosion progression rate. For example, bone 
erosion is computed as the net loss of bone volume due to bone synthesis and resorption, which 
in turn depend on density and activation state of osteoblasts and osteoclasts. Computed treat-
ment responses are in line with clinically observed responses.11 RA is a multi-factorial disease 
with a heterogeneous manifestation. To capture this heterogeneity the computer model uses 
the Virtual Patient concept. Diff erent settings for selected (combinations of) model parameters 
are used in parallel for the simulations. Th is results in a range of disease activities and therapy 
outcomes. Every combination of such pre-defi ned parameter sets represents a Virtual Patient 
(VP). Examples of these settings are an increased production rate of TNFα by TNFα producing 
cells or a decrease of the eff ect of MTX on MTX-sensitive pathways in the model (see reference 
for a more detailed description).12 We used RA PhysioLab version 3.2 and a set of 120 distinct 
VPs to predict candidate serological markers associating with localized bone loss, representing 
erosiveness. Th erefore erosiveness is the main outcome measure used in this study. Since the 
erosion score is part of the Sharp/van der Heijde score, the method used to score radiological 
joint damage, the total SHS is assessed as well.
Patients
Discovery cohort
Patients included in the BeSt cohort for whom baseline serum was available were used to test 
the association of serological markers with the level of joint destruction at 4 years of followup 
(total erosion score (ES) and total Sharp/van der Heijde score (SHS)) (n=74). Th e BeSt-cohort (a 
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Dutch acronym for “Behandel Strategieën”, treatment strategies), included patients with recent-
onset RA with a disease duration of 2 years or less that were randomly allocated to one of four 
treatment groups with diff erent DAS-guided combinations and applications of DMARDs.13 At 
the time this study was initiated, the four years of follow-up was the maximal available follow-
up duration. Applied treatments consisted of sequential disease-modifying antirheumatic drug 
monotherapy (group 1), step-up combination therapy (group 2), initial combination therapy 
with tapered high-dose prednisone (group 3), and initial combination therapy with the tumor 
necrosis factor antagonist infl iximab (group 4) respectively. 
At baseline blood samples were taken for routine diagnostic laboratory screening and serum 
was stored at -70 °C. Th ere were no signifi cant diff erences between baseline patient character-
istics of patients with and without serum data available, apart from slightly higher numbers of 
swollen joints in the group with missing data (data not shown). All 4-years radiographs were 
scored independently by two trained readers blinded to the patient’s identity, treatment group 
and sequence of the fi lms. Th e mean score of the two readers was used for the analysis. Th e 
interobserver correlation coeffi  cient (ICC) was 0.96.14 
Confi rmation cohort
Th e second set of RA patients was used to confi rm fi ndings between serological marker and 
severity of the disease course. Th is set comprised 155 early RA patients that were included in the 
Leiden Early Arthritis Clinic (EAC) cohort between 1993 and 2006 and for whom both baseline 
serum as well as yearly taken radiographs were available. No signifi cant diff erences were observed 
between baseline patient characteristics of patients with and without serum available (data not 
shown). Th e Leiden EAC is a large prospective cohort as previously described.15 Patients were 
referred by general practitioners when arthritis was suspected and included in the EAC cohort 
if arthritis was confi rmed at physical examination and symptom duration was less than 2 years. 
At inclusion, patients were inquired about their joint symptoms and subjected to a physical 
examination. At baseline blood samples were taken for routine diagnostic laboratory screening 
and serum was stored at -20 °C (start of the cohort) or -70 °C. Th e EAC patients studied were not 
included in the BeSt cohort.
Radiographs of hands and feet were taken at baseline and consecutive years and were scored 
chronologically by an experienced reader (MPMvdL) as previously described.16 ICCs were 0.91 
for all radiographs, 0.84 for baseline radiographs, and 0.97 for the radiographic progression rate. 
To encompass a reliable sample size, radiographic follow-up data were restricted to a maximum 
of 7 years. As mentioned, the total erosion score (ES) was the main outcome measure; in addi-
tion, the total SHS was assessed. Th e present study had a power of 96% to detect a diff erence of 
15 SHS points (SD25) at the seven year time point with an alpha of 0.05. Disease remission was 
assessed as a second outcome measure in order to further substantiate the fi ndings. Remission 
was defi ned in its most stringent form as the persistent absence of synovitis for at least one year 
aft er cessation of DMARD therapy and the identifi cation of remission by the patient’s rheu-
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matologist.17 Th e remission status could be reliably ascertained in 152 out of 155 RA patients. 
Most patients who achieved remission had a follow-up monitoring for longer than the minimally 
required 1 year; the median time of observation aft er discontinuation of DMARDs was 2.5 years.
Biomarker measurement
Serum measurements for biomarker levels in both independent patient cohorts were performed 
by ELISA according to the manufacturers’ instructions. Measured biomarkers were cross-linked 
N-teleopeptide of type I collagen (NTX) (Osteomark Ntx, Unipath Limited, Bedford, United 
Kingdom, 1:5 dilution), Tartrate-resistant acid phosphatase (TRAP) 5b (BoneTRAP® Assay SB-
TR201A, Immunodiagnostic Systems (IDS) Ltd., Boldon, United Kingdom), Angiopoietin 2 (1:3 
dilution) and Chemokine (C-X-C motif) ligand 13 (CXCL13) (both R&D systems, Minneapolis, 
MN, USA). 
Statistical analysis
RA PhysioLab platform 
RA PhysioLab version 3.2 was used for the simulations. Th e patient cohort consisted of 120 
Virtual Patients (VPs) with diff erent underlying pathophysiologies. Data for all VPs were ana-
lyzed aft er simulation of 1 year untreated disease. Erosiveness in each VP was determined by the 
volume of bone loss during the period of simulation. Th e bone loss values were categorized in 
quartiles and the lowest and highest quartile were compared. In total 150 simulation variables, 
including the concentrations of all mediators, were investigated for association to erosiveness. 
For the statistical analysis, Student’s t, Wilcoxon rank sum and Kolmogorov-Smirnov from R 
version 2.4.1 were used.
Discovery cohort
To investigate whether the in silico model accurately predicted that erosiveness during the dis-
ease course was associated with baseline biomarker serum levels, the 4-years ES and SHS scores 
were categorized into quartiles. Th e lowest and highest quartiles were compared for diff erences 
in baseline serum level using the Mann-Whitney U test. In addition, in all RA patients the cor-
relations between ES and SHS on a continuous scale and the serum levels were assessed using a 
non-parametric Spearman correlation test and a linear regression analyses on log transformed 
radiological data with adjustment for treatment strategy (randomization arm). 
Confi rmation cohort
Th e association between baseline CXCL13 serum levels and the rate of joint destruction during 7 
years of follow-up was assessed using a repeated measurement analysis on log-transformed radio-
logical data, correcting for age, gender and applied treatment strategy as previously described.16 
Th e repeated measurement analysis is performed using a multivariate normal regression model 
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that, on longitudinal data, evaluates the progression rates over time and takes into account the 
correlation between the measurements within one subject. In order to test whether biomarker 
levels were associated with joint destruction independent of infl ammation, adjustments for C-
reactive protein (CRP) were made as well. To test for associations between baseline CXCL13 
levels and baseline clinical characteristics, analyses were performed using the non-parametric 
Spearman correlation test. 
Analysis of sustained DMARD-free remission was performed by comparing Kaplan Meier 
curves and by Cox regression analysis, correcting for age and gender, taking into account the dif-
ferences in follow-up times among patients. For patients who achieved remission, the dependent 
variable was “time-to-event”, indicating the time until reaching remission. For non-remission 
patients the time to last follow-up was used. 
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used. P-values <0.05 were considered 
signifi cant. All reported p-values are two-sided. 
RESULTS
RA PhysioLab prediction results
Aft er simulation of one year of untreated disease the virtual patient cohort was categorized on 
a numerical read-out representing erosiveness. For the identifi cation of candidate biomarkers 
we focused on model variables related to proteins for reasons of biomarker detection feasi-
bility. Other variables like those related to cell densities were not taken into account for the 
analyses. We identifi ed a set of proteins of which the concentrations were signifi cantly diff erent 
between the lowest and highest erosiveness quartiles in each of three statistical tests (Student’s 
t, Wilcoxon rank sum, Kolmogorov-Smirnov; p-value < 0.0001). Four of these mediators were 
selected for follow-up: Ang-2, NTX, Trap5b and CXCL13. Selection of these 4 mediators was 
based on pragmatic criteria: assay availability and presence (NTX, Trap5b) or absence (Ang-2, 
CXCL13) of supportive literature linking the protein to bone erosion. Th e ability of CXCL13 to 
diff erentiate between high and low erosive virtual patients is illustrated in Figure 1. In the RA 
PhysioLab platform, most mediators are tracked as synovial quantities. For the four mediators 
selected transport between synovium and serum is modeled only for NTX. For Ang-2, Trap5b 
and CXCL13 the diff erence in mediator concentration between the erosiveness quartiles relates 
to synovial tissue concentrations; for NTX to synovial tissue and serum concentration.
Identifi cation and replication in two independent cohorts
Baseline characteristics
Baseline characteristics of the two sets of RA patients are presented in Table 1. 
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Discovery cohort
To study the results on markers and erosiveness predicted by the in silico model for an association 
in vivo, baseline serum levels for four biomarkers predicted in silico were determined. Th e mean 
(SD) levels were 4658.4 (1596.0) pg/ml, 51.9 (24.5) nM BCE/l, 2.19 (1.14) U/l and 166.7 (86.0) 
pg/ml respectively for Ang-2, NTX, Trap5b and CXCL13.
Figure 1. Boxplots of simulated synovial concentrations tested across 120 distinct Virtual Patients. For each 
mediator the synovial concentrations (ng/ml) are shown in the low and high erosive groups as defi ned in the 
text. Th e box indicates the lower and upper quartiles, the whiskers extend to the most extreme data point which 
is no more than 1.5 times the interquartile range from the box





Age at inclusion (yrs), mean (SD) 53.5 (14.4) 56.4 (13.6) 0.232
Female, N (%) 45 (60.8) 108 (69.7) 0.184
SJC, mean (SD) 9.27 (3.89) 8.95 (6.78) 0.107
CRP (mg/l), mean (SD) 32.0 (40.0) 31.0 (36.5) 0.774
Anti-CCP2-positive, N (%) 42 (56.8) 89 (58.2) 0.840
CRP: C-reactive protein; SJC: 66-swollen joint count. Th e p-value refl ects if both cohorts are signifi cantly 
diff erent for the indicated variable
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To analyze whether these biomarkers accurately predicted that erosion scores and the total 
level of joint destruction during the disease course were associated with baseline serum levels, 
the lowest and highest quartiles of 4-years erosiveness were studied in relation to the mark-
ers’ serum levels (Table 2). Th is revealed a signifi cant diff erence for CXCL13 (p=0.011 for the 
total erosion score (ES) and p=0.018 for the total Sharp/van der Heijde score (SHS). Similarly, 
signifi cant correlations between the CXCL13 levels and the ES (p=0.022, ρ=0.267) and the SHS 
(p=0.014, ρ=0.286) were observed when performing the analysis on continuous data of all RA 
patients. In addition, analyzing joint destruction data in all RA patients using linear regression 
analysis revealed that baseline CXCL13 levels remained signifi cantly associated with the 4-year 
ES and SHS (β=1.002 (95%CI 1.000-1.005), p=0.049 and β=1.002 (95%CI 1.000-1.005), p=0.033 
respectively) aft er adjustment for treatment strategy. For Ang-2, NTX and Trap5b, no signifi cant 
associations were observed (Table 2). Taken together these data indicate that out of 4 serum 
markers predicted by the in silico model one marker was actually observed to associate with joint 
destruction in patients using the analysis workfl ow described.
















1st quartile 4361.2 (1401.9) 48.47 (16.41) 2.45 (0.94) 137.7 (80.4)
4th quartile 5286.8 (1611.8) 62.89 (40.66) 2.61 (1.41) 189.8 (66.1)






1st quartile 4444.0 (1606.7) 51.61 (15.64) 2.41 (0.99) 139.6 (80.6)
4th quartile 5279.2 (1634.5) 55.83 (23.23) 2.08 (1.32) 186.9 (64.9)
p-value 0.190 0.800 0.373 0.018
ES: Erosion score; SHS: Total Sharp-van der Heijde score. Note that the SHS is composed of erosion and joint 
space narrowing scores. Diff erences in levels between quartiles 1 (low) and 4 (high) were compared using the 
non-parametric Mann-Whitney U test
Confi rmation cohort
For confi rmation, baseline serum CXCL13 levels were measured in a second set of patients, yield-
ing a mean concentration of 155.5 (98.9) pg/ml. Baseline serum levels were categorized as low or 
high based on quartile distribution and were studied in association with the rate of progression 
in joint destruction over 7 years. Using repeated measurement analysis, higher CXCL13 levels 
associated with signifi cantly higher progression rates in ES (p<0.001) as well as in SHS (p<0.001; 
analyses performed on log-transformed data) (Figure 2). For the erosion score, the increase per 
year in the original scale was 1.12, 1.08 and 1.18 times greater for CXCL13 quartiles 2, 3 and 4, 
respectively, than for quartile 1. For the total SHS, a 1.11, 1.09 and 1.18 times greater increase 
per year was observed compared to the lowest quartile. Over a period of 7 years this resulted in 
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2.2 (95%CI 1.5-3.3), 1.8 (95%CI 1.2-2.6) and 3.1 (95%CI 2.1-4.7) times larger progression rates 
for the ES and 2.1 (95%CI 1.4-3.3), 1.9 (95%CI 1.2-2.8) and 3.2 (95%CI 2.1-4.9) times larger 
progression rates for the SHS. Since categorical analysis generally results in less discriminative 
ability, the CXCL13 level was also included in the repeated measurement analysis as a continuous 
variable. Also here, higher CXCL13 levels associated signifi cantly with higher progression rates 
of ES and SHS (both p<0.001). Th is analysis was also used to determine the variance explained 
by CXCL13. Th is showed that 7% of the total variance in progression in ES was explained by 
CXCL13.
Clinical associations of CXCL13
To study clinical factors that possibly infl uenced the observed association of CXCL13 with 
the rate of joint destruction in the confi rmation cohort, baseline patient characteristics were 
analyzed in relation to baseline CXCL13 serum levels. Signifi cant correlations were found for 
CXCL13 level and CRP level (p<0.001, ρ=0.429), ESR level (p=<0.001, ρ=0.300) and the number 
of swollen joints (p=0.023, ρ=0.255). In addition, mean CXCL13 levels were signifi cantly higher 
in serum samples from anti-CCP2 positive patients than anti-CCP2 negative patients (172.0 
(104.7) pg/ml vs.134.8 (87.3) pg/ml, p=0.008). Similar results were observed for IgM-RF, yielding 
levels of 172.9 (104.8) pg/ml vs. 120.2 (77.7) (p<0.001) for IgM-RF positive compared to IgM-RF 
negative patients respectively. 
Figure 2. CXCL13 level and progression in radiographic joint damage in RA patients in the confi rmation 
cohort. Erosion (panel A: ES) and Sharp/van der Heijde (panel B: SHS) scores (n=155). Th e number of patients 
and levels (mean (SD)) for CXCL13 were n=37, 59.2 (15.9) pg/ml, n=40, 107.6 (13.8) pg/ml, n=39, 158.9 (17.4) 
pg/ml and n=39, 292.3 (90.9) pg/ml for quartiles 1, 2, 3 and 4 respectively
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CXCL13 in relation to other serological markers
It was studied whether CXCL13 serum levels associated with ES and SHS independently of the 
known serological markers CRP and anti-CCP2. First CRP was entered as adjustment variable in 
the repeated measurement analysis. Also here CXCL13 was signifi cantly associated with the ES 
(p=0.001) and the SHS (p=0.004). In addition, since anti-CCP2 positive and anti-CCP2 negative 
RA are considered to be separate subsets of the disease with diff erences in underlying pathogen 
mechanisms, the mentioned analyses were repeated in the anti-CCP2+ and anti-CCP2− subsets. 
In anti-CCP2 negative patients, high CXCL13 levels were also signifi cantly associated with larger 
ES and SHS progression rates (p<0.001 and p=0.001 respectively). Aft er adjustment for CRP 
level, the association remained signifi cant for the ES (p=0.002), but signifi cance was lost for the 
SHS (p=0.10). In anti-CCP2 positive patients no associations were observed for either the ES or 
SHS (data not shown).
Sustained DMARD-free remission
To further substantiate the CXCL13 fi ndings we investigated a diff erent outcome measure for RA 
severity and studied the eff ect of CXCL13 level on the achievement of DMARD-free remission. 
In addition to an observed association of CXCL13 levels and joint damage, comparison with the 
achievement of remission showed that higher CXCL13 levels were associated with signifi cantly 
lower chances of achieving remission. Compared to the fi rst quartile CXCL13, hazard ratios of 3.3 
(95%CI 1.0-11.1) (p=0.049), 4.1 (95%CI 1.1-14.8) (p=0.034) and 6.3 (95%CI 1.4-29.2) (p=0.019) 
for not achieving remission were observed for the 2nd, 3rd and 4th quartile of CXCL13 respectively 
(Figure 3). With an additional adjustment for CRP, the hazard ratios were respectively 4.1 (95%CI 
0.8-21.2), 2.6 (95%CI 0.7-10.2) and 2.6 (95%CI 0.7-9.0). Because only 3 patients achieved remis-
sion in the anti-CCP2 positive RA group, no stratifi ed analysis was performed here.
Figure 3. CXCL13 level and cumulative DMARD-free remission in RA patients in the replication cohort. Th e 
number of patients and levels (mean (SD)) for CXCL13 were n=35, 60.0 (15.9) pg/ml, n=39, 107.2 (13.7) pg/ml, 
n=39, 158.9 (17.4) pg/ml and n=39, 292.3 (90.9) pg/ml for quartiles 1, 2, 3 and 4 respectively. In total 19 patients 
achieved DMARD-free remission
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DISCUSSION
Th e heterogeneous nature of RA severity is presently incompletely understood and hampers 
accurate disease prognoses on the individual patient level. Th is underlines the need for new 
disease markers with improved prognostic potential of marker sets in order to guide adequate 
treatment regimes. Also, exploration of new markers will enhance our understanding of involved 
pathophysiological processes. Exploration of suitable new markers was initiated by candidate 
marker prediction using the RA PhysioLab computer model of the rheumatic joint. Th e value 
of PhysioLab simulation approaches has been shown previously in RA11 as well as in other dis-
eases.18-20 Th e PhysioLab simulation platform allows to perform question based simulation 
experiments from which the results contribute to hypotheses driven, focused follow-up experi-
mental research. For this approach it is assumed that the scope of the computer model resembles 
real disease and patient population behavior as well as possible. In this study we identifi ed a 
new biomarker, CXCL13, which showed an association between baseline serum level and the 
level of joint destruction at 4 years of disease, thereby validating the association predicted by the 
in silico model. Moreover, in an independent cohort relatively high serum CXCL13 levels were 
also associated with an enhanced progression of the rate of joint destruction over 7 years and 
a decreased chance of achieving DMARD-free remission, thereby confi rming the association 
between CXCL13 and disease severity.
Th e cytokine CXCL13 is also known as B lymphocyte chemoattractant (BLC) or B cell-
attracting chemokine 1 (BCA-1) and is part of the CXC chemokine family. One of the main 
eff ects of CXCL13 implemented in the RA PhysioLab platform is on B cell recruitment, thus 
supporting a mechanism directly dependent on B cells. CXCL13 serum levels were found to be 
signifi cantly higher in the serum of RA patients as compared to healthy controls.21,22 CXCL13 
serum levels were also reported to respond to therapeutic intervention with anti-TNFα therapy.12 
Evidence for joint localization of CXCL13 was found, both by the detection of mRNA in infl amed 
synovial tissue23 as well as the presence of ectopic lymphoid follicles expressing CXCL13 in the 
synovium of chronic RA patients.24 CXCL13 has been reported to attract B lymphocytes and to 
interact with the receptor CXCR5, which is expressed by B cells as well as follicular B helper T 
cells.25-28 High levels of CXCR5 were also found on human osteoblasts and activation by its ligand 
CXCL13 induced the release of extracellular matrix degrading enzymes. As such, CXCL13 may 
play an important role in the process of bone remodeling.29 Th ese data suggest that CXCL13 
may have an eff ect on joint damage in RA that is both dependent and independent of promoting 
eff ects on B cells. 
Since CXCL13 attracts B cells and CXCL13 levels are reported to be higher in autoantibody 
positive RA, which was also observed in the present study, and since anti-CCP2 positive and 
negative RA are subsets of RA with possible diff erences in the pathogenesis, the eff ect of CXCL13 
was evaluated for anti-CCP2 positive and negative RA separately. In the anti-CCP2 negative 
group CXCL13 associated signifi cantly with the progression of joint destruction. Adjustment 
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for baseline CRP levels did not alter this association for the ES, supportive of a CXCL13 eff ect 
on joint destruction that is independent of the level of infl ammation as expressed by the level of 
CRP. In anti-CCP2 positive RA, CXCL13 was not independently associated with progression in 
joint damage. Th us, from a clinical perspective, information on baseline CXCL13 levels seems 
most valuable in the anti-CCP2-negative sub-population of RA patients.
Analysis of the lowest and highest quartiles of erosiveness in the discovery cohort did not 
reveal a signifi cant diff erence for Ang-2. However, when comparing the upper two quartiles with 
the lower two quartiles, a signifi cant diff erence was found for Ang-2 (data not shown). Th is 
indicates that a second candidate marker from the four markers tested might be of interest for 
further exploration. In the RA-PhysioLab platform Ang-2 and CXCL13 both have an eff ect on 
endothelial lifecycle, which aff ects all recruitment processes.
To the best of our knowledge this is the fi rst time that a new serum marker for RA was con-
fi rmed that was initially predicted by a computer model simulation of the rheumatic joint. Th is 
fi nding illustrates that the present computer model has predictive potential and may be applied 
to other disease outcomes. 
Although the results presented in this manuscript provide a solid foundation for our conclu-
sions, this study also has limitations. Both the discovery and confi rmation cohorts consisted 
of a limited number of patients, which may result in limited power to accurately reach proper 
conclusions. As a result only relatively large diff erences in eff ect sizes may be detected and 
smaller eff ects could be missed. A strong association between CXCL13 levels and radiologic 
progression was observed in two separate cohorts. For Ang-2 the evidence is less conclusive than 
for CXCL13. Failure to detect an in vivo association for the other candidate biomarkers that were 
tested (NTX, Trap5b) despite their known association to bone biology could indicate that their 
behavior in a heterogeneous clinical population is not predictive.
Recently, draft  validation criteria for a soluble biomarker to be regarded as a valid biomarker 
refl ecting structural damage in RA have been established.9,30,31 Th ese criteria provide guidance to 
the types of studies needed to demonstrate the value of CXCL13 as a marker in clinical practice. 
Our present data reveal that it is a serological marker with a potent CRP-independent predictive 
value for long-term outcome in RA, thereby providing a rationale for further exploration.
In conclusion, the RA PhysioLab simulation platform has helped in the identifi cation of 
CXCL13 as a new serological marker for severity of RA as measured by the long-term joint 
destruction and the achievement of DMARD-free remission in two independent cohorts of RA 
patients.
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Two novel genetic polymorphisms on chromosome 6q23 are associated with susceptibility to 
rheumatoid arthritis (RA). Both polymorphisms (rs6920220 and rs10499194) reside in a region 
close to the gene encoding tumor necrosis factor α-induced protein 3 (TNFAIP3). TNFAIP3 is a 
negative regulator of NFκB and as such involved in inhibiting TNF-Receptor mediated signal-
ling eff ects. Interestingly, the initial associations were detected in patients with long-standing 
RA. However, no association was found for rs10499194 in a Swedish early arthritis cohort. As 
this could be caused by overrepresentation of patients with severe disease in cohorts with long-
standing RA, we analyzed the eff ect of the 6q23 region on the rate of joint destruction.
Methods
Five single nucleotide polymorphisms (SNPs) in 6q23 were genotyped in 324 Dutch patients 
with early RA. Genotypes were correlated to progression of radiographic joint damage for a 
follow-up time of 5 years.
Results
Two polymorphisms (rs675520 and rs9376293) associated with severity of radiographic joint 
damage in ACPA+ patients. Importantly, the eff ects were present aft er correction for confound-
ing factors such as secular trends in treatment.
Conclusions
Our data associate the 6q23 region with the rate of joint destruction in ACPA+ RA.
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INTRODUCTION
Recent whole genome association scans have revealed novel genetic polymorphisms associ-
ated with susceptibility to ACPA+ RA.1,2 Among those, two single nucleotide polymorphisms 
(SNPs), rs6920220 (A allele) and rs10499194 (C allele), were found to independently associate 
with ACPA+ disease. Both SNPs map to a single linkage disequilibrium block spanning ~60 kb 
in a region on chromosome 6q23 that lacks known genes or transcripts. Th e closest genes are 
oligodendrocyte lineage transcription factor 3 (OLIG3) and tumor necrosis factor α-induced 
protein 3 (TNFAIP3). Th e latter is of potential importance to RA pathogenesis, as the protein 
TNFAIP3 acts as a negative regulator of NF-κB.3 So far, however, functional relevance of the 
reported polymorphisms is unknown. 
Rs6920220 was initially identifi ed in ACPA+ RA patients (minor allele OR 1.38) originating 
from the United Kingdom (UK).1 It was further replicated in an extended UK-based case-control 
study.4 Rs10499194 was initially identifi ed in North American ACPA+ patients (the Brigham 
Rheumatoid Arthritis Sequential Study, BRASS; minor allele OR 0.67).2 Replication was suc-
cessful in two additional US cohorts selected from the North American Rheumatoid Arthritis 
Consortium (NARAC). Replication failed, however, in ACPA+ patients of a Swedish population-
based inception cohort (the Epidemiological Investigation of Rheumatoid Arthritis cohort, 
EIRA).2 Th is latter fi nding is of interest, as both BRASS and NARAC are cohorts of patients with 
long-standing RA (mean disease duration BRASS: 15.4 ± 12.8 years;5 NARAC: 14.3 ± 11.1 years).6 
Th e EIRA study, however, was designed to identify incident cases of RA as soon as possible aft er 
disease onset, resulting in an estimated mean disease duration at inclusion of only 10 months.7
Association of a genetic polymorphism in cohorts of patients with longstanding disease but 
absence of this association in an early arthritis cohort led us to hypothesize that the 6q23 region 
would associate with disease severity in ACPA+ patients. Very little information is currently 
available on the eff ects of genetic variation on outcome measures in RA.8 Th erefore, we geno-
typed fi ve SNPs in a Dutch early arthritis cohort (the Leiden Early Arthritis Clinic, EAC) and 
correlated genotyping data to progression of radiographic joint damage for a maximum follow 
up of 5 years.
PATIENTS AND METHODS
Patients
Th e Leiden EAC is a population-based inception cohort that includes patients with self-reported 
symptom duration of ≤2 years.9 DNA samples of 324 patients consecutively included between 
1993 and 2003 were used for analysis. For further details see supplementary fi le 1.
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SNP selection and genotyping
Five SNPs (rs1878658, rs675520, rs9376293, rs10499194 and rs6920220) were selected based 
on a haplotype analysis across the 6q23 locus published previously.2 All SNPs are in imperfect 
linkage disequilibrium to one another (supplementary table 1). Genotyping was performed using 
pre-designed Taqman allelic discrimination probes (Applied Biosystems). Each 384 well plate 
contained 10 ng sample DNA per well and at least 8 negative and 6 positive controls. Genotype 
calls and clusters were manually checked for discrepancies and doubtful calls were rejected. No 
SNP deviated from Hardy-Weinberg equilibrium. Genotyping call rates were 96.5 % (rs1878658), 
98 % (rs675520), 95 % (rs9376293), 94 % (rs10499194), and 98.1 % (rs6920220).
Serology and radiographs
Serum samples were tested for citrulline-specifi c IgG antibodies using a commercially available 
ELISA kit (Immunoscan Mark2, Eurodiagnostica, Th e Netherlands). Radiographs were scored 
according to the Sharp/van der Heijde method10 with known time order by one blinded, inde-
pendent trained reader (supplementary fi le 1).
Statistical analysis
Association between genotypes and radiographic scoring data was analyzed using SPSS version 
16.0 (SPSS Inc., Chicago, IL). P-values <0.05 were considered signifi cant. All p-values reported 
are two-sided.
Two approaches were chosen for statistical analysis. First, the average increase in Sharp/van der 
Heijde scores during the follow-up period was estimated per person by regression analysis. Sub-
sequently, the average increase (slope) of scores per genotype was compared non-parametrically 
using the Mann-Whitney rank-sum test.
We observed an infl uence of the time of inclusion (1993-2003) on the progression of radio-
graphic joint damage refl ecting most likely an improvement of treatment intensity during this 10 
year time period. In order to account for this eff ect, we performed, as a second approach, a mixed 
model analysis described in detail in supplementary fi le 1.
RESULTS
Radiographic scores of 324 Dutch RA patients (181 ACPA+, 143 ACPA-) were available for 
analysis. At least fi ve radiographic follow-up observations were available in 57% of patients. A 
dominant model was chosen for analysis, as the frequency of patients homozygous for the minor 
allele of rs1878658 (G), rs10499194 (T) and rs6920220 (A) was ≤5%. Figure 1 depicts the infl u-
ence of genotypes on radiographic joint damage. ACPA+ and ACPA- subgroups were analyzed 
separately. Median scores and interquartile ranges (IQR) are provided for ACPA+ patients in 
table 1 (for ACPA- patients see supplementary table 2).
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Figure 1. Development of median Sharp van der Heijde scores plotted according to genotype/allele in ACPA+ 
(left  column) and ACPA- (right column) RA patients. Year 0 equals baseline values. Regression analysis was 
performed in order to estimate the average increase (slope) in Sharp van der Heijde scores over time. Slopes 
were subsequently compared using the nonparametric Mann-Whitney test (for the ACPA+ subgroup: p = 0.37 
(rs1878658); p = 0.007 (rs675520); p = 0.021 (rs9376293); p = 0.05 (rs10499194); p = 0.76 (rs6920220))
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No infl uence of genotypes on radiographic joint damage was observed in ACPA- patients 
(Figure 1). In ACPA+ patients, however, two polymorphisms showed reproducible association 
with disease progression over time. Presence of the G allele of rs675520 was found to associate 
with increased Sharp/van der Heijde scores, as a signifi cant diff erence was observed when the 
average increase (slope) in radiographic scores over time was compared with G as the dominant 
allele (median slope AG/GG = 4.6, AA = 2.3; Mann-Whitney p = 0.007). In order to account for 
an eff ect of improving treatment strategies on radiographic progression during the 10 year pe-
riod in which patients were included into the study, we next performed a mixed model analysis. 
Th is analysis identifi ed the year of inclusion as a signifi cant variable infl uencing the extent of 
radiographic joint damage (p = 0.005). Aft er correcting for the year of inclusion, however, we still 
observed a signifi cant infl uence of the G allele of rs675520 (AG/GG vs. AA, p = 0.026).
Similar to the G allele of rs675520, we noted an infl uence of the C allele of rs9376293 on 
progression of radiographic joint damage (Figure 1). Th e average increase (slope) in Sharp/van 
der Heijde scores over time was signifi cantly higher for C allele carriers as compared to T homo-
zygotes (median slope CC/CT = 4.5, median slope TT = 3.0, Mann-Whitney p = 0.021). Aft er 
correcting for the year of inclusion as described above a trend eff ect of the C allele remained (p 
= 0.097).
For rs1878658, rs10499194 and rs6920220, no signifi cant infl uence of individual genotypes on 
radiographic joint damage was noted.
DISCUSSION
Th e 6q23 region has recently been associated with disease susceptibility in RA. Th is region 
contains no known transcripts. Th e closest genes with known function are OLIG3 and TNFAIP3. 
TNFAIP3 encodes protein A20, a TNF-α induced negative regulator of NF-κB.3,11 Decreased 
levels of A20 lead to uncontrolled NFκB-activity, resulting in increased infl ammation. Th is ob-
servation makes TNFAIP3/A20 and the 6q23 region interesting candidates that could modulate 
infl ammation also in RA.
We were intrigued by recent diff erential fi ndings for rs10499194, a SNP on chromosome 6q23 
close to TNFAIP3, in cohorts with diff ering disease duration. Th e major allele (C) was found to 
associate with disease susceptibility in ACPA+ RA patients in three cohorts with long-standing 
disease, but not in an early arthritis cohort.2 Th is indicated a potential impact of the 6q23 region 
on disease severity. In order to test for such an impact, fi ve SNPs were genotyped in a cohort 
of Dutch patients with early RA. Th ese SNPs had previously been shown to identify common 
haplotypes in 6q23.2 We identifi ed two SNPs for which presence of alleles was associated with 
increased joint destruction in ACPA+ patients. Carriers of the G allele of rs675520 developed 
increased Sharp/van der Heijde scores over time. A similar eff ect, although weaker, was found for 
the C allele of rs9376293. Interestingly, no association was found for any of the SNPs in ACPA- 
individuals. Although this does not exclude a contribution of the 6q23 region to disease severity 
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in ACPA- disease, the latter observation is in line with recent reports detecting an association of 
the 6q23 region with disease susceptibility in ACPA+ patients only.4 No eff ect on disease severity 
was observed for rs10499194 and rs6920220. Based on our data we cannot rule out the possibility 
that either SNP exerts a weak eff ect that requires larger sample numbers for detection or that 
cannot be observed during the fi rst years of disease. Interestingly, we observed nominally higher 
scores for the riskconferring A allele of rs6920220 without reaching statistical signifi cance. Th e 
discrepancy between SNPs associating with susceptibility and radiographic progression also 
indicates that the causal variant at this locus has not yet been identifi ed. Given the large area of 
linkage disequilibrium surrounding these SNPs, further fi ne-mapping and functional character-
ization will have to be performed.
Data linking newly identifi ed genetic polymorphisms to disease outcome in RA are only 
beginning to emerge. Our data are unique, as they cover a long period of radiographic follow-up 
and have been scrutinized for artefacts such as secular trends in treatment intensity. Albeit based 
on relatively low patient numbers, our data indicate a contribution of the 6q23 region to the 
rate of joint destruction in ACPA+ RA, thereby further refi ning our understanding of the eff ects 
exerted by this locus. Replication of our fi ndings in other cohorts is needed. Nonetheless, this 
is the fi rst study demonstrating such an eff ect for genetic polymorphisms located outside the 
HLA-region in ACPA+ RA patients.
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SUPPLEMENTARY INFORMATION ON PATIENTS AND 
METHODS 
Patients
All patients met the American College of Rheumatology 1987 revised classifi cation criteria for 
RA and were of Caucasian origin based on self-reported ethnicity. Written informed consent 
was obtained from all participants, and the study was approved by the local institutional review 
board.
Th e Leiden Early Arthritis Clinic (EAC) is a population-based inception cohort that includes 
patients with self-reported symptom duration of ≤2 years. Follow-up visits are performed and 
radiographs of hands and feet are taken on a yearly basis. DNA samples of 324 patients (67.6% 
female; mean age 56.3 ± 15.4 years) consecutively included between 1993 and 2003 for whom 
radiographic scoring data and ACPA status were available were used for analysis. 2003 as the 
latest year of inclusion was chosen in order to allow a fi ve year followup period for all patients.
Radiographic scoring
Th e number of patients with available radiographs varied per time-point (for ACPA+ patients: 
n = 168 at baseline and n = 153, 154, 134, 119, and 122 at year 1 to 5, respectively; for ACPA- 
patients: n = 135 at baseline and n = 121, 109, 93, 81, and 65 at year 1 to 5, respectively). In total, 
radiographs of 324 patients (181 ACPA+, 143 ACPA-) were used for analysis. All radiographs 
were scored by one experienced reader who was blinded with respect to the patient’s autoan-
tibody status, treatment, clinical outcome and genotyping results. Scoring was performed with 
known time order, which is more sensitive to change compared to scoring with unknown time 
sequence.1 For quality control, radiographs of 60 randomly selected RA patients were rescored 
by the same reader. Th is selection comprised 499 radiographs, consisting of 149 baseline radio-
graphs and 350 radiographs during followup. Reliability of radiographic scoring was calculated. 
Intraclass-observer correlation coeffi  cients (ICC) were 0.91 for all scored radiographs, 0.84 for 
baseline radiographs and 0.97 for the radiographic progression rate.
Statistical analysis
Four diff erent treatment strategies were applied to patients included in the EAC depending on 
the year of inclusion. Patients included between 1993 and 1995 were treated initially with anal-
gesics and subsequently with chloroquine or sulphasalazine if they had persistent active disease 
(delayed treatment).2 From 1996 to 1998 patients were promptly treated with either chloroquine 
or sulphasalazine (early treatment).2,3 From 1998 to 2002 patients were promptly treated with 
either sulphasalazine or methotrexate (early treatment) and patients included in 2002 or later 
were promptly treated with either sulphasalazine or methotrexate combined with treatment 
adjustments based on disease activity (early and disease activity based treatment).
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To take advantage of the prospective character of the EAC, consisting of repeated measure-
ments, and to avoid multiple testing by performing statistical tests for each time point, a linear 
mixed model for longitudinal data was used, with the log transformed sharp score as response 
variable, to compare the radiological progression between genotype groups. We explored diff erent 
correlation structures between the repeated measurements, and based on the Akaike’s informa-
tion criterion, an autoregressive correlation structure with heterogeneous variances was chosen. 
Th is model takes missing observations into account, assuming that the missing is at random. 
Diff erences in progression rates between the diff erent genotypes were tested by considering the 
signifi cance of the interaction between genotype and time with time as linear covariate. Th e year 
of inclusion into the study was entered into the model to correct for possible confounding eff ects. 
Inclusion period is a proxy for treatment modalities, because treatment strategies improved over 
time and an infl uence of the treatment strategy on the progression of radiographic joint damage 
was observed previously.2 Th e interaction between treatment strategy (i.e. inclusion year) and 
time was signifi cant in all fi ve analyses of the present study (p<0.05).
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logical order, in pairs or as single fi lms has important implications for the discriminative power of 
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Clin Exp Rheumatol 2003; 21(5 Suppl 31):S100-S105.
Supplementary table 1. Comparison of the LD-parameters obtained from HapMap (CEU population in rel. 24 
Phase II Nov 08) and the Leiden dataset
HapMap CEU Leiden Dataset
SNP1 SNP2 D’ r^2 D’ r^2
rs1878658 rs675520 1.0 0.112 1.0 0.155
rs1878658 rs9376293 1.0 0.274 1.0 0.263
rs1878658 rs10499194 1.0 0.623 0.98 0.5
rs1878658 rs6920220 1.0 0.028 0.929 0.04
rs675520 rs9376293 0.931 0.356 0.893 0.482
rs675520 rs10499194 1.0 0.191 0.98 0.289
rs675520 rs6920220 1.0 0.209 0.987 0.289
rs9376293 rs10499194 1.0 0.441 0.982 0.478
rs9376293 rs6920220 1.0 0.102 0.985 0.172
rs10499194 rs6920220 1.0 0.045 0.988 0.087
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Th e severity of joint destruction in rheumatoid arthritis (RA) is highly variable between patients 
and infl uenced by genetic factors. Genome-wide association studies (GWAs) have boosted the 
fi eld of the genetics of susceptibility to RA enormously, but risk loci for severity of RA remain 
poorly defi ned. A recent meta-analysis of GWAs identifi ed 6 genetic regions for susceptibility 
to autoantibody-positive RA, i.e. CD40, KIF5A-PIP4K2C, CDK6, CCL21, PRKCQ and MMEL1-
TNFRSF14. We have investigated whether these newly described genetic regions associate with 
the rate of joint destruction. 
Methods
RA patients enrolled in the Leiden Early Arthritis Clinic were studied (n=563). Yearly radio-
graphs were scored using the Sharp-van der Heijde method (median follow-up 5 years, maximal 
follow-up 9 years). Th e rate of joint destruction between genotype groups was compared using a 
linear mixed model correcting for age, gender and treatment-strategies. 393 ACPA-positive RA 
patients included in the NARAC with radiographic data were used for replication.
Results
Th e TT and CC/CG genotypes of two SNPs, rs4810485 (CD40) and rs42041 (CDK6) respectively, 
were associated with a higher rate of joint destruction in ACPA-positive RA (p=0.003 and 0.012), 
of which rs4810485 was signifi cant aft er Bonferroni correction for multiple testing. Th e associa-
tion of the CD40 minor allele with radiographic progression rate was replicated in the NARAC 
cohort (p=0.021).  
Conclusion
A polymorphism in the CD40 locus is associated with the rate of joint destruction in ACPA-pos-
itive RA and provides one of the fi rst non-HLA-related genetic severity factors that is replicated. 
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INTRODUCTION
Rheumatoid arthritis (RA) is characterized by infl ammatory arthritis and localized destruction 
of bone and cartilage. Th e severity of joint destruction is highly variable between patients and, 
according to twin studies, substantially infl uenced by genetic factors.1 Nevertheless, the precise 
contribution of genetic factors still has to be determined. To date only a small number of genetic 
risk factors has been identifi ed, and apart from HLA, none of these factors have been convinc-
ingly replicated.
In contrast, the genetics of susceptibility to RA has been boosted considerably, largely due to 
genome-wide association studies. In addition to the HLA-DRB1 shared epitope alleles, several 
new susceptibility factors, PTPN22, TRAF1-C5, OLIG3-TNFAIP3 and STAT4, have been identi-
fi ed and were independently replicated. Intriguingly, for many of these genetic risk factors the 
associations are confi ned to anti-citrullinated protein antibodies (ACPA)-positive RA patients. 
Whether genetic factors also diff erently aff ect the severity of joint destruction in ACPA-positive 
and ACPA-negative RA remains unknown. Nonetheless, compelling evidence demonstrates that 
ACPA-positive RA patients have a more destructive disease course compared to ACPA-negative 
patients. 
A recent meta-analysis on two genome-wide association studies identifi ed six new risk 
loci (rs4810485 (CD40), rs1678542 (KIF5A-PIP4K2C), rs42041 (CDK6), rs2812378 (CCL21), 
rs4750316 (PRKCQ) and rs3890745 (MMEL1-TNFRSF14)) as susceptibility factors for 
autoantibody-positive RA.2 Th e present study aimed to investigate the association between these 
single nucleotide polymorphisms (SNPs) and the rate of radiological joint destruction in RA, 
and ACPA+ RA in particular, using a large longitudinal cohort. A cohort of ACPA-positive RA 
patients was used for replication. Th is study shows that a genetic variant in the CD40 gene associ-
ates with the rate of joint destruction in ACPA-positive RA.
PATIENTS AND METHODS
Patients
Five hundred sixty three RA patients, consecutively included in the Leiden Early Arthritis 
Cohort (EAC) between 1993 and 2006 with both DNA and radiographs available were stud-
ied. Th e RA patients fulfi lled the 1987 ACR-criteria. Follow-up visits were performed yearly. 
Treatment strategies changed in time and diff ered for diff erent inclusion periods (before 1996, 
1996-1998, 1999-2001, aft er 2001) (see reference 3 for detailed description of the EAC). Anti-
CCP2 antibodies were measured using stored baseline serum samples (Immunoscan RA Mark 2; 
Euro-Diagnostica, Th e Netherlands).
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Replication cohort
393 ACPA-positive RA patients that were included in the North American Rheumatoid Arthritis 
Consortium (NARAC) that had hand radiographs available were studied. As the radiographs 
were taken at diff erent disease durations, the estimated radiological progression per year was 
determined by dividing the total Sharp-van der Heijde score of the hands by the disease duration 
at the time of the radiograph. 
SNP genotyping
Th e six recently identifi ed risk loci2 were genotyped in the 563 RA patients from the Leiden EAC 
using allele-specifi c kinetic PCR as previously described.4 Th e data were hand-curated without 
knowledge of clinical characteristics before statistical analysis with a 98% genotyping success 
rate; previous analyses suggest a genotyping accuracy of >99%. For the MMEL1-TNFRSF14 
locus, a perfect proxy of rs3890745 (as reported2) was used (rs6684865, r2=1).
In the NARAC genotyping was performed using the Illumina Hapmap500 BeadChip, as de-
scribed.5 Rs4810485 was not typed in the whole genome study, but a perfect proxy for this variant 
was genotyped (rs1569723, r2=1). For CDK6, neither rs42041 nor a perfect proxy were genotyped 
and therefore the data on rs42041 was imputed as described.2 
Radiographs
In the EAC, radiographs of hands and feet, taken on consecutive years, were scored according to 
the Sharp-van der Heijde method.6 To encompass a reliable sample size, radiographic follow-up 
data were restricted to a maximum of 9 years with a median of 5 years. All radiographs were 
scored by one experienced scorer who was blinded with respect to clinical and genetic data. 
499 radiographs were rescored (149 baseline radiographs and 350 radiographs during follow-up 
from 60 randomly selected RA patients). Intraclass correlation coeffi  cients (ICC) were 0.91 for 
all radiographs, 0.84 for baseline radiographs and 0.97 for the radiographic progression rate. In 
the NARAC the radiographs were scored by one reader blinded to clinical or genetic data. 25% 
of the radiographs were re-scored, the ICC was 0.99.
Statistical analysis
Analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL). As radiographic data 
were not normally distributed, the raw data on the Sharp-van der Heijde scores are presented 
using medians and were log-transformed in preparation for analysis. In the EAC, a linear model 
for longitudinal data was used to compare progression rates between groups. Age, gender, inclu-
sion period (a proxy for treatment strategy) and their interactions with time were entered in 
the model to correct for possible confounding eff ects (see below). As six SNPs were evaluated, 
a Bonferroni correction for multiple testing was applied; the p-value for signifi cance was set 
at p<0.008. Only the SNPs that were clearly related to the progression rate in the EAC were 
analyzed in the replication cohort. In the NARAC, the estimated radiological progression per 
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year was compared with the Kruskal-Wallis test. No corrections were made for age, gender or 
treatment in this cohort.
To take advantage of the prospective character of the data of the EAC, consisting of repeated 
measurements, and to avoid multiple testing by performing statistical tests for each time point, 
a linear model for longitudinal data was used, with the log transformed Sharp-score as response 
variable, to compare the radiological progression rates between genotype groups. Diff erent cor-
relation structures between the repeated measurements were explored, and based on the Akaike’s 
information criterion, an autoregressive correlation structure with heterogeneous variances was 
chosen. Due to the study design (an inception cohort) not all patients achieved a similar duration 
of follow-up. Th e model takes missing observations into account, assuming that the missing 
is at random. Diff erences in progression rates between the diff erent genotypes were tested by 
considering the signifi cance of the interaction between genotype and time with time as linear 
covariate. Age, gender and inclusion period (before 1996, 1996-1998, 1999-2001, aft er 2001) and 
their interactions with time were entered in the model to correct for possible confounding eff ects. 
In order to prevent overfi tting of the data no corrections were applied for other variables. Inclu-
sion period is a proxy for treatment modalities, because treatment strategies improved over time 
and an infl uence of the treatment strategy on the progression of radiographic joint damage was 
observed previously, as well as in the present study. Th e following treatment strategies were ap-
plied in the subsequent inclusion periods.. Patients included between 1993 and 1995 were treated 
initially with analgesics and subsequently with chloroquine or sulfasalazin if they had persistent 
active disease (delayed treatment). From 1996 to 1998 RA patients were promptly treated with 
either chloroquine or sulfasalazin (early treatment).3 From 1998 to 2002 patients were promptly 
treated with either sulfasalazin or methotrexate (early treatment) and patients included in 2002 
or later were promptly treated with either sulfasalazin or methotrexate combined with treatment 
adjustments based on the disease activity (early and disease activity based treatment).
RESULTS
Baseline characteristics of the RA patients are shown in Table 1. In the EAC, the minor allele 
frequencies were 0.242, 0.340, 0.267, 0.366, 0.204 and 0.307 for rs4810485, rs1678542, rs42041, 
rs2812378, rs4750316 and rs6684865 respectively and in agreement with previous results.2 Th e 
raw data on the Sharp-van der Heijde scores for the three genotypes at each SNP are depicted in 
Figure 1. To study the infl uence of the SNPs on the rate of joint destruction, a linear mixed model 
analysis was performed for each SNP. For rs4810485 (CD40) the GG and GT genotypes showed 
comparable radiographic scores, therefore the genotype data were combined and carriership-
analysis was performed. Similarly, the CC and CG genotypes of rs42041 (CDK6) were pooled. 
In the total group of RA patients an association was observed for rs42041 (CDK6) (p=0.033). 
For the other SNPs no signifi cant association with the radiological progression over time was 
detected (p=0.268, 0.369, 0.679, 0.583 and 0.451 for rs4810485, rs1678542, rs2812378, rs4750316 
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and rs6684865 respectively). Because the genetic regions studied are thus far observed to be 
susceptibility factors only for autoantibody-positive RA patients, analyses were repeated in the 
ACPA-positive subgroup. Here, two polymorphisms, rs4810485 (CD40) and rs42041 (CDK6), 
aff ected the rate of joint destruction (Figure 2). For rs4810485, the G-allele was associated with 
a lower progression rate (GG/GT vs. TT, p=0.003). Back transforming the regression coeffi  cient 
of the genotype in the model to the original scale yielded a 1.12 (95% CI 1.04-1.21) times larger 
increase in Sharp-score per year for carrying the risk genotype. For rs42041, the C-allele was 
associated with a higher rate of joint destruction (CC/CG vs. GG, p=0.012). For carriership 
of the C-allele a 1.09 (95% CI 1.02-1.16) larger yearly increase in Sharp-score was observed. 
Only rs4810485 was statistically signifi cant aft er correction for multiple testing. Th e interaction 
between inclusion period and time was signifi cant in all six analyses (p<0.001), demonstrating 
the eff ect of inclusion period on the radiological progression rate. Gender and age were not 
independently associated with progression. 
To fi nd replication, the eff ect of CD40 and CDK6 on radiological progression was analysed 
in 393 ACPA-positive RA patients from the NARAC. Using a perfect proxy for rs4810485, the 
genotype associated with severity in the EAC also revealed a higher estimated radiological pro-
gression per year in the NARAC: 3.40 Sharp-units/year (n=23) vs. 2.83 and 1.83 Sharp-units/year 
Table 1. Patient characteristics at baseline
Patient Characteristics EAC N=563
Age at inclusion (yrs), mean (SD) 56.0 (15.6)
Female, N (%) 394 (70.0)
Symptom duration at inclusion (months), mean (SD) 6.7 (10.5)
Swollen Joint Count, mean (SD) 5.72 (3.3)
Ritchie score, mean (SD) 10.3 (7.8)
ACPA-positive, N (%)† 250 (55.9)
IgM-RF-positive, N (%)† 322 (58.4)
HLA-DRB1 Shared Epitope +, N (%)† 339 (67.1)
CRP (mg/l), mean (SD)† 29.4 (34.2)
ESR (mm/h), mean (SD)† 39.5 (27.5)
HAQ, mean (SD) 1.1 (0.7)
Total Sharp-score, median (IQR) 5 (2-11)
Patient Characteristics NARAC N=393
Age at disease onset 40.8 (11.9)
Female, N (%) 286 (72.8)
ACPA-positive, (%)§ 100%
HLA-DRB1 Shared Epitope +, N (%)§ 100%
†Data on ACPA-, RF- and HLA DRB1 SE-status and CRP and ESR-levels were available in the EAC in 447, 551, 
441, 520 and 544 out of 563 genotyped patients respectively. §Data on ACPA- and HLA-DRB1 SE-status was 
available for all of the 393 genotyped patients
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Figure 1. Median Sharp-van der Heijde scores for the diff erent SNPs per genotype in all RA patients. Overview 
of the raw Sharp-van der Heijde scores, expressed as medians, of all 6 SNPs per genotype for the total patient 
population (n=563). Th e risk-alleles predisposing to RA in the study of Raychaudhuri et al2 were the G-, C-, 
G-, G-, G- and T-allele for the rs4810485, rs1678542, rs42041, rs2812378, rs4750316 and rs6684865 SNPs 
respectively. Th e number of available radiographs varied per time-point and declined to 466 aft er 1 year of 
follow-up, 426, 357, 299 and 269 aft er 2 till 5 years of follow-up and 206, 154, 116 and 84 radiographs aft er 
6, 7, 8 and 9 years of follow-up respectively. Th e number of patients in the diff erent genotype groups were 
respectively: GG:280, GT:198, TT:22 (rs4810485)*; CC:247, CG:248, GG:67 (rs1678542); CC:305, CG:215, 
GG:43 (rs42041); AA:217, AG:279, GG:66 (rs2812378); CC:23, CG:183, GG:355 (rs4750316); CC:166, CT:170, 
TT:26 (rs6684865)*. *Due to technical diffi  culties genotyping was not successful in 63 and 201 of cases for 
rs4810485 and rs6684865 respectively. SHS: Sharp-van der Heijde score
Figure 2. Median Sharp-van der Heijde scores for rs4810485 and rs42041 in ACPA-positive RA. Overview of 
the raw Sharp-van der Heijde scores, expressed as medians, in ACPA-positive RA (n=250). Th e G-allele was 
the risk-allele predisposing to RA in the study of Raychaudhuri et al2 for both the rs4810485 and rs42041 SNPs. 
Th e number of patients in the diff erent genotype groups were for rs4810485*: GG: 128, GT: 88, TT: 11 and for 
rs42041: CC: 131, CG: 101, GG: 18. *Genotype data for rs4810485 was not available in 23 cases. SHS: Sharp-van 
der Heijde score
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(n=122 and 248, p=0.021). Using imputed data for rs42041 no signifi cant diff erences between 
the three genotypes were observed (2.76, 2.38 and 2.07 Sharp-units/year, n=32, 163 and 188 
respectively, p=0.327). Th e total number of patients available for analysis of rs42041 was 383; 
genotyping data were missing in 10 cases.
DISCUSSION
Although several clinical and serological risk factors for RA severity are known, thus far the 
inter-individual variance in joint destruction is insuffi  ciently explained and genetic factors are 
scarcely investigated. A better comprehension of the factors that mediate joint damage in RA 
may lead to the development targeted therapies or may contribute to prediction of the disease 
outcome in individual RA patients. Most recently, six new loci were described to predispose to 
autoantibody-positive RA.2 Although susceptibility factors do not necessarily aff ect disease pro-
gression, this study investigated whether these six SNPs are also risk factors for a severe course 
of RA, measured by the rate of joint damage. Th e present data suggest that two SNPs, rs4810485 
(CD40) and rs42041 (CDK6), infl uence the rate of joint destruction in ACPA-positive RA. Of 
these, only rs4810485 was signifi cantly associated aft er correction for multiple testing and was 
replicated in an independent cohort of ACPA-positive RA patients. As such, CD40 is the fi rst 
non-HLA-related genetic risk factor for RA severity that is independently replicated. 
A recent study2 reported a common variant at the CD40 locus (the minor T-allele) to be protec-
tive for the development of RA. Surprisingly, here the minor T-allele associates with a higher rate 
of joint destruction in two cohorts. Th is fi nding is counter-intuitive, if one assumes that genetic 
variants associating with susceptibility also associate with severity. Although our fi ndings were 
observed in two independent cohorts, and thus replicated, a type I error cannot be ruled out. Th e 
disease associated (common) allele marks a haplotype of CD40 that contains a polymorphism 
in the upstream Kozak sequence that results in increased surface expression on B cells.7 To our 
knowledge, the eff ect of this haplotype on CD40 surface expression in synovial fi broblasts has not 
been directly studied. However, CD40 expression is increased on synoviocytes in RA and trigger-
ing of CD40 in synovial fi broblasts is associated with production of proinfl ammatory cytokines 
and osteoclastogenesis.8,9 It is likely that the biological pathways underlying susceptibility and 
severity are distinct with respect to CD40 triggering. Th is would provide an explanation for the 
fi nding that the minor T-allele has a protective eff ect in susceptibility studies but associates with 
a more severe disease course. Clearly it is essential to perform further studies on the mechanisms 
by which CD40 polymorphisms associate with erosive outcome in RA. 
A second SNP tended to associate with the rate of joint damage in RA in the EAC, rs42041. 
Absence of replication in the NARAC indicates that the observed association with the progres-
sion rate in the EAC cannot be interpreted. Nonetheless, it will be interesting to see the results on 
other studies analyzing CDK6 and RA severity. Th us, at present, of the two SNPs that tended to 
show an association with the rate of joint destruction, only the genetic variant in CD40 is statisti-
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cally signifi cant aft er correction for multiple testing and is replicated and is therefore identifi ed 
as a severity factor for RA.
Th e other four studied SNPs in the loci encoding for KIF5A-PIP4K2C, CCL21, PRKCQ and 
MMEL1-TNFRSF14 were not observed to associate with the severity of joint destruction. Th ere-
fore, these polymorphisms appear to be genetic risk-factors that are primarily associated with 
RA susceptibility. Indeed, all of these SNPs were recently replicated as true susceptible loci in RA 
patients of European ancestry.10
Th e prospective nature of the data of the EAC strengthens the impact of the fi ndings because 
higher radiological scores for risk genotypes were present at subsequent time points; as such the 
present data set is advantageous in comparison to studies that assessed cross-sectional radio-
logical data. Th e fact that a large number of patients with a long follow-up of up to 9 years were 
included for analysis is clearly an advantage, but also has a limitation. Inherent to the design of 
an inception cohort, not all patients had achieved maximum follow-up, so the number of miss-
ing data that the mixed-model had to take into account increased with longer follow-up. Small 
numbers of radiographs available at the latest time points are also the most likely explanation 
for the observed “bump” at the 8 year time point for the genotypes GG, CC and TT of the SNPs 
rs2812378, rs4750316 and rs6684865 respectively (Figure 1). 
Evaluation of the eff ect of genetic factors on the rate of joint destruction during the disease 
course inevitably implies that other factors that aff ect the disease course should be taken into 
consideration as well. Analyses for all six SNPs revealed that inclusion period, a proxy for treat-
ment strategy, was signifi cantly associated with the rate of joint damage, which is in line with 
previous results from the EAC.11 Th e analyses on CD40 and CDK6 showed that these SNPs were 
associated with joint damage, independent from treatment strategy. Nevertheless, corrections for 
treatment strategy were made on group-level and thus were an approximation for the real eff ect 
of treatment on the rate of joint destruction for individual RA patients.
In conclusion, a polymorphism in the CD40 locus shows a signifi cant association with the rate 
of joint destruction in ACPA-positive RA, a fi nding that is replicated in an independent cohort. 
Although further studies are needed to identify the causal variant, the data presented provide a 
foundation for further investigations of the role of CD40 in joint destruction in RA.
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A missense Single Nucleotide Polymorphism (SNP) in the protein tyrosine phosphatase nonre-
ceptor 22 (PTPN22) gene, that encodes an negative regulator of T-cell activation, is an important 
genetic risk factor for rheumatoid arthritis (RA) susceptibility.1 Th e association of PTPN22 
susceptibility risk allele and severity of joint destruction is unclear due to contradictory observa-
tions.2-6 To determine an individual patient’s rate of joint destruction accurately, it is required 
that radiological measurements are collected via standard procedures, scored quantitatively and 
sensitively and are repeated in time. Consequently, diff erences in used measurement and analysis 
methods may contribute to the occurrence of contrasting fi ndings. Second, although the eff ect of 
PTPN22 on RA susceptibility is confi ned to the ACPA-positive group,2,6 most studies on PTPN22 
and joint destruction did not analyze the ACPA+ subset.2-5 Th e present study studied the eff ect 
of the PTPN22 susceptibly risk variant on the rate of joint destruction in two large cohorts of 
ACPA+  patients, using sensitive methods for measurement and analysis. 
Th e fi rst cohort consisted of 593 RA patients from the Leiden Early Arthritis Clinic (EAC),7 of 
whom 55% were ACPA-positive. Radiographs were made at baseline and on consecutive years. 
Th e radiographs were scored by one experienced scorer. Th e intraclass-observer correlation 
coeffi  cient was 0.91. Th e progression in Sharp-van der Heijde score (SHS) during 6 years of 
follow-up was compared between RA patients with and without the risk variant (T-allele) of 
rs6679677, a perfect proxy for rs2476601/C1858T (r2=1), using a repeated measurement analy-
sis. Such analysis takes advantage of the longitudinal, repetitive character of the data and does 
not exclude patients with incomplete follow-up data, avoiding selection bias. In a linear mixed 
model with radiological score as response variable, the eff ect of time was assumed to be linear 
in the interaction terms. PTPN22 and its interaction with time were entered in the model, to 
test whether PTPN22 T/non-T carriers had diff erent radiological scores over time. Age, gender 
and inclusion period (a proxy for treatment strategy) were entered in the model to correct for 
possible confounding eff ects.8
Th e replication cohort consisted of 397 ACPA+  patients North American Rheumatoid Arthri-
tis Consortium (NARAC) with cross-sectional radiological measurements (SHS) and genotypic 
data of rs2476601. Estimated radiological progression rates per year were compared using the 
Mann-Whitney test. In this cohort, no corrections were made for age, gender or treatment.
In the fi  rst cohort, 69.0% of patients were female and the mean age was 56.4  15.8 years. Th e 
genotype frequencies (GG/GT/TT) were 462/120/11 (77.9%/20.2%/1.9%). Th e presence of the 
T-allele (TT+TG-genotype) was not associated with a higher rate of radiological joint destruc-
tion compared to the absence of this allele (GG-genotype) (p=0.10 and p=0.93 respectively in 
ACPA-positive and in all  patients) (Figure 1). In the second cohort, 72.8% of the patients were 
female and the mean age was 40.8 ± 12.0 years. Th e genotype frequencies (CC/CT/TT) were 
282/105/10 (71%/26%/3%). Again, no signifi cant diff erence in estimated radiologic progression 
per year was found (median 2.11 Sharp units per year in the CC group versus 2.4 Sharp units per 
year in the TT+TC-group, p=0.22). Exclusion of ten genetic outliers did not change these results. 
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Using the present EAC data, this study had a power of 0.986 to detect a diff erence of 2.14 
SH-scores with a SD of 4.07 (diff erence in increase in SHS over 6-years) and an alpha of 0.05; 
indicating this study was suffi  ciently powered to prevent false negative fi ndings. 
In conclusion, this study shows that PTPN22, although it predisposes to ACPA-positive RA, is 
not associated with RA severity measured by the radiological rate of joint destruction, proving 
a further indication that the contribution of PTPN22 to RA is primarily found in setting the 
balance involved in the emergence of ACPA.
Figure 1. Median Sharp van der Heijde scores during 6 years of follow-up for patients with and without the 
T-allele of PTPN22 in ACPA+ RA (A) as well as all RA (B) in the EAC. Th ree hundred fi ft een ACPA-positive 
patients had radiographs available. Th e number of radiographs declined from 303 to 267, 251, 212, 185, 169 and 
139 respectively from baseline to 6 year follow-up. Th e available radiographs of the total RA population were in 
total 593, this declined to 577, 488, 442, 365, 309, 263 and 212 respectively from baseline till 6 year follow-up
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During the last decade rheumatologists have learned to initiate disease-modifying-antirheumat-
ic-drugs (DMARDs) early to improve outcome of rheumatoid arthritis (RA). Th e eff ect of delay 
in referral to rheumatologists on the outcome of RA is scarcely explored. We studied the associa-
tion between delay in assessment by rheumatologists, rates of joint destruction, and probability 
of achieving DMARD-free-remission in RA. Patient characteristics associated with the patient 
and general practitioner (GP)-components of overall delay were assessed. 
Methods
1674 early arthritis-patients from the Leiden EAC were studied on patient, GP-, and total delays. 
Within 598 RA patients, associations between total delay, achievement of sustained DMARD-
free remission, and the rate of joint destruction over six years follow-up were determined.
Results
Th e median patient, GP-, and total delays in early arthritis-patients were 2.4, 8.0 and 13.7 weeks 
respectively. From all diagnoses, early arthritis patients diagnosed with RA or spondylarthropa-
thy had the longest total delay (18 weeks). 69% of RA patients were assessed in ≥12 weeks; this 
was associated with a hazard ratio of 1.87 for not achieving DMARD-free remission and a 1.3 
times higher rate of joint destruction over six years compared to assessment <12 weeks. Older 
age, female gender, gradual symptom onset, small joint involvement, lower CRP levels, and 
autoantibody presence associated with longer total delay. 
Conclusion
Only 31% of RA patients were assessed <12 weeks. Assessment <12 weeks is associated with less 
joint destruction and a higher chance on DMARD-free remission compared to a longer delay in 
assessment. Th ese results imply that attempts to diminish delay in seeing rheumatologists will 
improve disease outcome in RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a common chronic disease, aff ecting 1% of the population. It is 
associated with signifi cant morbidity, mortality and cost for the health service and society. Th e 
disease is characterized by infl ammation of the synovium, most frequently in the small joints 
of hands and feet; this infl ammatory process frequently leads to loss of cartilage and bone ero-
sions. Th e level of joint destruction is correlated with the severity of infl ammation.1,2 At present, 
potent Disease Modifying Antirheumatic Drugs (DMARDs) and biological agents are available 
to treat RA synovitis. It has been unequivocally demonstrated that early initiation of aggressive 
treatment schedules results in less joint damage and disability.3-6 Th is has led to the concept of 
the ‘window of opportunity’.7 Indeed it has been demonstrated that initiation of treatment within 
12 weeks aft er disease onset results in lower levels of joint destruction8 and increases the chance 
of achieving remission,9 which is increasingly regarded as the targeted outcome in therapeutic 
trials. Many studies focused on the importance of diminishing delay between the diagnosis of RA 
and treatment initiation. However, shortening the time period between fi rst symptoms and fi rst 
visit to a rheumatologist might be equally important. Th us far the eff ect of delayed assessment by 
rheumatologists on disease outcome has scarcely been investigated. 
We aimed to assess the association between delay in assessment and disease outcome in RA, 
measured by the rate of joint destruction and the chance of achieving sustained DMARD-free 
remission. Second, we also aimed to determine the patient characteristics associated with longer 
patient and GP-delay. Knowledge of these factors is of utmost importance. Rheumatologists 
nowadays are aware of the need to treat early. Th is implies that to further improve the outcome of 
RA, strategies should be put in place to ensure that delays in assessment are as short as possible. 
Understanding factors that associate with delayed assessment is the fi rst step required to achieve 
this. 
PATIENTS AND METHODS 
Patients
All patients come from the Leiden Early Arthritis Clinic (EAC) cohort, a large inception cohort 
that enrolled all consecutive patients between 1993 and 2006.10 Th is clinic is the only referral 
center in a health care region of about 300,000 inhabitants. Patients were referred by their 
general practitioners (GPs) when arthritis was suspected and GPs were encouraged to refer as 
soon as possible. Inclusion took place when synovitis was confi rmed by physical examination 
and symptom duration was less than 2 years. At baseline, patients were asked about their joint 
symptoms and subjected to a physical examination, which included a 66 swollen and 68 tender 
joint count (Ritchie score). Blood samples were taken for routine diagnostic laboratory screening 
(including C-reactive protein (CRP) and IgM-rheumatoid factor (RF)) and stored to determine 
other autoantibodies (anti-CCP2) at a later time. Follow-up visits were performed on a yearly 
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basis and included radiographs of hands and feet.10 Written informed consent was obtained from 
all participants. Th e study was approved by the local Medical Ethical Committee. 
Of all 1881 patients included in the EAC cohort, information on the dates of symptom onset 
was available for 1674 patients. Th ere were no signifi cant diff erences between baseline patient 
characteristics of patients with and without information on this date, apart from slightly lower 
titers of acute phase reactants in the group with missing data (data not shown). Among the 1674 
patients who had information on the date of symptom onset available, 598 patients (35.7%) were 
diagnosed with RA according to the 1987 ACR criteria within the fi rst year of follow-up and had 
radiographs available. Th ese patients were consecutively included between 1993 and 2006. Treat-
ment strategies for RA changed over time and became more aggressive in subsequent inclusion 
periods (1993-1996, 1996-1998 and 1999-2006).10 Patients included before 1996 were treated 
initially with analgesics and subsequently with chloroquine or salazopyrin if they had persistent 
active disease (delayed treatment). Between 1996 and 1998 RA patients were promptly treated 
with either chloroquine or salazopyrin, and from 1999 onward patients were promptly treated 
with either salazopyrin or methotrexate. 
Delay 
We studied delay at 2 levels. Level 1 related to the delay from the onset of symptoms to a patient 
being seen by their GP. Th is delay is a composite of the delay on the part of the patient in seeking 
an appointment with the GP and the time the patient has to wait to see the GP once they have 
approached the GP for an appointment. In practice, the Dutch healthcare system is such that the 
second component of this is almost always very short and for simplicity we have referred to level 
1 delay as “patient delay”. Level 2 delay related to the delay from when the patient fi rst saw their 
GP to when they were seen in the Leiden Early Arthritis Clinic. Th is delay is also a composite; 
in this case of the time it takes a GP to decide to make a referral and the time it takes for the 
rheumatologist to see the patient once the referral is made. Th e average wait for a patient to be 
seen in the Leiden EAC, once a referral has been made, is short (2 weeks) and for simplicity 
we have referred to level 2 delay as “GP-delay”. Th e total delay was calculated as the sum of both 
patient and GP-delay. Th e duration of total delay was known for 1674 early arthritis patients. 
Data on the fi rst visit to a GP was available for ~1100 early arthritis patients. Th ere were no 
signifi cant diff erences between characteristics of patients with and without information on the 
date of visiting the GP (data not shown). Analysis of associations between patient characteristics 
and delay were carried out for patient delay, GP-delay, and total delay. For all other analyses, the 
total delay was used. Since the literature indicates that the time period known as ‘the window of 
opportunity’ is about 12 weeks, the total delay was divided into two categories: <12 weeks and 
≥12 weeks.7-9
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Radiographs
Radiographs of hands and feet of 598 RA patients were scored according to the Sharp-van der 
Heijde method.11 Due to the study design (an inception cohort) not all patients had an equal 
duration of follow-up (median 4 years, IQR 2-6). Radiographic follow-up data were restricted 
to a maximum of 6 years because of increasing frequency of missing radiographs later on. All 
radiographs were scored by one experienced scorer (MPMvdL) who was blinded with respect 
to clinical and treatment data. 499 radiographs were rescored (149 baseline radiographs and 
350 radiographs during follow-up from 60 randomly selected RA patients). Intraclass-observer 
correlation coeffi  cients (ICC) were 0.91 for all radiographs, 0.84 for baseline radiographs, and 
0.97 for the radiographic progression rate.
Sustained DMARD-free remission in RA
Remission was defi ned in its most stringent form as the persistent absence of synovitis for at least 
one year aft er cessation of DMARD therapy and the identifi cation of remission by the patient’s 
rheumatologist.12 As such, this defi nition approaches cure of the disease. Th e remission status 
could be reliably ascertained in 557 out of 598 RA patients. 72 Patients (12.9%) achieved sustained 
DMARD-free remission aft er a median follow-up of 3.33 years (IQR 2.02-5.48). Most patients 
who achieved remission had a synovitis-free follow-up longer than the minimum requirement of 
one year; the median time of observation aft er achieving sustained DMARD-free remission was 
two-and-a-half years.
Statistical analysis
Th e duration of patient delay and GP-delay within a patient were compared using the Wilcoxon 
signed ranks test. 
Th e association between delay and the rate of joint destruction during follow-up aft er the visit 
to a rheumatologist was assessed in 598 RA patients using repeated measurement analysis on 
log-transformed radiological data of subsequent yearly measurements. Log transformation was 
performed because of skewness of radiological data. Visit number and delay group were entered 
as categorical variables. Adjustments were applied for age, gender, and inclusion period (a proxy 
for treatment strategy) and their interaction with time as described before,13 since these factors 
are known to infl uence the rate of joint destruction. Diff erence in the rate of joint destruction 
between the delay groups was assessed by testing the interaction between time and delay group. 
Th e association between delay and disease progression was also analyzed with the onset of symp-
toms as a starting point. Th is was done with a repeated measurement analysis with a random 
person and time eff ect, where the fi xed eff ect of time was modeled with linear spline functions 
with knots at each year.
Analysis of sustained DMARD-free remission was performed by comparing Kaplan-Meier 
curves and by Cox regression analysis, taking into account the diff erences in follow-up times 
among patients. For patients who achieved remission, the dependent variable was “time-to-
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event”, indicating the time until reaching remission. For non-remission patients the time to last 
follow-up was used. Again two diff erent starting points were considered: time from the onset of 
symptoms and time from the fi rst visit to a rheumatologist. Cox regression for left  truncated data 
was used for the analysis with time from onset of symptoms to account for the fact that remission 
status was only observed aft er the fi rst visit to a rheumatologist. 
Univariate analyses of baseline patient characteristics associating with delay in early arthritis 
patients were performed using Mann-Whitney U and Kruskal-Wallis tests as delay data were not 
normally distributed. In order to identify baseline characteristics that independently associated 
with delay, variables that associated with delay in univariate analyses (p<0.05) were entered in a 
multivariate regression analysis with backward selection method. For these analyses delay data 
were log-transformed. To prevent exclusion of patients with missing data from the multivariate 
model, multiple imputations were performed (SPSS 17.0). Th e complete set of data was used to 
generate 10 imputations that were subsequently applied to the multivariate analysis. 
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and R (http://www.R-project.org) were used. 
P-values <0.05 were considered signifi cant. All reported p-values are two-sided.
RESULTS
Duration of delay in assessment
Baseline characteristics of all early arthritis patients and the patients that were diagnosed with 
RA are presented in Table 1. 
In all early arthritis patients the median total delay was 13.7 (IQR: 5.7-28.5) weeks, the GP-
delay 8.0 (IQR: 2.7-18.4) weeks, and the patient delay 2.4 (IQR: 0.7-7.4) weeks. Th e GP-delay was 
signifi cantly longer (median 8.0 weeks) than the patient delay (median 2.4 weeks) (p<0.0001). 
Th e total delay in the subgroup of early arthritis patients who developed RA within the fi rst year 
of follow-up was 18.4 weeks (median, IQR: 10.4-35.0). Also here, the GP-delay was signifi cantly 
longer than the patient delay (median 11.8 (IQR: 5.2-22.9) vs. 3.3 (IQR: 1.0-8.9) weeks; p<0.0001). 
Th e applied treatment strategies for the RA patients diff ered for three inclusion periods; the 
median total delays for patients in these inclusion periods were 22.1 weeks for 1993-1996, 18.3 
weeks for 1996-1998, and 18.3 weeks for 1999-2006 (p=0.38). From all RA patients, only 186 
patients (31.1%) were assessed within 12 weeks of symptom onset.
Delay and outcome of RA
Within the 598 patients diagnosed with RA, we investigated whether the degree of delay in as-
sessment has an eff ect on the disease outcome, measured by the progression in Sharp-van der 
Heijde score over a six year period of followup and the achievement of sustained DMARD-free 
remission. Th ose RA patients who saw a rheumatologist within 12 weeks aft er symptom onset 
had a lower rate of progression in Sharp-van der Heijde score (Figure 1A) than those with a 
delay of ≥12 weeks. Repeated measurement analysis comparing patient groups with delays of 
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Table 1. Baseline characteristics of all early arthritis patients and the subset of early arthritis patients that were 
diagnosed with RA
Characteristics Early arthritis patients(n=1674)
RA
(n=598)
Female, n (%) 989 (59.1) 405 (67.7)
Age at inclusion (yrs), mean (SD) 51.7 (17.5) 56.8 (15.8)
SJC, mean (SD) 7.1 (6.4) 9.2 (7.0)
Ritchie score, mean (SD) 7.2 (5.6) 9.2 (6.0)
Anti-CCP2-positive, n (%) 391 (28.5)§ 309 (53.3)§
IgM-RF-positive, n (%) 480 (29.2)‡ 343 (58.0)‡
CRP (mg/l), mean (SD) 28.9 (38.8) 31.0 (35.3)
SJC: 66-swollen joint count; Ritchie score: 68-tender joint count; CRP: C-reactive protein; IgM-RF: Rheumatoid 
factor. §Data on anti-CCP2 status was available for 1373/1674 early arthritis patients and 580/598 RA patients. 
‡Data on IgM-RF was available for 1645/1674 and 591/598 patients respectively
Figure 1. Th e rate of joint destruction during 6 years of follow-up aft er fi rst assessment by a rheumatologist 
for RA patients in diff erent delay categories (A), and separated by treatment strategy aft er inclusion (B-D). 
Because of a non-normal distribution of radiological data median Sharp van der Heijde scores are presented. 
Figure 1A presents data on the total RA group and in Figure 1B-D data were separated for diff erent treatment 
strategies which became more aggressive over time. Th e applied treatment strategies were (B) initial treatment 
with analgesics and subsequently with chloroquine or salazopyrin if they had persistent active disease (delayed 
treatment), (C) prompt treatment with either chloroquine or salazopyrin, and (D) prompt treatment with either 
salazopyrin or methotrexate. SHS: Sharp-van der Heijde Score; Time aft er fi rst assessment (yrs): follow-up time 
in years aft er the fi rst visit to a rheumatologist
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<12 weeks and ≥12 weeks showed that the diff erence in progression rate was statistically signifi -
cant (p=0.001). Because of skewness of the data, radiological data were log transformed before 
analysis; back transforming the regression coeffi  cient showed that over a period of six years 
aft er the fi rst visit to the rheumatologist, patients with a delay ≥12 weeks had a 1.34 fold larger 
rate of progression in Sharp-van der Heijde score than patients with a delay <12 weeks. In this 
analysis adjustments were made for age, gender, and the diff erent treatment periods. Plotting 
the observed median radiological scores over time for the diff erent treatment periods separately 
(Figure 1B-D), illustrated that RA patients assessed within 12 weeks of symptom onset had lower 
progression rate, irrespective of the treatment period. Th us although the increase in aggressive-
ness of treatment aft er assessment reduced the overall level of Sharp-van der Heijde scores, this 
did not diminish the eff ect of delay in referral on progression in Sharp-van der Heijde scores. 
Th e lower progression rate in the patients with a short delay (<12 weeks) could have been due 
to the fact that these patients presented in an earlier phase of the disease course, with concomi-
tantly less severe joint damage. To investigate whether this explained the observed diff erence, a 
second analysis of the progression in Sharp-van der Heijde score was performed while taking 
into account the symptom duration before the fi rst radiograph, i.e. before presentation. Th us, the 
follow-up time for all patients now commenced at the (self-reported) fi rst date of symptoms. In 
this analysis, patients with a delay <12 weeks had a signifi cantly lower progression rate during six 
years aft er the onset of the fi rst symptoms, compared to patients with a delay ≥12 weeks (p<0.001 
aft er adjustment for age, gender, and treatment period). 
Reports in literature suggest that anti-CCP positive and anti-CCP negative RA are two subsets 
of RA with diff erences in the underlying pathophysiological mechanisms and disease course.14,15 
To explore whether the eff ect of delay was diff erent in anti-CCP positive and negative RA, strati-
fi ed analyses were performed. Although stratifi cation resulted in reduced power, a statistically 
signifi cant association of a delay <12 weeks with a lower progression in Sharp-van der Heijde 
score was observed in anti-CCP negative RA (test for interaction p=0.002 without and p<0.001 
with adjustments for age, gender, and treatment period). In anti-CCP positive RA a similar, 
though not signifi cant, tendency was seen with an observed lower rate of destruction in the <12 
weeks delay group (test for interaction p=0.07 without, and p=0.18 with adjustments for age, 
gender, and treatment period).
Similar results were seen for the achievement of sustained DMARD-free remission as were 
observed for the progression in Sharp-van der Heijde scores. Sustained DMARD-free remission 
was achieved most frequently in patients with a total delay of <12 weeks (Figure 2). In the <12 
weeks delay group, 18.5% (31/168) of patients achieved remission, and in the >12 weeks delay 
group, 10.5% (41/389) achievement of remission was observed. Th e hazard ratio for not achiev-
ing sustained DMARD-free remission was 1.87 (95%CI 1.18-2.99, p=0.008) for a total delay of 
≥12 weeks compared to <12 weeks. Th e diff erence did not change aft er adjusting for age, gender, 
and treatment period (HR 1.87 (95%CI 1.17-3.00, p=0.009)). Similar results comparing patients 
with a total delay of <12 weeks and ≥12 weeks were obtained when the analysis was repeated 
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with the date of the fi rst symptoms as a starting point, both without (HR 1.90, 95% CI 1.19-3.03) 
and with (HR 1.90, 95%CI 1.18-3.05) correction for age, gender, and year of inclusion. Since in 
the anti-CCP2 positive subset only 8 patients achieved DMARD-free remission, no stratifi ed 
analysis was performed. 
Figure 2. Th e probability of achieving sustained DMARD-free remission for the diff erent delay categories. 
Remission as outcome measure for the amount of total delay. Remission was defi ned as the persistent absence of 
synovitis for at least one year aft er cessation of DMARD therapy and the identifi cation of remission by the patient’s 
rheumatologist.12 Time aft er fi rst assessment (yrs): follow-up time in years aft er the fi rst visit to a rheumatologist
Characteristics associated with delay in assessment
Subsequently, patients characteristics associating with an increased delay in assessment were 
investigated in early arthritis patients (n=1674). Univariate analysis showed that female gender, 
gradual symptom onset, older age at inclusion, symmetric distribution of symptoms, involve-
ment of small joints and joints of the upper extremities, presence of RF and anti-CCP antibodies, 
and lower levels of CRP were all signifi cantly associated with a longer duration of total delay 
(p<0.001) (Table 2).
Multivariate regression analysis identifi ed the following variables as independently associated 
with a longer duration of total delay: older age, gradual symptom onset, involvement of small 
joints, presence of anti-CCP2 and RF, and lower CRP-levels. As regression analysis was per-
formed on log transformed delay data, the relative estimated progressions were back transformed 
to the original scale (Table 3). Patient characteristics associated with patient delay and GP-delay 
showed comparable fi ndings (Table 2 and Table 3). 
Th e fi ndings that the presence of autoantibodies (anti-CCP2 and RF), symmetric involvement 
of small joints and a gradual onset of symptoms were associated with a longer delay, leads to 
the presumption that the delay in assessment diff ers for early arthritis patients with diff erent 
diagnoses. To study this, early arthritis patients were grouped according to the diagnoses that 
were achieved within the fi rst year of follow-up and the total delay durations were compared. 
Th is showed that reactive arthritis, sarcoidosis and crystal arthritis have the shortest delay in 
assessment (Figure 3). In contrast, RA patients and patients with psoriatic arthritis and spondy-
larthropathy had the longest delay in assessment.
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Table 2. Baseline characteristics of early arthritis patients associated with patient, GP and total delay in a 
univariate analysis
Early arthritis patients 
Total delay(n=1674) GP-delay(n=1111) Patient delay(n=1078)




































<.001*Subacute 11.8 (5.9-22.0) 7.7 (3.0-14.8) 2.1 (0.9-5.3)








<.001*Large 9.7 (2.9-23.4) 4.4 (1.2-15.6) 1.4 (0.3-4.6)








<.001*Lower 8.6 (2.9-24.6) 4.4 (1.0-15.4) 1.3 (0.3-4.4)




















































≥13.0§ 12.1 (4.5-24.1) 7.1 (2.1-15.1) 2.0 (0.6-4.7)
Delay durations are presented in weeks, median (IQR). Th e shown p-values refl ect the diff erence within each 
delay group (total, GP- or patient delay), thus the comparison made is for instance whether the total delay is 
diff erent between males and females. §Th e continuous variables age, CRP, SJC and Ritchie score were analyzed 
by creating two groups based on median values. ‡Defi ned durations of symptom onset: acute <24 hours; 
subacute <1 week and gradual ≥1 week. IgM-RF: Rheumatoid factor; CRP: C-reactive protein; SJC: 66-swollen 
joint count; Ritchie score: 68-tender joint count. *P-value <0.05; Mann-Whitney U/Kruskal-Wallis tests
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Variable ratio lower upper p-value
Age at inclusion (yrs)‡ 1.004 1.002 1.007 <.001
Female gender§ 1.12 1.02 1.22 .014
Gradual onset§ 2.22 2.02 2.44 <.001
Involvement of small joints vs. large§ 1.31 1.18 1.46 <.001
Involvement of both small and large joints vs. large§ 1.16 1.02 1.32 .021
Anti-CCP2§ 1.31 1.13 1.51 <.001
IgM-RF§ 1.20 1.04 1.37 .010
CRP-level‡ 0.995 0.993 0.995 <.001
GP-delay
95%CI
Variable ratio lower upper p-value
Age at inclusion (yrs) ‡ 1.004 1.002 1.009 .004
Female gender§ 1.14 1.01 1.29 .040
Gradual onset§ 1.93 1.69 2.20 <.001
Symmetric distribution of complaints§ 0.79 0.69 0.90 <.001
Anti-CCP2§ 1.33 1.09 1.63 .006
IgM-RF§ 1.22 1.01 1.47 .039
CRP-level‡ 0.995 0.993 0.995 <.001
Patient delay
95%CI
Variable ratio lower upper p-value
Gradual onset§ 2.38 2.09 2.70 <.001
Involvement of joints of lower extremities vs. upper§ 0.73 0.63 0.84 <.001
Involvement of joints of both extremities vs. upper§ 0.90 0.77 1.04 .155
Anti-CCP2§ 1.21 1.04 1.39 .010
CRP-level‡ 0.995 0.995 0.998 <.001
Th e linear regression analysis was performed on log-transformed delay data and the regression coeffi  cients were 
back transformed for comprehensible results. Th e inverse log-transformed coeffi  cients represent the estimated 
relative progression in delay. §In a categorical variable for instance, a ratio of 1.31 (Involvement of small joints 
vs. large) represents a 1.31 times longer delay. ‡In a continuous variable, a ratio of 1.004 (age at inclusion) 
indicates a 1.004 times longer delay when there is an increase in age of one year. 95CI: 95% confi dence interval; 
lower: lower bound; upper: upper bound; IgM-RF: Rheumatoid factor; CRP: C-reactive protein
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DISCUSSION
Early initiation of treatment dramatically improves clinical outcomes in patients with RA. In the 
last decade, rheumatologists have developed growing awareness of the need to treat early, and 
this, together with the availability of newer therapies and improved predictive algorithms for 
patients with early arthritis,16,17 has improved the outcome of arthritis patients considerably.18 
Th e present study shows that RA patients who have a delay longer than 12 weeks between fi rst 
symptoms and visiting a rheumatologist have a worse disease outcome, measured by two out-
comes, the rate of joint destruction, and achievement of sustained DMARD-free remission. Th e 
eff ect of delay did not disappear when a more potent treatment strategy was applied aft er assess-
ment by the rheumatologist. Importantly, amongst all early arthritis patients, patients diagnosed 
with RA had the longest delay in assessment and the majority of RA patients were assessed aft er 
12 weeks of symptoms, a period which has been referred to as the window of opportunity. Th ese 
results suggest that, to further improve the outcomes of RA patients, an important challenge is 
to get patients with arthritis to see a rheumatologist as early as possible aft er symptom onset. 
Figure 3. Total delay in assessment by rheumatologists for separate diagnoses. Total delay before visiting a 
rheumatologist divided per disease category. Depicted are the distribution and median of the total delays per 
diagnosis (at one year). React: reactive arthritis; Sarc: sarcoidosis; Cryst: crystal arthritis; CTD: connective tissue 
disease (including SLE and scleroderma); UA: undiff erentiated arthritis; OA: Infl ammatory osteoarthritis; 
RA: Rheumatoid arthritis; SpA/PsA: spondylarthropathy/psoriatic arthritis; Other. Horizontal bars represent 
median delays
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Diminishing the delay in assessment requires awareness on the part of both patients and their 
GPs. For that reason, the present study also evaluated which factors associate with the duration 
of the delay in assessment by a rheumatologist. Th is revealed that one of the important factors for 
early presentation to both the GP and to hospital was the acuteness of the start of the complaints. 
Patients with a gradual symptom onset had a longer delay than patients with an acute or subacute 
onset of symptoms. Other patient characteristics associated with a longer delay were female 
gender and an older age. A gender specifi c delay in referral has been reported before.19,20 Th us 
to prevent a worse outcome of arthritis, our fi ndings suggest that attention needs to be focused 
on the education of patients, in particular the older and female patients, about the signifi cance 
of their symptoms and the education of GPs to rapidly refer patients, in particular older, female 
patients with a gradual onset of symptoms.
Several of the patient characteristics that were associated with the duration of delay in as-
sessment of early arthritis patients belong to clusters of variables that are characteristic for spe-
cifi c diagnoses. For instance, an acute onset of symptoms and involvement of large joints of the 
lower extremities frequently occur in reactive arthritis or sarcoidosis; patients in these diagnostic 
groups had a short delay. In contrast, a gradual symptom onset and symmetrical involvement of 
small joints is more common in patients with RA. Both these characteristics and this diagnosis 
were associated with a longer delay in presentation and referral. Altogether, patients with chronic 
destructive diseases such as RA, but also psoriatic arthritis and spondylarthropathy, who should 
be seen particularly early by rheumatologists, had the longest delays in assessment. Th erefore the 
present results underline the importance of putting in place strategies to tackle reasons underly-
ing delay that have been identifi ed at the level of the patient and the GP.21,22 
Although our fi ndings provide insight into delay in assessment and its association with patient 
characteristics and disease outcome, the present study has several limitations. Patients were 
included in the EAC only if they had a symptom duration of <2 years; patients who at fi rst 
presentation had symptoms for more than 2 years were not studied. However, patients with such 
a long delay are observed to be very infrequent in our outpatient clinic. Secondly, data were 
obtained from a single country. In the present study the largest contribution to the total delay 
was delay in referral by the GP. Th is is in line with a study from the US23 and in contrast to recent 
fi ndings in British cohorts, where the largest contribution to total delay was delay on the part of 
the patient.24,25 Diff erences in health care systems, but also cultural diff erences26 could, at least 
partially, provide an explanation for the contrasting observations. Nevertheless, the median total 
delay for RA patients was well over 12 weeks in the UK, Canada and in the Netherlands (23 
weeks,24 ~17 weeks27 and 18.4 weeks respectively) and the present study highlights the conse-
quences of that delay.
Th e fi ndings that RA patients with a longer delay had more severe joint destruction and less 
sustained DMARD-free remission are in line with fi ndings that an early initiation of treatment 
is benefi cial to the disease outcome.8,9 It was questioned whether the patients with a shorter 
delay had a truly better disease course or were just seen earlier in the disease course, resulting in 
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a seemingly lower level of joint destruction. Th erefore, analyses were repeated with the date of 
the fi rst complaints as a starting point. Th is showed that patients who had a delay of <12 weeks 
indeed developed less severe disease compared to patients with a longer delay. 
Th ere are two potential explanations for the observed diff erence in severity between the <12 
weeks and ≥12 weeks delay groups. First, it may be that RA patients that were assessed in a 
short time constitute a subset of RA that by itself is characterized by a better outcome. It is 
known that the subset of RA characterized by the absence of anti-CCP antibodies has a better 
disease outcome than the anti-CCP positive subset,14 and in our data anti-CCP positive patients 
had more oft en a gradual onset of complaints (49.3% vs. 38.2%) and more delay (22.0 vs. 14.3 
weeks, median) than anti-CCP negative RA patients. To account for such diff erences between 
RA patients, the eff ect of delay was studied in both the anti-CCP positive and anti-CCP negative 
subset. Th is showed a signifi cant association between delay in assessment and joint destruction 
in anti-CCP2 negative RA patients and a similar tendency in anti-CCP positive RA patients. Th e 
present data however do have insuffi  cient power for these sub-analyses and more specifi cally do 
not allow making defi nite conclusions on the eff ect of delayed assessment on joint destruction 
in the subset of anti-CCP positive patients. Alternatively, patients assessed within 12 weeks were 
treated earlier which may have contributed to a less severe course of RA which is in line with 
previous data,4 and supports the hypothesized existence of a window of opportunity. Nonethe-
less, regardless of the explanation of the fi ndings (better outcome in anti-CCP negative patients 
with a more acute symptom onset or better outcome due to early initiation of treatment) the 
main argument to refer as early as possible is that it provides the opportunity to modify RA in an 
early phase with potential benefi cial eff ects on the future disease course. 
In conclusion, a shorter time to assessment by a rheumatologist is associated with more 
DMARD-free remission and less joint destruction in RA. Despite this association, among all 
early arthritis patients, those diagnosed with RA had one of the longest delays in assessment 
and only one third was assessed within the so-called window of opportunity. Since rheumatolo-
gists are nowadays aware on the importance to treat early, our results suggest that in order to 
further improve disease outcomes in RA it will be crucial to diminish the delay in assessment by 
a rheumatologist. Further work could test whether accelerated treatment strategies indeed leads 
to improve disease outcomes in RA.
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Very early therapy of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs is 
associated with lower levels of joint destruction and a higher chance on achieving remission.1-5 
Having symptoms for >12 weeks at treatment initiation is a strong and independent risk factor 
for a persistent disease course.1,3-5 Th ese observations have led to the concept of the ‘window of 
opportunity’.2 Th is hypothesis presumes that underlying disease processes are not fully matured 
in the very early stage of arthritis, making modulation more successful. However, putative bio-
logical mechanisms remain unexplored. 
Anti-cyclic citrullinated protein antibodies (ACPA) precede arthritis development and are 
associated with a severe disease course.6 We hypothesized that the ACPA-response broadens 
within the very early phase of RA and in doing so limits the ‘window of opportunity’. Th erefore 
it was examined whether patients that are assessed within 12 weeks of symptom onset have a less 
broadened ACPA-response than patients with longer symptom duration. 
309 ACPA-positive patients (defi ned by anti-CCP2-positivity) fulfi lling the 1987-ACR criteria 
for RA and included in the Leiden Early Arthritis Clinic7 were studied on the association between 
symptom duration and the progression in joint destruction over 7.5 years, with symptom onset 
as starting point.3 Yearly radiographs of hands and feet were scored according to the Sharp-
van der Heijde method.7 A repeated measurement analysis was used with a random person 
and time eff ect; the fi xed eff ect of time was modeled with linear spline functions with knots 
at each year.3 Adjustments were made for age, gender and treatment strategy. RA patients that 
presented with <12 weeks or ≥12 weeks of symptoms were compared for level, isotype-usage and 
fi ne specifi city of ACPA at inclusion. Antibody reactivity against peptides derived from human 
proteins (the citrullinated (Cit) and the uncitrullinated form of two linear peptides derived from 
vimentin (Vim1-16:STCitS VSSS SYCitCit MFGG and Vim59-74:VYAT CitSSA VCitLCit SSVP), 
two linear peptides derived from fi brinogen (Fibα27-43:FLAE GGGV Cit GPR VVER H and 
Fibβ36-52:NEEG FFSA CitGHR PLDK K), one linear peptide derived from α-enolase (Eno5-
20:KIHA CitEIF DSCitG NPTV) and Myelin Basic Protein (MBP)) were determined by ELISA 
and described previously.3,7-9 Anti-CCP3 and anti-MCV were also measured by ELISA (Quanta 
Lite CCP version 3.1 for IgG/IgA, Inova Diagnostics San Diego, USA and Orgentec Diagnostika, 
Mainz, Germany). 
RA patients that presented <12 weeks of symptom onset had less progression in joint destruc-
tion over 7.5 years (p=0.04) (Figure 1). Patients with symptoms <12 weeks revealed no diff erences 
in anti-CCP2 level, isotype usage or fi ne-specifi city recognition profi le compared to patients with 
longer symptom duration (Table 1). 
To our knowledge this is the fi rst study investigating ACPA-characteristics in relation to the 
so-called ‘window of opportunity’. Recently published data showed a trend for less joint destruc-
tion in ACPA-positive RA patients presenting with symptoms <12weeks.3 In the present study 
the radiographic data were extended. No clear diff erences were observed with respect to ACPA-
characteristics in relation to symptom duration. Although it cannot be excluded that other 
ACPA-characteristics, such as glycosylation patterns or other ‘fi ne-specifi cities’, would show 
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Table 1. ACPA characteristics at inclusion of ACPA-positive RA patients with symptoms for <12 or ≥12 weeks












































































































































































Fine-specifi city data were assessed in patients included between 1993 and 2006. Fine-specifi city data were 
missing for 61 patients. Isotype data were determined previously in patients included between 1993 and March 
2004 and are therefore missing in 116 patients. *Diff erence in anti-CCP2 levels was analyzed using Mann-
Whitney test. IQR=interquartile range. cVim=citrullinated vimentin; cFib=citrullinated fi brinogen; cEno5-
20=citrullinated Enolase 5-20; MBP=myelin basic protein; MCV=mutated citrullinated vimentin.**8 peptides 
were included for the high versus low recognition analyses: cVim1-16, cVim59-74, cFib-α, cFib-β, cEno5-20, 
MBP, MCV, CCP3. ***ACPA isotypes were measured using anti-CCP2 peptides
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diff erences, our data indicate that the ‘window of opportunity’ is not refl ected in the maturation 
of the ACPA-response. 
A longitudinal study-design with regular assessments of ACPA-characteristics within the same 
patients would be more appropriate than a cross-sectional study. However, as ACPA-positive 
RA patients oft en present relatively late (only 22.7% of the ACPA-positive RA patients visited 
a rheumatologist <12 weeks of symptom onset), it will be diffi  cult to obtain adequate patient 
numbers. 
In conclusion, ACPA-positive RA patients with symptoms <12 weeks have less progressive 
disease than patients with a longer symptom duration. However, the broadness of the ACPA-
response is not diff erent between these groups; indicating that maturation of the autoantibody 
response occurs even earlier.10
Figure 1. Joint destruction (Sharp/van der Heijde scores) over time in ACPA-positive RA patients with <12 or 
≥12 weeks of symptoms at fi rst presentation at the rheumatologist. Th e date of symptom onset is used as starting 
point. 70 ACPA-positive patients (22.7%) presented <12 weeks (median aft er 8 weeks of symptoms) and 239 
ACPA-positive patients presented aft er ≥12 weeks of symptoms (median symptom duration at fi rst presentation 
at 27 weeks). Th e RA patients studied were included in the Leiden Early Arthritis Clinic between 1993 and 2006
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Joint destruction in rheumatoid arthritis (RA) was until recently seen as an irreversible state. 
Lately, it was defi ned that repair of bone erosions occurs; however little is known about its preva-
lence. Th is study investigates the frequency of repair and patients characteristics associated with 
repair in an inception cohort.
Patients and methods
250 RA patients, included in the Leiden Early Arthritis Clinic between 1993-2000 and treated 
with conventional DMARD-therapy, were studied (mean follow-up 10.1 years). Yearly made 
radiographs were scored using the Sharp-van der Heijde method, initially aware of the chronol-
ogy. Patients with a negative change in erosion scores on subsequent radiographs were selected 
and their series of radiographs were rescored with concealed time sequence by three readers. 
Repair was defi ned as agreement of two readers in having a negative change in erosion scores that 
persisted for at least two years. 
Results
Repair was identifi ed in 32 joints in 18 patients (7.2%). Patients with repair had more frequent 
autoantibodies (RF, ACPA) and a higher level of joint destruction. In the joints with repair 
arthritis was absent in the two years preceding repair. 
Conclusions
Repair occurred in 7.2% of the RA patients, particularly in clinically inactive joints in patients 
with severe destructive disease.
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INTRODUCTION
Rheumatoid arthritis (RA) oft en results in destruction of bone and cartilage, visualized on 
radiographs as erosions and joint space narrowing respectively. For a long time the bone damage 
was considered to be permanent.1 Recently some studies sustained the possibility of radiologi-
cal repair.2-6 Dedicated research in the context of Outcome Measures in Rheumatoid Arthritis 
Clinical Trials (OMERACT),7,8 along with recent literature reviews,9,10 led to the conclusion 
that “repair does exist”. Th is is of utmost clinical relevance because it demonstrated that the 
“repair machinery” is able to take away, at least partly, the consequences of damage by RA. If the 
biological basis of this phenomenon could be understood, it would allow the development of 
therapies specifi cally targeted to stimulate these repair mechanisms. Th is study aims to assess the 
frequency of repair in a large inception cohort of RA patients treated with conventional disease 
modifying antirheumatic drugs, and to characterize the patients expressing repair.
PATIENTS AND METHODS
Patients
250 RA patients, consecutively included in the Leiden Early Arthritis Clinic (EAC) between 1993 
and 2000 were studied. Th e era 1993-2000 was chosen as it has the longest duration of follow-
up (mean 10.1 years, SD=2.3), resulting in a real opportunity to express repair. Clinical and 
laboratory characteristics were yearly measured and radiographs of hands and feet were yearly 
taken.11 Treatment strategies diff ered per inclusion period. Patients included between 1993-1995 
were treated with delayed therapy (initially analgesics, subsequently chloroquine or salazopyrin) 
and between 1996-2000 with prompt initiation of chloroquine, salazopyrin or methotrexate. 
Biologicals or aggressive combination therapy were not applied. 
Radiograph scoring
Th e radiographs were scored using the Sharp–van der Heijde method12 by one reader, blinded 
to the clinical data, initially aware of the chronology. Patients with a negative change in erosion 
scores on subsequent radiographs were selected. Th eir series of radiographs were mixed with se-
ries of patients with stable or positive change in erosion scores, so that the readers were unaware 
of the scores that were assigned previously. Th ese radiographs were rescored with concealed time 
sequence by three trained readers. Th e intrareader intraclass correlation coeffi  cient for the status 
scores was 0.91. Th e intraclass correlation coeffi  cient between reader 1 and 2 was 0.94, between 
reader 1 and 3 0.95 and between reader 2 and 3 0.93. 
Defi nition of repair
Repair was defi ned as fulfi lling all of the following three criteria a) presence of a negative change 
in erosion score on a joint level on two subsequent time points both when scored with known 
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and concealed time order, b) persistency of the lower erosion score ≥2 subsequent years, c) agree-
ment on the negative change in erosion score between at least two of the three readers. In case 
data on two subsequent years were not available, all three readers had to agree with the negative 
change in erosion score. 
Patient characteristics
Patients with and without repair were compared for several baseline characteristics and for the 
total Sharp-van der Heijde scores during follow-up. Th e achievement of sustained DMARD-free 
remission (the persistent (≥1 year) absence of arthritis aft er cessation of therapy with disease 
modifying antirheumatic drugs)13 was evaluated in both groups. Th e annually assessed swollen 
joint count was studied in order to investigate whether the joints that showed repair had clinically 
detectable arthritis in the two years preceding the development of radiologically visible repair. 
Statistical analysis
Diff erences in means were analyzed with the Mann-Whitney test. Proportions were compared 
using the chi-square test. Th e Statistical program for Social Sciences (SPSS) version 14 was used. 
P-values <0.05 were considered signifi cant.
RESULTS
Prevalence of repair
Seventy of 250 RA patients had at least once a decrease in erosion score in any of the joints, evalu-
ating all series of radiographs with known time-order. Aft er rescoring with concealed time-order, 
32 joints with repair were identifi ed in 18 (7.2%) patients. Of these, 26 concerned small joints 
of the hands (8 MCP joints, 9 PIP joints and 9 radiocarpal joints) and 6 concerned MTP joints. 
Th irty joints showed persistency of the negative change in erosion score for ≥2 years and for 2 
joints no data on two additional years were available but there was agreement of all three readers 
in the identifi cation of repair. 61% of the patients showed repair in one joint; 11%, 17% and 11% 
expressed repair in 2, 3 and 4 joints respectively. Th e highest frequency of repair occurred aft er 
4 to 6 years follow-up (Figure 1). Th e frequency of repair was 13.0% for inclusion between 1993 
and 1995 and 5.2% for inclusion between 1996 and 2000. 
Baseline characteristics of patients expressing repair
Patients with and without repair revealed no diff erence in age, gender, Ritchie score, swollen 
joint count, CRP level and total Sharp-van der Heijde score at baseline (Table 1). In contrast, 
patients with repair were more oft en RF-IgM positive (OR 3.7, 95%CI 1.2-11.5, p=0.025) and 
anti-CCP positive (OR 7.9, 95%CI 1.8-35.2, p=0.007) compared to the non-repair group.
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Disease course of patients expressing repair
Seventeen patients with repair (94%) had an increase in total Sharp score at the same time as 
showing repair in individual joints; only one patient showed a decrease in total Sharp-score, 


















Figure 1. Frequency of repair during the years of follow-up, indicated for small joints of the hands and the feet 
separately. Th e total number of small joints assessed in the hands is 32 and in the feet is 12. Th e joints assessed 
in the hands are the proximal inter-phalangeal (PIP) joint in digits 1 to 5, the metacarpo-phalangeal (MCP) 
joint in digits 1 to 5 and 6 radio-carpal sites (base of metacarpal bone digit 1, trapezium, lunate, scaphoid, distal 
ulna and distal radius and in the feet are the inter-phalangeal (IP) joint digit 1 and metatarso-phalangeal (MTP) 
joint in digits 1 to 5





Age at baseline, mean (SD) 59.3 (9.3) 55.1 (16.9) 0.30
Female gender, No (%) 13 (72) 155 (67) 0.67
Ritchie score, mean (SD) 11.5 (8.0) 10.8 (7.8) 0.73
44 Swollen Joint Count, mean (SD) 5.9 (2.4) 6.0 (3.4) 0.86
ESR in mm/h, mean (SD) 44.2 (25.0) 41.6 (29.9) 0.68
CRP in mg/l, mean (SD) 26.4 (21.3) 29.4 (28.2) 0.59
RF-IgM positive, No (%) 14 (77.8) 112 (48.7) 0.025
Anti-CCP2 positive, No (%) 15 (88.2) 106 (48.8) 0.007
Total Sharp score, mean (SD) 8.1 (6.1) 7.5 (9.1) 0.79
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation date; RF, rheumatoid 
factor.
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During the disease course patients with repair had signifi cant higher Sharp-van der Heijde 
scores compared to patients without repair (Figure 2A). A similar observation was done for the 
total erosion score (Figure 2B).
Th e achievement of sustained DMARD-free remission was compared for patients with and 
without repair. One patient of the repair group had clinical remission (5.5%), compared to 16 % 
(56 out of 232 patients) in the non-repair group (OR 0.15, 95%CI 0.01-1.37, p=0.07).
Th e presence of joint swelling for the 23 joints showing repair in the MCP, PIP or MTP-joints 
was evaluated at the two previous years. Th is showed that joint swelling was absent in 22 joints in 
two years preceding repair and in 1 joint swelling was absent one year preceding repair.
Figure 2. Total Sharp-van der Heijde scores (mean  SEM) (A) and total erosion scores (mean  SEM) (B) 
during follow-up in patients with and without repair. From the patients with repair, the number of radiographs 
available per year were: 18 at baseline, 18 aft er 1 year of follow-up, 18 aft er 2 years of follow-up, 15 aft er 3 years 
of follow-up, 14 aft er 4 years of follow-up, 17 aft er 5 years of follow-up and 12, 12 , 10, 8 and 8 aft er 6-10 years 
of follow-up respectively. *p<0.05
DISCUSSION
Th e present study investigated repair in an inception cohort with a long duration of follow-up. 
Previous studies concerned data from clinical trials or evaluated a selected set of RA patients.2,5,6,14 
Importantly, these studies formed the basis for the acceptance of the existence of repair. We now 
report on the prevalence in a large longitudinal cohort of RA patients treated with conventional 
treatment strategies. Our results show that, despite the absence of aggressive or biological anti-
rheumatic therapy, repair occurs in part of the general RA population. 
Th e prevalence of repair observed here (7.2%) is somewhat lower than reported previously 
(10.7%).14 We have chosen a strict defi nition of repair to reduce the chance on false-positive fi nd-
ings; this may indicate that our prevalence is an underestimation. In addition, the comparison 
of erosion scores of individual joints between two consecutive time-points may have introduced 
misclassifi cation, in some cases repair would have been more easily detected in case a larger 
interval between the radiographs was compared. Th ird, the fi nding of a lower prevalence may be 
caused by the fact that we studied a general RA population and not a selection of RA patients. 
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Interestingly, repair occurred preferentially in patients with severe joint destruction. Th is 
might seem surprising as it could be hypothesized that repair will predominantly be present 
in the patients with a low total level of joint destruction. Several possibilities may explain this 
observation. First, it may be a methodological issue based on the presumption that a refi ll is 
more easily detected in large erosions. If this is true, repair should predominantly be present in 
joints with a high erosion score. Our data are not supportive for this notion. Th e erosion score for 
individual joints ranges between 0 (no erosion) and 5 (maximum score). Th e majority of patients 
with repair showed a decrease in the erosion score from 2 till 1 or from 1 till zero, and thus did 
not reveal repair in joints that are particularly severely damaged. A second possibility is again 
methodological. In patients with a lot of damage, many joints show erosions and therefore in 
these patients more joints are ‘at risk’ for showing repair. A third possible explanation is biologi-
cal. In general the human body tends to heal destruction and aims for homeostasis. It can be 
hypothesized that the more destruction is present, the more regenerating processes are activated. 
Th en aft er the infl ammation or the processes that drive the destruction of bone are disappeared, 
the enhanced regenerating mechanisms may result in repair.
At the same time repair occurred in some joints, the total Sharp-van der Heijde score increased, 
indicating progression in other joints. Th is is in concordance with a study performed by the 
OMERACT group,4 and implies that repair is a localized process. Th e observed absence of joint 
swelling in the two years preceding repair is in line with similar fi ndings in the TEMPO-trial.15 
In conclusion, repair occurs in 7.2% of conventionally treated RA patients, particularly in 
clinically inactive joints in patients with severe destructive disease. Further studies on the bio-
logical basis of repair are challenging as they may allow the development of therapies specifi cally 
targeted to stimulate these repair mechanisms.
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Th e relation between joint infl ammation and destruction is characteristic for RA. Individual 
patients diff er in the amount of joint damage in response to infl ammation; the mechanisms un-
derlying coupling/uncoupling are incompletely understood. Evaluation of patients with extreme 
erosive responses to local infl ammation may increase our comprehension. Th is study explored 
whether this approach is feasible.
Methods
RA patients included in the Leiden Early Arthritis Clinic with complete 5 years follow-up data 
(n=159) were studied. Yearly visits included radiographs of hands and feet and swollen joint 
counts (SJC). Th e cumulative infl ammatory burden was expressed with an AUC of SJCs. Patients 
with high-infl ammatory non-erosive (‘resistant’) and low-infl ammatory high-erosive (‘sensitive’) 
phenotypes were identifi ed.
Results
Six patients (4%) had a resistant phenotype; these were rheumatoid factor negative and had 
short symptom duration. Seventeen patients (11%) had a sensitive phenotype; these patients had 
a lower SJC at baseline and were oft en rheumatoid factor positive. Power analyses performed 
with diff erent risk factor frequencies, diff erent levels of signifi cance and the number of extreme 
patients identifi ed yielded powers >80%.
Conclusion
Patients with extreme erosive responses to local infl ammation were identifi ed. Further evalua-
tions on these patients may elucidate mechanisms contributing to the connection of infl amma-
tion and destruction of joints in RA.
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INTRODUCTION
Understanding of the mechanisms involved in disease progression or resistance to progression 
is required to derive strategies to diminish such progression. Generally a whole population of 
patients is studied to identify such factors. Alternatively, the most and least progressive patients 
can be compared. Th is extremes-of-the-phenotype approach reduces the number of patients that 
need to be studied; this is benefi cial when it is impractical or expensive to determine risk factors 
in large numbers of patients. A third approach, the extreme-discordant-phenotype methodology, 
studies the response of individuals on an increasing dose of stimuli; the extremes of this gradient 
are identifi ed as ‘sensitive’ or ‘resistant’ phenotypes.1,2
Th is extreme-discordant-phenotype methodology has been successful in the identifi cation of 
genetic variants involved in responsiveness to drugs, malignancies, and infectious diseases.3-5 
An example of a ‘sensitive phenotype’ is the observation that some patients with malignancies 
developed severe toxicity aft er receiving 5-fl uorouracil. Th orough evaluation of these patients led 
to the association with a complete defi ciency of dihydropyrimidine dihydrogenase activity in pe-
ripheral blood mononuclear cells, which is caused by diverse genetic alterations.5 An outstanding 
example of the identifi cation of a resistant factor is based on the observation that some individu-
als highly exposed to HIV never developed the infection. Th is resulted in the identifi cation of 
a deletion in the gene encoding the chemokine coreceptor CCR-5, which is now a drug target.4
Infl ammation and destruction of joints are hallmarks of Rheumatoid Arthritis (RA) and the 
notion that local infl ammation leads to destruction of joints is basic to the concept of RA. On 
the group level, the amount of infl ammation is indeed correlated with the amount of erosive 
joint damage. However, the degree of erosiveness in response to infl ammation is highly variable 
between RA patients and also disconnection has been observed.6-11 Th e mechanisms underlying 
such coupling/uncoupling are incompletely understood. Since the readiness for bone to erode in 
response to local infl ammation appears to be an individual’s characteristic, genetic factors may 
play a role.
Our ultimate aim is to unravel processes contributing to an individual RA-patient’s predis-
position to develop joint erosions in response to local infl ammation. In this study we evaluate 
whether the extreme-discordant-phenotype methodology is feasible to this end.
PATIENTS AND METHODS
Patients
RA patients included in a population based inception cohort, the Leiden Early Arthritis Clinic 
(EAC), were studied. For an extensive cohort description see reference.12 Written informed 
consent was obtained from all participants. Th e study was approved by the local medical ethics 
committee. All RA patients satisfi ed the 1987 ACR-criteria for RA. From the total number of 
695 RA patients, 441 RA patients had achieved 5 years of follow-up. Of these, 159 RA patients 
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had missed none of the yearly follow-up visits and had complete follow-up data during 5 years. 
Baseline characteristics were not signifi cantly diff erent between patients with and without miss-
ing follow-up visits (data not shown). Th e 159 RA patients were studied to identify patients 
with high-infl ammatory non-erosive (‘resistant’) and low-infl ammatory high-erosive (‘sensitive’) 
phenotypes.
Joint damage
All 1908 hand and feet radiographs were scored by one experienced reader (MPMvdL) according 
to the Sharp-van der Heijde score (SHS) in chronological order. 499 radiographs were rescored; 
the interclass-observer correlation coeffi  cient was 0.91. Th e total erosion SHS was used. Based 
on previous fi ndings,13 patients whom had a SHS erosionscore ≤1 aft er 5 years were defi ned as 
having non-erosive disease. To select the patients with a high-erosive disease course, the patients 
with the highest quartile of SHS erosionscores at the 5-years visit were evaluated.
Joint infl ammation
Local infl ammation of the joints was assessed by the 44-swollen joint count (SJC) at each visit. 
For classifi cation as ‘high-infl ammatory’ synovitis had to be observed almost persistently during 
the follow-up period; a SJC of 0 was allowed at only one point in time. For classifi cation of 
‘low-infl ammatory’ the SJC during follow-up required to be 0 in three out of the fi ve follow-up 
time-points and to be ≤5 at the other follow-up timepoint(s). Th ese cut-off  values are arbitrary 
and were chosen based on visual evaluation of the SJCs of the whole RA-population during 
the follow-up visits. To appraise whether these cut-off s allowed the identifi cation of extreme 
discordant phenotypes, for each patient the cumulative infl ammatory burden over 5 years was 
estimated by calculating an area under the curve (AUC) and plotted against the SHS-erosionscore 
at 5 years.
In the evaluation on joint infl ammation above, 44 joints (44 SJC) were studied. Although it was 
observed that in the present dataset the SJC was mainly driven by the number of infl amed small 
joints, a comparison of joint destruction in the small joints with joint infl ammation in small 
and large joints may be considered inequitable. Th erefore we also evaluated infl ammation in 32 
small joints (the wrist, MCPs, PIPs and MTPs joints that were assessed in the SHS) and again 
identifi ed patients that were ‘high infl ammatory’ and ‘low infl ammatory’ using the cut-off  values 
as described above.
Statistical analysis
Patient characteristics were compared using crosstabs and Chi-square, Fisher exact, Mantel-
Haenszel statistics in SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Power calculations were 
performed for testing two independent proportions based on the Z-test in Pass 2008 (NCSS, LCC 
Kaysville, Utah, USA), using two signifi cance levels namely 0.05 and 0.005.
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RESULTS
Extreme discordant phenotypes
Applying the defi nitions of non-erosive, high-erosive, low-infl ammatory and high-infl ammatory 
as indicated, resulted in the selection of 6 RA patients with a high-infl ammatory non-erosive (‘re-
sistant’) phenotype and 17 patients with a low infl ammatory high-erosive (‘sensitive’) phenotype 
(Figure 1A). Th e remaining 136 patients (85%) were labeled as the reference group. Th e AUC of 
the SJC over time was plotted against the erosion score at 5-years (Figure 1B); the patients with 
the ‘sensitive’ and ‘resistant’ phenotype are indicated in red and blue respectively.
Evaluations of infl ammation in small and large joints and joint damage in only small joints 
may be imbalanced when infl ammation is predominantly present in large joints. To explore this, 
analyses were repeated comparing infl ammation and destruction in small joints only. Th en, 6 
High Erosive (n=91) Non-erosive (n=35) 
159 RA patients with complete followup data for erosion 


















Figure 1. Flow diagram of the selection of extreme discordant phenotypes (A), graphic representation of the 
cumulative level of infl ammation and damage over 5 years of disease evaluating infl ammation in 44 joints (B) 
and evaluating infl ammation of small joints only (C). As shown in panel A, patients were used for analysis if 
they had complete radiographic and SJC data during 5 years of follow-up. Patients were non-erosive when 
having SHS erosion score ≤1. High-erosive patients were within the highest quartile of erosions scores at year 
5. In high-infl ammatory patients synovitis had to be present in almost all visits as a SJC of 0 was allowed only 
at one point in time. Low-infl ammatory patients the SJC was 0 for at least three out of fi ve follow-up time 
points and ≤5 at the other followup time points. For Figure 1A and 1B infl ammation was assessed in 44 joints, 
for Figure 1C infl ammation was assessed in 32 small joints (wrists, MCPs, PIPS, and MTP joints that are also 
evaluated on joint destruction in the Sharp/van der Heijde method)
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RA patients were identifi ed with a high-infl ammatory non-erosive (‘resistant’) phenotype and 20 
patients with a low-infl ammatory high-erosive (‘sensitive’) phenotype (Figure 1C). Th e patients 
with the resistant phenotype were the same individuals as in Figure 1B. Also the patients with 
the sensitive phenotype were similar but extended with three additional patients. Th ese three 
additional sensitive patients were “low-infl ammatory” when assessing small joints only, but not 
when assessing 44 joints as they had infl ammation in large joints. Th erefore, to study the most 
extreme discordant patients, patients that in both analyses were identifi ed as extreme discordant 
were evaluated in further analyses.
Patient characteristics
Baseline characteristics of the patients with the ‘sensitive’ or ‘resistant’ phenotype were compared 
to that of patients in the reference group (Table 1). Compared to the reference group, patients with 
the ‘resistant phenotype’ were characterized by the absence of IgM-rheumatoid factor, a low fre-
quency of anti-CCP2-positivity, more frequently an acute onset of symptoms, a shorter symptom 
duration and a higher SJC at fi rst presentation. Patients with the ‘sensitive phenotype’ were more 
oft en rheumatoid-factor positive, had a longer symptom duration and a lower SJC at baseline than 
the reference group. Th e erythrocyte sedimentation rate and C-reactive protein (CRP) levels at 
baseline were not statistically diff erent between the ‘sensitive’, ‘resistant’ or reference groups.
Power of extreme discordant phenotype approach
Next we aimed to evaluate the power to identify genetic variants associating with these pheno-
types, using the number of patients identifi ed. Our hypothesis is that these extreme discordant 
phenotypes are multi-factorial and caused by either recessive eff ects of common genetic variants 
or rare genetic variants. For the recessive eff ect we assume that the penetrance is not 100%, i.e. 
that also in the reference group recessive genotypes occur. Concerning rare variants it is assumed 
that multiple deleterious and neutral variants are present in the studied genomic region.14 For 
comparisons of the number of patients carrying the recessive genotype or the number of patients 
carrying rare mutations between the two groups the same Z-test can be used; hence one power 
study is required applying to both situations. For the non-erosive group, the power to detect 
diff erences between the high-infl ammatory (n=6, ‘resistant’) and non-high-infl ammatory group 
(n=29) was determined. For an α of 0.005 and for instance carrier frequencies of 0.83 (5 out of 6) 
in group 1 (P1) and 0.03 (1 out of 26) to 0.10 (3 out of 26) in group 2 (P2), the power to detect a 
diff erence is above 90% (Figure 2A). When using an α of 0.05 and similar frequencies, the power 
is 97% (Figure 2B). For the high-erosive group, the power to detect diff erences between the 
low-infl ammatory (n=17, ‘sensitive’) and non-low-infl ammatory group (n=74) was determined. 
In case of carrier frequencies of 0.8 and 0.1, the power to detect a diff erence is 100%, both for α’s 
of 0.005 and 0.05 (Figure 2C, D). Th e power for other genotype frequencies is depicted in Figure 
2. Overall, it was observed that evaluations on the present number of patients with extreme 
discordant phenotypes and rare genetic variants have suffi  cient power.
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DISCUSSION
Th e relation between infl ammation and subsequent joint damage is characteristic for RA and is 
basic to current treatment strategies that aim to prevent or retard joint damage by reducing the 
infl ammatory load. Although this strategy is eff ective on the group-level, the coupling between 
infl ammation and destruction of joints in individual patients is variable. One method to identify 









Female, n (%) 106 (66.7) 90 (66.2) 10 (58.8) 6 (100)
Age at inclusion (yrs), 
mean (SD) 55.2 (13.8) 55.1 (13.8) 57.5 (13.9) 51.3 (13.8)
Symptom duration at fi rst 
presentation, weeks mean 
(SD)
31.9 (26.8) 32.1 (26.5) 37.9 (31.6) 16.1 (20.2)
< 6 weeks, n(%) 36 (24.8) 32 (25.2) 1 (5.9) 3 (50.0)
≥ 6 weeks, n (%) 109 (75.2) 95 (74.8) 11 (91.7) 3 (50.0)
Onset of symptoms
(Sub)Acute 76 (50.7) 64 (48.5) 8 (61.5) 4 (80.0)
Gradual 74 (49.3) 68 (51.5) 5 (38.5) 1 (20.0)
Morning stiff nes (min), 
mean (SD) 89.6 (97.7) 88.5 (86.2) 92.5 (171.6) 105.0 (92.5)
44 Swollen joint count,  
mean (SD) 10.1 (7.7) 10.5 (7.7) 5.2 (3.3) 14.8 (10.1)
1 medium-large joint, 
n (%) 3 (1.9) 1 (0.7) 1 (5.9) 1 (16.7)
2-10 medium-large joints, 
n (%) 3 (1.9) 3 (2.2) 0 (0) 0 (0)
1-3 small joints, 
n (%) 19 (11.9) 15 (11.0) 4 (23.5) 0 (0)
4-10 small joints, 
n (%) 54 (34.0) 44 (32.4) 9 (52.9) 1 (16.7)
> 10 joints, 
n (%) 80 (50.3) 73 (53.7) 3 (17.6) 4 (66.7)
ESR (mm/hr), mean (SD) 46.1 (32.7) 46.1 (32.7) 46.3 (32.4) 46.3 (38.1)
CRP (mg/l), mean (SD) 36.6 (40.9) 34.7 (40.4) 52.6 (44.1) 40.7 (43.2)
IgM-RF-positive, n (%) 101 (64.7) 88 (64.7) 13 (92.9) 0 (0)
Anti-CCP2-positive, n (%) 103 (66.5) 91 (67.9) 11 (73.3) 1 (16.7)
HAQ, mean (SD) 0.91 (0.68) 0.92 (0.66) 0.66 (0.88) 1.14 (0.70)
Comparison of ‘resistant’ phenotype versus reference group: IgM RF p=0.003, anti-CCP p=0.018, symptom 
duration  p=0.057, onset of symptoms p=0.2 and SJC p=0.2. Comparison of ‘sensitive phenotype’ versus 
reference group: IgM-RF p=0.036, SJC p=0.004
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factors relevant in protection or progression is to appraise patients with extreme responses on 
infl ammation. Th e present study reports that RA patients with extreme discordant phenotypes 
can be identifi ed.
We identifi ed two extreme responses on joint infl ammation. Th e ‘resistant’ phenotype, 
characterized by the absence of erosive damage despite high cumulative levels of infl ammation 
throughout the studied period, and the ‘sensitive’ phenotype, characterized by the lowest cumu-
lative infl ammation but the highest levels of erosiveness. Considering the ‘sensitive’ phenotype, a 
question is whether physical examination on swollen joints was sensitive enough to detect joint 
infl ammation. It is possible that subclinical infl ammation was present.15 However, even in this 
case, these patients have an extreme sensitive response to subtle local infl ammation.
We did not intend to evaluate whether infl ammation is associated with joint destruction; this 
has been studied before on joint level.16 Moreover, in the present study analyses were performed 
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Figure 2. Results of the power analyses. Th e power is indicated to detect diff erences between the non-erosive 
high-infl ammatory (‘resistant’, n=6) and low-infl ammatory (n=29) groups (Panel A and B) and high-erosive 
low-infl ammatory, (‘sensitive’ n=17) and high-infl ammatory (n=74) groups (Panel C and D). Power calculations 
were done for diff erent levels of signifi cance: α of 0.005 (Panel A, C) and 0.5 (Panel B, D). P1 represents the 
proportion of patients carrying the recessive genotype or the proportion of patients carrying rare mutations in 
the resistant or sensitive group and P2 represents these proportions in the other group
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we did not perform analyses on joint level, as this would have resulted in 32 comparisons per 
patient.
Th e ultimate question is what processes underlie these extreme phenotypes. Genetic factors 
may account for an individual’s degree of sensitivity to infl ammation. It was observed that the 
power of future genetic studies on rare genetic variants using the number of patients identifi ed 
is suffi  cient.
Th e present study has several limitations. First, the AUC of the SJC was determined using 
yearly measurements. Th is may lead to bias since the number of swollen joints at one time-point 
may not refl ect the average number of swollen joints during a year. To prevent misclassifi cation, 
the medical fi les of all patients in the high or low infl ammatory groups were studied to verify 
whether the classifi cation fi tted with clinical evaluations at time points in between yearly visits. 
Second, treatment was not taken into consideration. Th e variety of medications used made 
adjusting for treatment challenging. It is generally presumed that anti-rheumatic treatment 
suppresses the level of infl ammation. Th is does not hamper the subject of the present study, 
which concerns the degree of joint damage in response to infl ammation. In case treatment was 
prescribed that directly aff ected bone destruction, joint damage may be more diminished than 
would be the result of suppressing infl ammation only. At present, to our knowledge, the only 
anti-rheumatic treatments that may reduce bone damage to a higher extend than suppressing 
infl ammation are the TNFα inhibitors.6-9 None of the 6 ‘resistant’ patients were treated with 
anti-TNF. A third issue is that we studied the SJC and not the level of acute phase reactants or 
the disease activity score (DAS). We did not study the DAS as it is a composite measure. Pain 
may increase the DAS also in the absence of synovitis and, vice versa, it is known that a low DAS 
can be achieved in the presence of infl amed joints. We also chose not to use the CRP as this is a 
systemic infl ammatory-marker, rather than a refl ection of local infl ammation. A recent study on 
data from fi ve randomized trials also showed that joint swelling rather than CRP contributes to 
joint damage.17
In conclusion, RA patients with extreme responses in joint destruction to local infl amma-
tion are infrequent but prevailing. Further studies in these patients may elucidate mechanisms 
contributing to the coupling between infl ammation and destruction of joints in RA.
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New criteria to classify RA have been derived in order to increase the specifi city and sensitivity 
for early RA compared to the 1987 ACR-criteria. Th is study evaluated diff erences in classifi cation 
between the 1987 ACR-criteria and 2010 ACR/EULAR-criteria in an early arthritis cohort and 
determined the test characteristics of the 2010 ACR/EULAR-criteria. 
Methods
2258 early arthritis patients included in the Leiden EAC cohort were studied. Fulfi lment of the 
1987- and 2010-criteria for RA was determined at baseline. Th e diagnosis at 1 year was assessed. 
Th e sensitivity and specifi city of the 2010-criteria were determined using the following outcome 
measures: initiation of methotrexate-therapy or any DMARD-therapy during the fi rst year of 
follow-up and having persistent arthritis during 5 years of follow-up.
Results
At fi rst presentation, 1099 patients fulfi lled the 2010-criteria and 726 patients the 1987-criteria 
for RA. 82 of the 726 patients fulfi lling the 1987-criteria did not fulfi ll the 2010-criteria. 68% of 
the patients that fulfi lled the 1987-criteria during the fi rst year of the disease but not at baseline, 
did fulfi ll the 2010-criteria at baseline. Th e 2010 classifi cation also led in 18% to a revoked classi-
fi cation at year 1. Th e sensitivity and the specifi city were 0.84 and 0.60 with methotrexate therapy 
as outcome and 0.74 and 0.74 with DMARD therapy as outcome. With arthritis persistency as 
outcome, the sensitivity and specifi city were 0.71 and 0.65. 
Conclusion
Compared to the 1987-criteria, the 2010-criteria classify more patients with RA and at an earlier 
phase. Th e discriminative ability of the 2010 criteria is acceptable.
Michael vd Linden bw.indd   172 01-08-11   16:09
1987 ACR Criteria versus 2010 ACR/EULAR criteria for RA 173
INTRODUCTION
During the last decades the focus of the management of RA has shift ed to the early phase of 
the disease. Th is change was fuelled by studies showing that early achievement of low disease 
activity states is benefi cial for the further course of RA. Th ese studies raised the awareness on 
the importance of treating early and pointed to the relevance of early recognition of RA. From 
this perspective, the 1987 ACR criteria for RA1 have been criticized as they are not equipped to 
diagnose RA early. Th is is not surprising as they have been developed in order to defi ne homo-
geneous patient groups for research purposes and therefore were based on patients with average 
disease duration of 7 years. 
In order to be able to identify early RA patients for clinical trials and other studies new clas-
sifi cation criteria for RA have been derived by a task force of experts from both the EULAR 
and ACR.2 Th e main purpose of these 2010 criteria is to achieve an increased sensitivity and 
specifi city for RA in an early phase. 
At present the diagnostic and discriminative abilities of these new criteria are not known. In 
addition it is unclear how the 2010 criteria behave in relation to the 1987 ACR criteria. Th is is 
especially relevant because the Working group that developed the 2010 criteria stressed in their 
discussion that the patients fulfi lling the 2010 criteria are probably less homogeneous and that 
therefore in clinical trials researchers should document both the proportions of study subjects 
that fulfi ll the previous (1987) and new RA classifi cation criteria to enable comparisons. More-
over, the working group warned that the 2010 criteria may probably increase heterogeneity by 
including diff erent phenotypes, thereby making basic science studies more diffi  cult. Th erefore, 
the present study evaluated the following questions: What proportion of early arthritis patients 
that do not fulfi ll the 1987 criteria can according to the 2010 criteria be classifi ed as RA? Do all 
early arthritis patients that fulfi ll the 1987 criteria fulfi ll the 2010 criteria as well? Do RA patients 
indeed fulfi ll the 2010 criteria at an earlier point in time than the 1987 criteria? In addition, the 
sensitivity and specifi city of the 2010 criteria for RA were assessed; for this analysis three outcome 
measures were studied: initiation of methotrexate (MTX), initiation of any disease-modifying-
antirheumatic-drug (DMARD) and having persistent arthritis over a 5 years follow-up period.
PATIENTS AND METHODS
Patients
Th e early arthritis patients studied are from the Leiden Early Arthritis Clinic (EAC) cohort, a 
population-based prospective cohort that started in 1993.3 Inclusion took place when arthritis 
was confi rmed at physical examination and symptom duration was <2 years. Th e inclusion 
criteria had not changed over time. At the fi rst visit, patients and rheumatologists completed 
questionnaires, physical examination was performed, radiographs were taken and blood was 
taken for determination of amongst other C-reactive protein (CRP), erythrocyte sedimenta-
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tion rate (ESR), IgM-rheumatoid factor (RF) and ACPA (anti-CCP2, Immunoscan RA Mark 2; 
Euro-Diagnostica, Arnhem, Th e Netherlands). Follow-up visits were performed yearly. Written 
informed consent was obtained from all participants. Th e study was approved by the local Medi-
cal Ethical Committee.
2258 early arthritis patients with at least one year of follow-up were included between 1993 and 
February 2009. Of these, 1632 were formerly classifi ed as RA (1987 ACR criteria) or undiff erenti-
ated arthritis. Th e remaining 626 early arthritis patients were classifi ed with other diagnoses. Th e 
treatment of patients with RA diff ered; hydroxychloroquine, penicillamine or suphasalazine were 
the initial DMARDs in the ‘90s, methotrexate was the initial DMARD since 1999.4 Patients that 
were classifi ed for other diagnoses than RA were treated accordingly. Th e treatment of patients 
that were undiff erentiated was not protocollized. 
Application of the 2010 criteria
Th e 2010 ACR/EULAR criteria were applied as described by Aletaha et al.2 We used the 66-swol-
len joint count and 68-tender joint count. According to the guideline, the distal phalangeal joints, 
1st carpo-metacarpal joint and 1st metatarso-phalangeal joints were excluded from assessment. 
Involvement of interphalangeal joints of the feet was considered as small joint involvement. Th e 
reference value for RF positivity in our cohort is 5, therefore a level ≥15 was considered high 
positive. Similarly, the reference value for anti-CCP2 positivity is 25 AU in our cohort and a 
level of ≥75 AU was considered high positive. An abnormal CRP was according to the reference 
value defi ned as ≥10 mg/l, and an abnormal ESR was ≥25 mm/hr for females and ≥15 mm/hr for 
males. In the new criteria it is stated that presence of a signifi cant erosion is prima facie evidence 
of RA which precludes the need for applying other criteria. However, it is not yet agreed on what 
size, number or site of erosions is necessary to defi ne erosiveness. Because of this uncertainty, we 
initially did not consider radiological information when applying the 2010 ACR/EULAR criteria. 
Aft erwards analyses were repeated when patients with a SHS erosionscore ≥2 were classifi ed as 
having RA as well, irrespective of fulfi lling any of the other criteria. In addition, the eff ect of 
evaluating 44 or 28 instead of 66/68 joints was assessed.
Analysis
Th e following analyses were done. First, baseline characteristics of all 2258 early arthritis patients 
were studied to defi ne the proportions of early arthritis patients that were classifi ed as RA ac-
cording to the 2010 criteria and the 1987 ACR-criteria. It was assessed whether patients that were 
diagnosed with RA using the 1987 ACR criteria fulfi lled the 2010 criteria as well. 
In order to determine whether the 2010 criteria are indeed fulfi lled in an earlier stage than the 
1987 criteria, patients that did fulfi ll the 1987 criteria during the fi rst year of disease but not at 
fi rst presentation were studied (n=297). It was determined how many of these patients already 
fulfi lled the 2010 ACR criteria at baseline, and thus were indeed recognized in a more early phase 
by the 2010 criteria. 
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It was also evaluated whether the 2010 criteria would yield “false-positive” classifi cations. To 
this end, patients that at baseline fulfi lled the 2010 ACR criteria were studied for their diagnosis 
aft er one year to determine whether they were classifi ed diff erently at that time-point. 
Finally, the sensitivity and specifi city of the 2010 criteria were determined and the area under 
the receiver operator characteristic curve (AUC) assessed in the patients that were formerly clas-
sifi ed as RA or undiff erentiated arthritis (n=1632). Patients that received DMARD treatment 
in a randomized trial were not studied, leaving 1404 regularly treated patients for evaluation. 
Th ree outcome measures were used. First, initiation of methotrexate therapy within the fi rst 
year of follow-up, the same outcome measure as used for the derivation of the 2010 criteria. 
Since methotrexate was not the anchor drug before 1999, initiation of any DMARD within 
the fi rst year was studied as well. Th irdly, in the subgroup of patients that achieved 5 years of 
follow-up (n=790), arthritis persistency was assessed and defi ned by the absence of a sustained 
DMARD-free remission. Patients were defi ned as being in remission if DMARD therapy could 
be discontinued and no synovitis was detected for at least one year.5 Analyses were done using 
SPSS (version 17.0).
RESULTS
Th e baseline characteristics of all early arthritis patients are presented in Table 1. Th e characteris-
tics of the subset of patients that at baseline were classifi ed as RA according to the 1987 and 2010 
criteria are presented as well.
Agreement in classifi cation
At baseline, 1099 out of 2258 early arthritis patients fulfi lled the 2010 criteria for RA. 726 patients 
fulfi lled the 1987 ACR criteria for RA. From these 726 patients, 644 (88.7%) also fulfi lled the 
2010 criteria whereas 82 (11.3%) patients did not fulfi ll the 2010 criteria. From the 1099 patients 
that fulfi lled the 2010 criteria, 455 patients did not fulfi ll the 1987 criteria (Table 2A). From the 
1099 patients that fulfi lled the 2010 criteria, 455 patients did not fulfi ll the 1987 criteria (Table 
2A). Th e agreement in classifi cation criteria was not diff erent when patients included before of 
aft er 1999 were studied separately (data not shown). Characteristics of the patients that fulfi lled 
both the 1987 and 2010 criteria and that fulfi lled the 1987 but not the 2010 criteria are presented 
in Supplementary Table 1.
Baseline classifi cation in relation to the disease course
297 patients fulfi lled the 1987 ACR criteria during the fi rst year, but not at baseline. From these, 
202 (68.0%) did fulfi ll the 2010 criteria at baseline, indicating that the 2010 criteria indeed clas-
sify RA patients in an earlier phase of the disease.
Th e 1099 early arthritis patients that fulfi lled the 2010 ACR criteria at baseline were studied for 
their diagnosis at year 1. In 194 cases patients were classifi ed diff erently at that time-point. Study-
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ing the medical records of these patients confi rmed that these patients clinically had evidently 
another diagnosis than RA. Th e diagnoses of these patients were: psoriatic arthritis (n=46), 
infl ammatory osteoarthritis (n=28), reactive arthritis (n=20), RS3PE (n=17), sarcoidosis (n=15), 
(pseudo)gout (n=15), para-malignant arthritis (n=6), spondylarthropathy (n=6), SLE (n=10), 
MCTD (3), other systemic disorders (n=21) and other diagnoses (n=7). Th ese patients concern 
17.7% of the total population of patients fulfi lling the 2010 ACR criteria and 27.7% of the patients 
that at baseline did fulfi ll the 2010 criteria but not the 1987 criteria.
In the description of the 2010 criteria is stated that these should be applied only in case no 
other diagnosis can be established. Th us this means that in case a patient can be classifi ed with 
two diagnoses, the other diagnosis prevails. Th erefore we repeated the analysis presented above 
in the patients that were formerly classifi ed as RA or undiff erentiated arthritis (n=1632). Of 
Table 1. Baseline characteristics of all early arthritis patients, the subset of early arthritis patients that fulfi lled 
the 1987 ACR criteria and the subset that fulfi lled the 2010 ACR/EULAR criteria at fi rst presentation





Age at inclusion (yrs), mean (SD) 51.9 (17.2) 57.4 (16.3) 56.1 (16.4)
Female, N (%) 1340 (59.3) 470 (64.7) 718(65.3)
Symptom duration at fi rst presentation,
weeks, mean (SD)‡ 25.9 (41.6) 31.6 (36.3) 29.8 (43.4)
< 6 weeks, N (%)§ 436 (21.4) 0 (0)† 98 (9.6)
≥ 6 weeks, N (%)§ 1602 (78.6) 726 (100)† 925 (90.4)
66 Swollen joint count, mean (SD) 6.5 (6.8) 11.6 (7.3) 10.3 (7.7)
1 medium-large joint, N (%)§ 253 (11.2) 0 (0) 0 (0)
2-10 medium-large joints, N (%)§ 142 (6.3) 0 (0) 3 (0.3)
1-3 small joints, N (%)§ 532 (23.6) 48 (6.6) 106 (9.6)
4-10 small joints, N (%)§ 560 (24.8) 206 (28.4) 236 (21.5)
> 10 joints, N (%)§ 771 (34.1) 472 (65.0) 754 (68.6)
ESR (mm/hr), mean (SD)‡ 33.2 (28.1) 40.3 (28.2) 38.3 (28.0)
CRP (mg/l), mean (SD)‡ 27.1 (28.1) 28.2 (35.2) 28.3 (35.1)
Normal CRP and ESR, N (%)§ 747 (33.1) 147 (20.2) 251 (22.8)
Abnormal CRP or ESR, N (%)§ 1511 (66.9) 579 (79.8) 848 (77.2)
RF positive, N (%)‡ 671 (30.1) 399 (55.0) 601 (55.3)
Anti-CCP2-positive, N (%)‡ 506 (29.7) 323 (51.4) 472 (52.2)
Negative RF and ACPA, N (%)§ 1484 (65.7) 285 (39.3) 412 (37.5)
Low positive RF or ACPA, N (%)§ 203 (9.0) 78 (10.7) 145 (13.2)
High positive RF or ACPA, N (%)§ 571 (25.3) 363 (50.0) 542 (49.3)
Erosive, N (%) 590 (26.1) 392 (54.0) 467 (42.5)
$applied without considering data on erosiveness at baseline. ‡Data missing for analysis (n): symptom duration 
(220); ESR (15); CRP (219); RF (32); anti-CCP2 (553). †According to the 1987 ACR criteria, 4/7 criteria have to 
exist for >6 weeks to be a valid criterion. §Subdivision of criteria according to the score based algorithm from 
the 2010 ACR/EULAR criteria
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these, 939 patients fulfi lled the 2010 ACR criteria at baseline and were studied for their diagnosis 
at year 1. In 88 cases patients were classifi ed diff erently at that time-point.
Studying the medical records of these patients confi rmed that these patients clinically had evi-
dently another diagnosis than RA. Th e diagnoses of these patients then were: psoriatic arthritis 
(n=20), infl ammatory osteoarthritis (n=13), reactive arthritis (n=7), RS3PE (n=7), (pseudo)gout 
(n=7), SLE (n=6), para-malignant arthritis (n=4), spondylarthropathy (n=4), sarcoidosis (n=3), 
MCTD (2), other systemic disorders (n=12) and other diagnoses (n=3). Th ese patients concern 
9.4% of the 939 patients that fulfi lled the 2010 ACR criteria and 14.1% of the patients that at 
baseline did fulfi ll the 2010 criteria but not the 1987 criteria.
Test characteristics of the 2010 criteria
When using initiation of methotrexate-therapy within the fi rst year as outcome the sensitivity 
and specifi city of the 2010 criteria were 0.84 and 0.60. With initiation of any DMARD-therapy 
within the fi rst year as outcome the sensitivity and specifi city were 0.74 and 0.74. Th e AUCs 
when using these two outcomes were 0.72 and 0.74 respectively. Th e third outcome measure was 
arthritis persistency over 5 years. Here the sensitivity of the 2010 criteria was 0.71, the specifi city 
0.65 and the AUC 0.65 (Table 3A).
Value of baseline erosiveness
It is unclear what number of erosions in early arthritis patients is specifi c for early RA. In the 
evaluation of the consequences of considering erosiveness, here defi ned as total SHS erosion 
score ≥2, we observed that 1222 patients were at baseline classifi ed as RA according to the 2010 
criteria. Th us when including erosiveness in the evaluation, 123 (5.4%) early arthritis patients 
were additionally classifi ed as RA. Th e analyses on the agreement in classifi cation and on the test 
Table 2. Classifi cation according to the 1987 and 2010 criteria for RA without A) and with B) including 
radiologic information on erosiveness when applying the 2010 ACR/EULAR criteria
(A) 2010 ACR/EULAR 
Classifi cation Criteria§
(B) 2010 ACR/EULAR 
Classifi cation Criteria†







baseline 644 82 678 48 726
no RA at 
baseline 455 1077 544 988 1532
Total 1099 1159 1222 1036 2258
§application of the 2010 ACR/EULAR criteria without the use of radiologic information on erosiveness. 
†application of the 2010 ACR/EULAR criteria with the use of radiologic information on erosiveness and 
defi ning erosiveness as a total SHS erosion score ≥2. Criteria were applied using data on 66/68 joints for 
swelling/tenderness
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characteristics were repeated (Table 2B and 3B), but the results were not substantially diff erent 
compared to the results when radiological information was disregarded.
Eff ect of number of assessed joints
We used a 66/68 count for swollen and tender joints. In clinical practice 44 or 28 joints may be 
evaluated more frequently. In order to determine whether this would results in diff erent clas-
sifi cation, the 2010 criteria were applied with the 44 and 28 joint counts. Th e numbers of patients 
classifi ed as RA were then 1082 and 940 respectively, instead of 1099 (Supplementary Table 2). 
Th e test characteristics were fairly comparable when a lower number of joints was considered 
(Supplementary Table 3). 
DISCUSSION
Th e present study compared classifi cation of RA using the 1987 and 2010 criteria in a large early 
arthritis cohort. It was observed that the 2010 criteria classifi ed more patients with RA than the 
1987 criteria and that 11.3% of the patients with RA according to the 1987 criteria were not clas-
sifi ed as RA according to the 2010 criteria. A large proportion of the early arthritis patients that 
developed RA according to the 1987 criteria during the disease course could at fi rst presentation 
be classifi ed as RA according to the 2010 criteria. Th is denotes that the 2010 criteria have come 
up to the demand of classifying RA in an earlier phase of the disease than the 1987 criteria. Th e 
2010 classifi cation also led in 18% (or 9.4% dependent on the studied population) to a revoked 
diagnosis in a later phase, substantiating the concerns with regard to increase in heterogeneity 
by use of the 2010 criteria. Compared to the 1987 criteria, the sensitivity of the 2010 criteria was 
higher but the specifi city lower. 
In this study several choices were made when applying the 2010 ACR/EULAR criteria. Initially 
we left  out information on hand and feet radiographs as a clear description of erosive disease 
resembling RA was not provided by Aletaha et al.2 Aft erwards we repeated analyses defi ning 
total SHS erosionscore ≥2 as erosiveness. Fairly similar observations were done. Th is may suggest 
that evaluating radiographs in this early phase is not highly relevant for classifi cation of RA. 
A moderate predictive ability of the number of erosive joints in early arthritis patients for RA 
development has been described recently.6 
We used a 66/68 count for swollen and tender joints. In clinical practice 44 or 28 joint counts 
are frequently used. To evaluate the eff ect of assessing diff erent numbers of joints we repeated the 
analyses with these joint counts. Th e number of patients classifi ed with RA decreased but the test 
characteristics were only marginally aff ected.
Th is study has some limitations. First of all it is based on one inception cohort and more 
studies are needed to establish the sensitivity and specifi city of the new criteria. A complicating 
factor is that it is somewhat ambiguous what outcome measure to take as the gold standard for 
RA. Th is has been subject to discussion within the working group that derived the 2010 criteria 
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and usage of methotrexate was chosen. Th is outcome may not be appropriate when studying 
older cohorts. For example in the 1990’s it was not common practice to start methotrexate early 
in a patient with arthritis of recent onset that did not fulfi ll the 1987 criteria. For this reason we 
chose any DMARD-therapy instead of methotrexate-therapy as outcome. Additionally we chose 
a second outcome (arthritis persistency over 5 years) for verifi cation. However, diff erences in the 
outcome measure may yield variations in observed test characteristics.
Th e three outcome measures used here (initiation of methotrexate or any DMARD or arthritis 
persistency) all contain risk of misclassifi cation as these can also be fulfi lled in case of other 
diagnoses, for example in psoriatic arthritis. Psoriatic arthritis was also the most frequent cause 
of a revoked classifi cation at year 1.
Another consideration is that 213 early arthritis patients included in the EAC aft er 2000 were 
used in the derivation phase of the 2010 criteria. In the present study we evaluated a considerable 
larger number of patients, as well as two outcome measures additional to methotrexate usage. In 
order to see whether this subset of patients aff ected the results, analyses were repeated excluding 
the 213 patients. Th is did not yield substantially diff erent results (data not shown). Nonetheless, 
validation of the 2010 criteria in other cohorts is required as well.
Given the emerging evidence on a “window of opportunity”,7 pointing to the need to treat as 
early as possible, the question is what method serves best to identify individual patients in an 
early phase of RA. Th e authors of the 2010 criteria underline that the new classifi cation criteria 
were not developed as a diagnostic tool and that a separate body of work is needed to develop 
such tools.2 Prediction rules aiming at early diagnosis have been developed and validated.8,9 Th e 
question what method is best to identify early RA on the individual patient level is still open and 
a subject for future studies.
In conclusion, the 2010 criteria for RA classify more patients with RA and do so in an earlier 
phase. Th e discriminative ability of the 2010 ACR/EULAR criteria is reasonable, indicating that 
these criteria perform well to classify early RA. 
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Supplementary Table 1. Baseline characteristics of all early arthritis patients, the subsets of early arthritis 
patients that fulfi lled the 1987 ACR criteria but not the 2010 criteria and that fulfi lled both the 1987 and the 
2010 ACR/EULAR criteria at fi rst presentation. Data are presented without and with assessing radiologic 













Age at inclusion (yrs), mean 
(SD) 51.9 (17.2) 55.8 (17.4) 57.6 (16.2) 53.3 (18.8) 57.7 (16.1)
Female, N (%) 1340 (59.3) 51 (62.2) 419 (65.1) 29 (60.4) 441 (65.0)
Symptom duration at fi rst 
presentation in weeks, mean 
(SD)
25.9 (41.6) 25.4 (23.1) 32.4 (37.6) 26.3 (24.6) 32.0 (37.0)
< 6 weeks, N (%) 436 (21.4) 0 (0)† 0 (0) 0 (0) 0 (0)
≥ 6 weeks, N (%) 1602 (78.6) 79 (100)† 626 (100) 47 (100) 658 (100)
66 Swollen joint count, mean 
(SD) 6.5 (6.8) 5.9 (2.2) 12.3 (7.4) 5.6 (2.1) 12.3 (7.4)
1 medium-large joint, N (%) 253 (11.2) 0 (0) 0 (0) 0 (0) 0 (0)
2-10 medium-large joints, 
N (%) 142 (6.3) 0 (0) 0 (0) 0 (0) 0 (0)
1-3 small joints, N (%) 532 (23.6) 19 (23.2) 29 (4.5) 10 (20.8) 38 (5.6)
4-10 small joints, N (%) 560 (24.8) 63 (76.8) 143 (22.2) 38 (79.2) 168 (24.8)
> 10 joints, N (%) 771 (34.1) 0 (0) 472 (73.3) 0 (0) 472 (69.9)
ESR (mm/hr), mean (SD) 33.2 (28.1) 32.9 (23.9) 41.3 (28.5) 32.3 (26.7) 40.8 (28.2)
CRP (mg/l), mean (SD) 27.1 (28.1) 27.5 (29.5) 31.6 (35.9) 23.3 (29.5) 31.7 (35.5)
Normal CRP and ESR, N (%) 747 (33.1) 23 (28.0) 124 (19.3) 16 (33.3) 275 (40.9)
Abnormal CRP or ESR, N (%) 1511 (66.9) 72.0 (72.0) 520 (80.7) 32 (66.7) 398 (59.1)
RF positive, N (%) 671 (30.1) 1 (1.2) 399 (62.4) 1 (2.1) 399 (62.4)
Anti-CCP2-positive, N (%) 506 (29.7) 2 (3.0) 321 (57.1) 2 (5.7) 321 (57.1)
Negative RF and ACPA, N (%) 1484 (65.7) 80 (97.6) 205 (31.8) 45 (93.8) 240 (35.4)
Low positive RF or ACPA, 
N (%) 203 (9.0) 0 (0.0) 76 (11.8) 0 (0) 75(11.1)
High positive RF or ACPA, 
N (%) 571 (25.3) 3 (3.7) 363 (56.4) 3 (6.3) 363 (53.5)
Erosive, N (%) 590 (26.1) 34 (41.5) 356 (55.3) 0 (0) 390 (57.5)
§application of the 2010 ACR/EULAR criteria without the use of radiologic information on erosiveness. 
†application of the 2010 ACR/EULAR criteria with the use of radiologic information on erosiveness and 
defi ning erosiveness as a total SHS erosion score ≥2
Michael vd Linden bw.indd   182 01-08-11   16:09
1987 ACR Criteria versus 2010 ACR/EULAR criteria for RA 183
Supplementary Table 2. Classifi cation according to the 1987 and 2010 criteria for RA without (A) and with (B) 
including radiologic information on erosiveness when applying the 2010 ACR/EULAR criteria
(A) 2010 ACR/EULAR 
Classifi cation Criteria§
















baseline 639 87 677 49 726
no RA at 
baseline 443 1089 533 999 1532







baseline 603 123 653 73 726
no RA at 
baseline 337 1195 443 1089 1532
Total 940 1318 1096 1162 2258
‡Criteria were applied using the 44 joint counts data. $Criteria were applied using the 28-swollen joint counts. 
§application of the 2010 ACR/EULAR criteria without the use of radiologic information on erosiveness 
†application of the 2010 ACR/EULAR criteria with the use of radiologic information on erosiveness and 
defi ning erosiveness as a total SHS erosion score ≥2
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Predicting arthritis outcomes - 
what can be learned from the 
Leiden Early Arthritis Clinic?
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In order to allow personalized medicine, adequate prediction of the disease outcome is required. 
In early undiff erentiated arthritis (UA) prediction of the development of rheumatoid arthritis 
(RA) is crucial and in case of RA predicting the severity of the disease course may guide indi-
vidualized treatment decisions. 
Methods 
570 UA patients and 676 RA patients included in the Leiden Early Arthritis Clinic cohort were 
studied for baseline characteristics. Th e disease outcomes studied were fulfi llment of the 1987 
ACR RA criteria and arthritis persistency in UA patients and the rate of radiological joint de-
struction and achieving sustained DMARD-free remission in RA patients.
Results 
Predictive factors for fulfi llment of the 1987 ACR RA criteria and for persistent arthritis in UA 
were largely similar. Risk factors for a severe rate of joint destruction were: (p-value) older age 
(<0.001); male gender (<0.001); longer symptom duration at fi rst visit (0.048), involvement 
of lower extremities (<0.001); BMI (<0.001); high acute phase reactants, presence of IgM-RF 
(<0.001); anti-CCP2 antibodies (<0.001); anti-MCV antibodies (<0.001) and HLA-SE alleles 
(0.001). A high BMI was associated with a lower rate of joint destruction but with a higher risk 
on disease persistency. Th e proportion of variance in joint destruction explained was 32%.
Conclusion 
Predictors for RA development, previously used to develop a prediction rule in UA patients, are 
largely similar to predictors for arthritis persistency. Only part of the level of joint destruction 
in RA is explained by currently known risk factors. New factors need to be identifi ed in order to 
guide pharmaceutical intervention at the level of individual RA patients.
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INTRODUCTION
Th e outcome of early arthritis patients is highly variable. Approximately only one-third of the 
patients with a recent-onset undiff erentiated arthritis (UA) progresses towards rheumatoid 
arthritis (RA). Th e severity of the progression of joint destruction in RA is highly variable as 
well, as only a minority will become severely destructed. In order to achieve individualized treat-
ment decision making, the severity of the disease outcome needs to be estimated adequately. 
Th is is particularly relevant since it is widely acknowledged that early initiation of treatment of 
RA is eff ective in diminishing the level of joint destruction and disability.1-3 Fewer studies are 
performed on the eff ects of early intervention in recent-onset UA, but available data suggest that 
early treatment strategies hamper progression in UA as well.4-6 Potent treatment strategies such as 
targeted therapies are generally not started in an early phase because of the risk of overtreatment. 
However, when the individuals who will have an unfavorable disease outcome can be identifi ed 
at fi rst presentation, the risk on overtreatment and undertreatment can be balanced, resulting in 
a personalized pharmaceutical regimen.
Observational studies of unselected patients are most appropriate to identify risk factors for a 
certain disease course. Following patients with and without risk factors allows direct assessments 
of absolute risks on a disease outcome. Th e Leiden Early Arthritis Clinic cohort is a population 
based inception cohort including early arthritis patients since 1993. Patients are being followed 
as long as they are seen at the rheumatologist and follow-up ends in case patients are discharged 
because of having a sustained DMARD-free remission or when patients die. During the past 
years several risk factors for a mild or progressive disease course, both in UA and RA, have been 
identifi ed.
Th e present manuscript in this themed issue on Registries in Rheumatologic conditions re-
views to what extend the disease outcome in early UA and early RA can be predicted, using data 
from the Leiden Early Arthritis Clinic cohort. Th e two disease outcomes studied in UA are fulfi ll-
ing the 1987 ACR criteria for RA and having persistent arthritis. Th e disease outcomes studied 
in early RA patients are the progression in joint destruction over time and disease persistency. 
Th ese evaluations allow comparison of risk factors for joint destruction and RA persistency. 
Since it is thus far unclear to what extent the processes underlying joint destruction are similar 
to the processes that mediate disease persistency, evaluation of overlapping and dissimilar risk 
factors may increase understanding and the subsequent elucidation of the underlying biological 
pathways leading to these phenotypic characteristics. Finally, the fraction of explained variance 
of progression in joint destruction by the currently known risk factors is determined to asses how 
complete our current understanding is.
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PATIENTS AND METHODS
Design of Leiden Early Arthritis Clinic 
Th is Leiden EAC is a population-based prospective cohort that was started in 1993 in order to 
detect and treat infl ammatory disorders early in the disease state, especially early RA. In order 
to obtain early referrals by general practitioners (GPs), a campaign was started among GPs to 
refer patients with suspected arthritis as soon as possible to the rheumatology department of the 
Leiden University Medical Center. Th is is the only centre for rheumatic diseases in a semi-rural 
area with more than 400,000 inhabitants. Patients are seen within 2 weeks. Inclusion took place 
when arthritis was confi rmed at physical examination and symptom duration was less than two 
years. Written informed consent was obtained from all participants. Th e study was approved by 
the local Medical Ethical Committee. At the fi rst visit, the rheumatologist completed a ques-
tionnaire regarding the presenting symptoms, as reported by the patient: type, localization and 
distribution of initial joint symptoms, symptom duration, and course of the initial symptoms. 
Th e patient’s smoking history and family history were assessed. Patients rated morning stiff -
ness on a visual analogue scale (VAS; range 0-100 mm); the duration of morning stiff ness was 
also assessed. Th e Health Assessment Questionnaire (HAQ) was used to provide an index of 
disability. A 66-joint count for swollen joints (SJC) was performed. Blood samples were taken 
for routine diagnostic laboratory screening (including C-reactive protein (CRP), Erythrocyte 
sedimentation rate (ESR) and immunoglobulin (Ig)M-rheumatoid factor (RF)) and stored to 
determine other serum markers (amongst others antibodies against citrullinated peptide anti-
bodies) at a later time. Blood samples were taken for DNA extraction as well. Follow-up visits 
with standard clinical assessments (including a SJC and a HAQ) were performed 3 months aft er 
the fi rst presentation and yearly thereaft er. Radiographs of the hands and feet were taken at base-
line and yearly thereaft er. Two weeks aft er inclusion, when results of laboratory investigations 
and radiography were known, patients that had a form of arthritis that could not be classifi ed 
according to American College of Rheumatology (ACR; formerly, the American Rheumatism 
Association) criteria were documented as having UA. Th e diagnosis RA was established in case 
patients fulfi lled the 1987 ACR criteria for RA. Th e initial treatment of RA patients had changed 
in time and diff ered according to the inclusion period.7 Patients included between 1993 and 1995 
were initially treated with analgesics and were subsequently treated with hydroxychloroquine 
or sulfasalazine if they had persistent active disease. Between 1996 and 1998, patients who were 
included were promptly treated with chloroquine or sulfasalazine, while aft er 1998, the initial 
treatment strategy consisted of either methotrexate or sulfasalazine.7 Treatment of UA patients 
was not protocolized. 
Defi nition of outcome measures
Patients with UA were assessed on two outcomes. First, aft er one year of follow up, the fulfi llment 
of the 1987 ACR criteria for RA was evaluated. As previously described, 31% of UA patients pro-
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gressed to RA during 1 year of follow-up. Th e majority of the patients (94%) had been followed 
up for more than 1 year (mean follow-up 8 years, SD 3 years) and 4.4% of UA patients developed 
RA later than one year aft er inclusion.8 Th e second disease outcome was disease persistency. As 
a generally accepted defi nition for persistency is lacking, we defi ned persistent arthritis as the 
absence of sustained DMARD-free remission. Sustained remission was diagnosed when patients 
had no swollen joints for at least one year aft er cessation of eventual DMARD therapy. Th e 
absence of swollen joints had to have been observed by a rheumatologist for at least one year to 
ensure that remission was not temporary, but rather sustained. When remission was not obtained 
aft er 5 years of disease, a patient was classifi ed as having persistent disease in the present study.
Th e RA patients were studied for the rate of radiological joint destruction and for achieving 
sustained DMARD-free remission or having persistent RA, also during a fi ve years period of 
follow-up. In order to study the progression rate in a sensitive way all serial radiographs were 
scored by one experienced reader (MvdL) according to the Sharp-van der Heijde method 
(SHS) in chronological order. Four hundred and nine radiographs belonging to 60 randomly 
selected RA patients were rescored. Th e intraclass-observer correlation coeffi  cient was 0.91 for 
all scored radiographs, and 0.97 for the radiographic progression rate. Th e means (±SEM) at 
the subsequent time points were 9.15 (0.43) at baseline; 15.65 (0.72) at one year follow up; 20.0 
(0.93) at two years; 24.79 (1.36) at three years; 34.83 (2.14) at four years and 34.8 (2.14) at fi ve 
years of follow-up. Persistent RA was defi ned as the absence of a sustained DMARD-free remis-
sion. A sustained DMARD free remission in RA was defi ned as the absence of swollen joints 
for at least one year aft er cessation of DMARDs and classifi cation as DMARD-free remission 
by the rheumatologist. To ensure that remission was not temporary but rather sustained and 
long-lasting, the absence of swollen joints had to have been observed by a rheumatologist for at 
least 1 year aft er discontinuation of DMARD therapy. Corticosteroids were here considered to 
be equivalent to DMARDs. Th e majority of patients with disease in remission were discharged 
from the outpatient clinic at any time, however most patients who achieved remission were fol-
lowed up longer than the minimum requirement of 1 year; the median time of observation aft er 
discontinuation of DMARDs in the absence of swollen joints was 2.5 years. Patients who had a 
recurrence of their arthritis aft er discharge could easily return to the Leiden University Medical 
Center. Th e frequency of disease relapse was 6%; these patients were included in the persistency 
group. We observed previously that sustained DMARD-free remission was obtained by 15% of 
RA patients aft er a median disease duration of 43 months.9 Th erefore, for the present study, 
patients that within the fi rst 5 years did not achieve a sustained DMARD-free remission were 
classifi ed as having persistent RA.
Statistical analysis
Predictors for RA development and arthritis persistency were analyzed univariately with a 
logistic regression analysis. Since the aim of the present study was to review predictive factors 
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and not to develop a prediction rule for the outcome of UA, which has been done before,10 no 
multivariate regression analysis was performed in UA patients.
Associations between baseline factors and rate of joint destruction were analyzed with a linear 
multivariate regression model see ref. for detailed description.7 Th is was done for each variable 
separately, but all analyses were adjusted for the applied treatment strategy. In a previous study 
we showed that the inclusion period is an adequate proxy for the diff erent treatments strategies 
that were applied over time.7 Th e baseline characteristics were tested with an interaction term of 
a linear function of time. Th e risk estimate (β) resulting from these analyses refl ected the relative 
diff erence in slopes between the groups over fi ve years of follow-up. To test for a diff erence that is 
not progressive but stable over time, a model without interaction term was fi tted; the overall ef-
fect of the risk factor then refl ected a constant eff ect in time. Th is model does not exclude patients 
in case of missing radiographs and can deal with missingness provided that it is missingness at 
random.7 Patients with complete datasets are weighted more heavily in the analysis than patients 
with missing radiographs. 
All factors that were associated with the progression of joint destruction were entered in a 
multivariate analysis to determine the variance of joint destruction explained by these factors. 
Th is variance was defi ned by comparing the residual variance of the analysis including all risk 
factors with the residual variance of the analysis including only the adjustment factor for treat-
ment strategy (inclusion period). Th e proportional reduction of the residual variance was the 
explained variance of the risk factors analyzed. 
P-values <0.05 were considered signifi cant. Since the aim was to review baseline characteristics 
in relation to the disease outcome, p values were presented without corrections for multiple 
testing. Analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Predictors for disease outcome in UA
177 UA patients developed RA (31%). An overview of baseline characteristics associating with 
RA development and persistency of arthritis is presented in Table 1. Part of the variables pre-
dictive for the development of RA was described previously.10-12 Identifi ed variables associating 
with the development of RA were patients’ characteristics (age, gender, having a positive family 
history of RA), morning stiff ness, infl ammatory characteristics (CRP, ESR, number of swollen 
joints), localization of involved joints, and presence of auto-antibodies (RF, anti-CCP2, and anti-
MCV). Th e environmental factors smoking and BMI were not associated with progression from 
UA to RA. Th e acuteness of the start of the complaints was associated with RA development; 
UA patients with a gradual onset of symptoms had a 1.5 higher odds ratio to develop RA than 
patients with a subacute symptom onset. A longer duration of symptoms at fi rst presentation was 
associated with a higher risk on the development of RA as well.
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As the outcome measure of fulfi lling the 1987 ACR criteria for RA might be subject to discus-
sion (because these criteria were not designed to identify RA in an early phase) and to circular 
reasoning (because the presence of hand erosions are part of the ACR criteria), we also tested 
these baseline characteristics in relation to arthritis persistency, defi ned as the absence of sus-
Table 1. Baseline characteristics of patients with undiff erentiated arthritis in relation to the outcome measures 
RA development and persistency of arthritis
RA development Arthritis Persistency
Baseline characteristic Frequency OR (95%CI) P OR (95%CI) P
Age, mean (SD), years 60.0 (16.8) 1.03 (1.01-1.04) <0.001 1.00 (0.99-1.01) 0.90
Female gender, n (%) 329 (57.7) 2.00 (1.35-2.86) <0.001 1.47 (1.03-2.08) 0.034
Pos. family history for RA, n (%) 135 (23.7) 1.65 (1.11-2.45) 0.013 1.32 (0.87-1.98) 0.20
Chronic symptom vs. (sub)acute, n 
(%) 244 (42.8) 1.54 (1.11-2.23) 0.010 1.19 (0.84-1.69) 0.34
Symptom duration at fi st visit, mean 





Morning stiff ness severity - VAS (0-
100), mean (SD) 41.3 (31.1) 1.02 (1.01-1.03) <0.001 1.00 (1.00-1.01) 0.19
BMI, mean (SD) 26.0 (12.0) 1.03 (0.99-1.08) 0.18 1.07 (1.01-1.13) 0.013
Localization initial joint symptoms
Small vs. large joints, n (%) 266 (57.5) 2.48 (1.63-3.79) <0.001 0.95 (0.65-1.40) 0.80
Large & small vs. large joints, n (%) 107 (35.2) 4.18 (2.50-6.97) <0.001 1.25 (0.76-2.06) 0.38
Upper vs. lower extremities, n (%) 248 (43.5) 2.21 (1.36-3.57) 0.001 1.02 (0.68-1.53) 0.92
Upper & lower vs. lower extremities, 
n (%) 161 (50.0)
6.07 (3.63-
10.10) <0.001 2.13 (1.31-3.46) 0.002
Symmetric vs. asymmetric, n (%) 265 (46.5) 2.82 (1.98-4.03) <0.001 1.20 (0.85-1.71) 0.29
Past or present smoker vs. non-
smoker, n (%) 271 (48) 1.0 (0.9-1.4) 0.98 0.7 (0.5-1.1) 0.10
SJC, mean (SD) 3.8 (4.0) 1.17 (1.11-1.23) <0.001 1.07 (1.02-1.13) 0.01
CRP (mg/L), mean (SD) 21.4 1.01 (1.00-1.02) 0.001 1.01 (1.00-1.01) 0.03
ESR (mm/1hr), mean (SD) 29.5 (24.8) 1.02 (1.01-1.02) <0.001 1.01 (1.00-1.02) 0.003
IgM-RF positive, n (%) 140 (24.6) 5.10 (3.39-7.66) <0.001 3.55 (2.18-5.76) <0.001
Anti-CCP2 positive, n (%) 121 (21.2) 8.74 (5.51-13.84) <0.001 5.97 (3.30-10.78) <0.001
Anti-MCV positive, n (%) 172 (33.9) 6.48 (4.32-9.71) <0.001 4.53 (2.87-7.17) <0.0001
HLA-SE positive, n (%) 309 (55.9) 1.96 (1.36-2.81) <0.001 1.76 (1.23-2.51) 0.002
Age, BMI, ESR, CRP, SJC, symptom duration at fi rst visit and morning stiff ness were analyzed as continuous 
variables; this means that the presented OR indicates the odds per unit. For instance, an OR of 1.03 for age in 
relation to the risk on RA development means that per year increase in age, the OR is 1.03. Morning stiff ness is 
displayed in millimetres. From all 570 patients data on RA-development was present, the remission/persistency 
state could be reliably determined in 538 patients and was not clear recorded in the medical fi le in 43 cases. 
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BMI: Body Mass Index; SJC: swollen joint count; 
HLA-SE: HLA-DRB1 shared epitope alleles; RF: rheumatoid factor; anti-CCP2: anti-cyclic citrullinated peptide 
antibody; anti-MCV: anti-modifi ed citrullinated vimentin antibodies
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tained remission. During the fi ve year period of follow up, 210 UA patients achieved remission 
(39%). Th e median disease duration till remission was achieved was 17 months (IQR 6.3-37). 
Factors signifi cantly associated with disease persistency were infl ammatory markers (the num-
ber of swollen joints, CRP and ESR) and presence of auto-antibodies. Other characteristics such 
as the distribution of involved joints, the acuteness of the onset of the complaints, and morning 
stiff ness were not predictive for having a persistent form of arthritis.
Predictors for outcome of RA
Baseline characteristics of RA patients associated with the severity of joint destruction over time 
are presented in Table 2. Th e strongest association with the rate of joint destruction was seen 
for presence of anti-cyclic citrullinated peptide 2 (anti-CCP2). Anti-CCP positive RA patients 
had over the 5 year period a 2.4 times higher progression rate than anti-CCP negative patients. 
A similar eff ect was seen for presence of IgM-RF. Higher levels of acute phase reactants at fi rst 
presentation were also associated with more severe joint damage over time. RA patients whom 
initial joint symptoms were located at the lower extremities had a higher rate of joint destruction. 
Interestingly, the severity of morning stiff ness at fi rst presentation was not associated with the 
severity of joint destruction over time. Th e body mass index (BMI) was inversely correlated with 
the progression of joint destruction over time. Few genetic factors are convincingly reported to 
associate with progression of joint destruction. Here we studied the HLA-Shared Epitope (SE) 
alleles and CD40, both are identifi ed risk factors for anti-CCP positive RA only.11,13 Although 
presence of the HLA-SE alleles associated with the progression of joint destruction in RA, CD40 
did not reveal such an association in a cohort consisting of both anti-CCP positive and anti-CCP 
negative RA patients. All the analyses on the rate of joint destruction were adjusted for the treat-
ment strategy applied; this variable was signifi cantly associated with the rate of joint destruction 
in all performed analyses.
Since it is unclear whether the processes driving joint destruction are the same that drive 
RA persistency, predictive factors for both outcomes of RA were compared. Th e proportion of 
patients that achieved a sustained DMARD-free remission was 0.157, thus 84.3% of the patients 
were classifi ed as having persistent RA. Th e median disease duration till remission was 40 months 
(IQR 25.5-66.5). Th e factors that were clearly associated with RA persistency were presence of 
auto-antibodies, the HLA-SE alleles and the duration of symptoms at the fi rst visit. A high BMI 
was associated with a higher chance on RA persistency. Although the characteristics indicative 
for the level of infl ammation (CRP, ESR, and SJC) were associated with severity of joint destruc-
tion, they were not predictive for having a persistent form of RA.
Fraction of variance of progression in joint destruction explained
Th e total variance of joint destruction at 5 years explained by the baseline characteristics studied 
was 32%. Subsequently we aimed to study the contribution of the individual risk factors to the 
explained variance. Th is was accomplished by calculating the proportion of the eff ect size of the 
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individual factors in the multivariate analysis to the total eff ect. Th e proportional eff ect size of 
these variables is depicted in Figure 1.
Table 2. Baseline characteristics of patients with rheumatoid arthritis in relation to the outcome measures rate 
of joint destruction and RA persistency
Rate of joint destruction
over 5 years of follow-up RA Persistency
Baseline characteristic Frequency β (95%CI) P OR (95%CI) P
Age, mean (SD), years 56.4 (15.7) 1.14 (1.11-1.16) <0.001* 0.99 (0.97-1.00) 0.070
Female gender, n (%) 459 (67.9) 0.74 (0.63-0.86) <0.001* 0.85 (0.50-1.45) 0.553
Pos family history for RA, n (%) 173 (26.5) 1.079(0.92-1.27) 0.354 2.27 (1.18-4.36) 0.014
Chronic symptom vs. (sub)acute, n 
(%) 287 (44.6) 1.10 (0.94-1.27) 0.234 1.55 (0.93-2.59) 0.095
Symptom duration at fi st visit, mean 
(SD), weeks 26.4 (22.4) 1.00 (1.00-1.00) 0.048 1.02 (1.01-1.03) 0.007
Morning stiff ness severity - VAS (0-
100), mean (SD) 55.2 (28.7) 1.00 (1.00-1.00) 0.874 1.00 (0.99-1.01) 0.827
BMI, mean (SD) 25.8 (3.8) 0.96 (0.94-0.98) <0.001 1.11 (1.01-1.23) 0.034
Localization initial joint symptoms
Small vs. large joints, n (%) 356 (75.7) 1.01 (0.83-1.24) 0.923 0.66 (0.34-1.28) 0.216
Large & small vs. large joints, n (%) 177 (60.8) 0.92 (0.74-1.15) 0.470 0.96 (0.45-2.06) 0.911
Upper vs. lower extremities, n (%) 268 (39.2) 0.62 (0.50-0.76) <0.001 0.76 (0.35-1.62) 0.468
      Upper & lower vs. lower 
extremities, n (%) 222 (44.6) 0.72 (0.57-0.92) 0.009 1.01 (0.46-2.26) 0.972
Symmetric vs. asymmetric, n (%) 415 (69.6) 0.93 (0.79-1.10) 0.396 0.89 (0.51-1.55) 0.687
SJC, mean (SD) 9.5 (7.4) 0.99 (0.98-1.00) 0.010 0.99 (0.96-1.02) 0.379
CRP (mg/L), mean (SD) 30.4 (34.7) 1.01(1.00-1.01)* <0.001
1.005 (1.997-
1.013) 0.210
ESR (mm/1hr), mean (SD) 39.7 (27.4) 1.01(1.01-1.01)* <0.001
1.005 (0.995-
1.015) 0.314
IgM-RF positive, n (%) 378 (58.0) 1.76 (1.50-2.02) <0.001 6.66 (3.69-12.02) <0.001
Anti-CCP2 positive, n (%) 217 (32.1) 2.31 (2.00-2.67) <0.001 11.46 (5.85-22.46) <0.001
Anti-MCV positive, n(%) 373 (54.6) 1.97 (1.68-2.30) <0.001 6.13 (3.48-10.79) <0.001
HLA-SE positive, n (%) 393 (63.8) 1.31 (1.12-1.52) 0.001 2.25 (1.35-3.74) 0.002
CD40 (rs4810485) non-G carrier, n 
(%) 22 (4.4) 1.02 (0.67-1.58) 0.915 0.78 (0.17-3.54) 0.751
*Outcome of analysis without interaction with time, evaluating whether a factor has an eff ect on the progression 
rate that is stable over time. Age, BMI, ESR, SJC, CRP, symptom duration at fi rst visit and morning stiff ness were 
analyzed as continuous variables; this means that the presented OR indicates the odds per unit. For instance, a 
beta of 1.01 for CRP indicates a 1.01 times higher progression of SHS-score per mg/L CRP. From all 676 patients 
data on the rate of joint destruction was available, the remission/persistency state was reliably determined in 
491 patients
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DISCUSSION
Cumulating evidence supports the relevance of initiating DMARD therapy as early as possible. 
Individualized treatment decision making is hampered by the variability of the outcome of early 
arthritis. In case of early undiff erentiated arthritis, the question is when DMARD therapy should 
be initiated. In early RA it would be benefi cial to recognize the patients who will have a severe 
disease course, since in these patients the benefi ts of early combination therapy with potent tar-
geted therapies will up weight the associated costs and risks on side eff ects. In this themed issue 
risk factors for the outcome of UA and RA patients are explored based on data of the Leiden EAC.
With regards to early UA it was observed that predictive factors for the fulfi llment of the 
1987 ACR RA criteria and for having a persistent arthritis were largely similar. A predictive tool 
for RA development was derived before using a combination of identifi ed risk factors.10 Th is 
prediction rule is now well-validated.14-16 Since the present study did not intend to re-derive or 
improve this predictive tool, no multivariate regression analyses were performed in UA patients. 
Some studies tried to improve this prediction rule and assessed the additive value of baseline 
erosiveness and genetic markers.8,17 Unfortunately, these attempts did not result in an increased 
prognostic performance of this model. Further improvements of the model may be expected to 
come from ultrasound and MR imaging studies. Although at present not much data on US and 












Figure 1. Contribution of baseline variables to the explained variance of Sharp-van der Heijde score over fi ve 
years. Presented is the explained variance at 5 years of baseline variables that were associated with the progression 
of joint destruction. CCP: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; BMI: Body Mass 
Index; ESR: erythrocyte sedimentation rate, sympt.dur.: symptom duration at fi rst visit; lower extremity: initial 
complaints at lower extremity versus upper extremities; HLA: HLA-DRB1 shared epitope alleles; SJC: swollen 
joint count; MCV: anti-modifi ed citrullinated vimentin antibodies. All continuous variables were categorized in 
two groups in order to derive this fi gure: BMI was grouped in lower or higher than 25; Symptom duration at fi rst 
visit (sympt.dur.) was grouped in lower or higher than 12 weeks; SJC was grouped lower and above 6 swollen 
joints; Age under and above the median of 57 years; ESR normal or elevated according to reference value
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Fulfi lling the 1987 ACR criteria as outcome of UA has the disadvantage that it may introduce 
some circle reasoning; in contrast the diffi  culty with the outcome measure disease persistency 
is that classifi cation depends on the duration of follow-up. In UA patients included in this study 
remission was achieved aft er a median period of 17 months, whereas in the RA patients the me-
dian disease duration till remission was 40 months. A too early comparison of disease outcomes 
may result in misclassifi cation of potential remission patients into the persistent disease category. 
In order to diminish the risk on misclassifi cation, in this study we chose to classify patients with 
≥5 years of arthritis as being persistent. Th is follow-up duration is arbitrary and results may have 
been slightly diff erent in case a shorter or longer follow-up period was chosen.
Th e most potent predictors for having a persistent course of arthritis in UA patients and a per-
sistent course of RA were the presence of auto-antibodies. Infl ammatory markers (the number of 
swollen joints, ESR and CRP) were associated with the development of RA and a persistent form 
of arthritis in UA patients as well as the severity of joint destruction in RA patients, which is in 
line with fi ndings in older studies. However, no signifi cant association between these infl am-
matory markers and disease persistency was found in RA patients.19,20 Th is may be due to the 
fact that the number of patients with sustained DMARD-free remission in RA was low, thereby 
reducing the power to identify signifi cant associations with this outcome measure.
It is interesting to note that morning stiff ness is strongly associated with the development of 
RA but not with disease persistency or the severity of joint destruction. Several explanations may 
account for this feature. One of them is that morning stiff ness is mainly related to RA according 
the 1987 criteria because of circle reasoning. Morning stiff ness is not part of the 2010 EULAR/
ACR criteria for RA and it would be an interesting subject for further studies to see whether the 
association between morning stiff ness and the risk on RA is still present when the new defi nition 
of RA is used.
Other intriguing fi ndings concern the observations on BMI. Obese RA patients are found to 
have less severe joint destruction. Th is observation was not only observed in the present study 
but also in other populations.21-23 Th e present study revealed that BMI was not associated with 
progression from UA to RA, but it was associated with having a persistent arthritis or persistent 
RA. Th us this indicates that obese patients have more oft en a persistent disease than non-obese 
arthritis patients. Th is observation is highly fascinating and may point to the notion that the role 
of fat tissue in rheumatoid arthritis is incompletely clear. Fat tissue secretes pro-infl ammatory 
as well as anti-infl ammatory adipocytokines.24 It is clear that some of the mechanisms of joint 
destruction like osteoclast activation are diff erent than infl ammatory pathways and as such it 
is tempting to speculate that diverse adipocytokines may have diff erent preferential eff ects on 
arthritis persistency and on and joint destruction.
Th e associations between disease outcomes and involvement of the joints of the lower or upper 
extremities were diff erent for patients with UA and RA. Whereas within UA presence of arthritis 
on lower extremities was associated with a lower OR on RA, within RA patients it was associated 
with a higher rate of joint destruction. Th is fi nding is in line with previous fi ndings demon-
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strating that patients presenting with knee arthritis had a more severe rate of joint destruction 
compared to patients without knee arthritis, when measured using destruction of small feet and 
hands joint.25 
Emerging evidence indicates that anti-CCP positive and anti-CCP negative RA are subsets of 
RA with diff erences in the underlying pathologic mechanisms.26,27 Th e present study addressed 
all UA patients and RA patients; stratifi ed analyses on anti-CCP positive and anti-CCP negative 
patients were not performed. Th is may be an explanation why CD40, a genetic risk factor joint 
destruction in anti-CCP positive RA is not associated with the rate of joint destruction in the 
whole RA population.13
Th e baseline characteristics associated with the severity of joint destruction in RA were mainly 
auto-antibodies and other patient characteristics and to a lower extend factors expressing the 
level of infl ammation. Although the present study did not evaluate the contribution of infl amma-
tion over time on the fi nal level of joint destruction, such analyses have been performed before. 
Some of these studies also suggested that the largest part of joint destruction is not directly 
related to cumulative infl ammatory markers.28
Th e data presented are limited to data of the Leiden Early Arthritis Clinic cohort. However, 
many of the associating risk factors for UA and RA are observed in individual studies originating 
from diff erent early arthritis cohorts as well.29-34
Th e proportion of the explained variance in progression of joint destruction by the identi-
fi ed risk factors was 32%. Although no clear guidelines are available what the level of variance 
explained is required in order to derive a prediction model with an adequate discriminative 
performance, previous investigations and experience10,35 are highly suggestive that the explained 
variance is insuffi  cient to proceed with a derivation of a prediction rule for the rate of joint de-
struction in RA. Th is notion is exemplifi ed by recent attempts to derive prediction models; with 
the current prediction rules about 50% of the RA patients could not be adequately classifi ed.35-37
In conclusion, although the processes determining the persistency and severity of arthritis 
are incompletely understood, the identifi cation of risk factors may help in individualization of 
therapy in patients with recent-onset UA. In RA, in contrast, the currently known risk factors for 
a progressive destructive disease course explain only part of the individual diff erences in level of 
joint destruction and more risk factors need to be identifi ed in order to achieve at individualized 
treatment decision making.
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SUMMARY AND DISCUSSION
RA is a chronic and progressive autoimmune disease aff ecting approximately 1% of the popula-
tion worldwide, and has a large risk for causing disability of patients and consequently high 
costs in health care if left  un- or improperly treated. To prevent this, patients with RA need to be 
identifi ed as early as possible and treated adequately to prevent worse outcome. Early recogni-
tion, together with prediction of the disease outcome at the individual patient level would allow 
to achieve personalized medicine. Th e main scope of this thesis was to identify and evaluate the 
quality of risk factors for their usefulness in predicting disease course and outcome of RA. To 
this end, characteristics and disease outcome of RA patients included in the Leiden EAC were 
studied.
To treat patients with RA adequately and swift ly, the fi rst requirement is a tool to correctly identify 
patients with early RA. Th e benefi t of early detection and treatment has been recognized many 
years ago. Although the 1987 classifi cation criteria for RA incorporated a minimally required 
symptom duration of 6 weeks, the majority of the items of these criteria relate to long standing 
RA.1 Although the 1987 criteria have been used for many years and were considered as a huge 
improvement over the criteria for RA that were formulated in the 1950s,2 still, the 1987 criteria 
perform rather poorly in defi ning RA in a early disease phase.3,4 Th e advancing knowledge of the 
disease course of RA and the need to perform trials in early RA have led to the development of 
a new set of criteria. Th ese 2010 ACR/EULAR criteria, which now include acute phase reactants 
and an updated item serology, were devised with the intention to classify patients in an earlier 
stage of the disease.5 
Although in the process of deriving the new criteria multiple datasets have been used,6 their 
performance in various individual datasets will be the focus of attention in the coming years. Our 
study (chapter 13) indicates that the 2010 criteria, in comparison to the 1987 criteria, classify 
more patients as having RA. Most importantly, these patients are indeed classifi ed in an earlier 
stage of the disease. Th e observation however that an increased number of patients is classifi ed 
with RA, may indicate a certain degree of false positive misclassifi cation, an expectation that we 
seem to confi rm with our fi ndings. We observed that, depending on the population, 9 or 18% 
fulfi lled other diagnoses during their fi rst year of the disease. Psoriatic arthritis was the most 
frequent cause of “misclassifi cation”. Although the user manual of the 2010 criteria clearly states 
that these new criteria should only be applied to a set of patients that cannot be classifi ed with 
another rheumatologic diagnosis, it would be most interesting to be able to use these criteria 
for every new arthritis patient that visits a rheumatologist. Another issue is that the presence of 
erosions is ‘prima facie’ evidence for the classifi cation of RA within the new criteria, meaning that 
the other criteria do not have to be fulfi lled.5 Although not a focus of attention in this thesis, the 
exact defi nition of an erosion typically for RA should be defi ned. Th is has to some extent already 
been the subject of discussion.7 A third issue that has not been settled yet, is how an increased RF 
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level can be defi ned. As shown in chapter 4, the variance in IgM-RF level obtained with diff erent 
methods is considerable. When evaluating three diff erent outcome measures (MTX initiation 
during the fi rst year, initiation of any DMARD during the fi rst year and arthritis persistency over 
5 years), the new criteria showed a better sensitivity but a lower specifi city for the outcome of 
RA compared to the 1987 criteria. However, since this is the fi rst study published on this topic, 
replication in other cohorts is needed. Nonetheless, the 2010 criteria could well be regarded as a 
fi rst step towards earlier recognition of patients at risk and the development of a more accurate 
set of criteria.
Th e importance of an earlier detection of RA has been clearly shown by various studies that 
observed benefi cial eff ects of treating patients as soon as possible. Th e increase in evidence dur-
ing the last decade for the existence of a so-called “window of opportunity’ of 3 months in which 
RA patients are most sensitive to treatment,8-10 is a good example of the growing awareness of 
the importance to treat early. Th e eff ect of treatment within this 3 month period on the eff ective-
ness of response to therapy has been established with signifi cant associations in terms of better 
outcomes of RA.11,12 In particular, Finckh et al13 indicate that early treatment (<3 months) would 
not only limit the amount of joint damage that can accumulate prior to treatment but in addition 
it can also slow down the rate of progression aft erwards. Although the period of 12 weeks may 
be somewhat arbitrary, evaluating the eff ect of early assessment (<12 weeks) in the present study 
yielded signifi cant support for the importance to treat early (<12 weeks) in terms of long-term 
outcome of the rate of joint destruction over 6 years and the achievement of sustained DMARD-
free remission (chapter 9), thereby strengthening prior investigations. Studying the eff ect of delay 
on the rate of joint destruction in ACPA subsets showed that the observed association remains 
present in the ACPA-negative group of patients. Notably, although we did not unequivocally 
establish a similar result in the ACPA-positive patients, a similar tendency however was observed 
(chapter 9). Although it needs to be considered that this is an observational study and not a ran-
domized trial so it may be that these patients had an innate diff erence in outcome, we have not 
been able to identify such diff erences. Extension of the radiographic data in chapter 10, revealed 
that the eff ect of delayed assessment on the rate of joint destruction was statistically signifi cant 
as well in ACPA-positive RA. Th is indicates that the suggested the “window of opportunity” 
might apply to both ACPA-negative and -positive RA, but that we lack suffi  cient statistical power 
(chapter 9). We also observed that among all early arthritis patients ACPA-positive RA patients 
had the longest delay, and at least 77% of them were assessed aft er 12 weeks of symptoms. We 
evaluated whether the “window of opportunity” was explained by diff erent characteristics of the 
ACPA response (chapter 10) and observed that patients that were assessed within or aft er 12 
weeks of symptoms had comparable numbers of isotypes or recognized peptides. Th e observed 
lack of an association between the broadness of the ACPA-response and the groups with <12 
weeks and ≥12 weeks of delay, might indicate that maturation of the autoantibody response oc-
curs even earlier. Th is notion would be in line with the observation that autoantibodies, among 
which ACPA, are already present in the serum of future RA patients in the preclinical phase 
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several years before the onset of symptoms.14 Th e observations that the autoantibody response 
appears to be initiated before symptom onset, and that levels of acute phase reactants and mark-
ers refl ecting alteration of bone metabolism are simultaneously elevated as well,15-17 could lead to 
the hypothesis that the “window of opportunity” does not lie in the fi rst 12 weeks aft er initiation 
of the fi rst symptoms, but is actually located before the clinical onset of disease. 
Having established a solid foundation for the need to treat early it is important to raise the 
question where the observed delay comes from. Since the EAC is organized such that referred 
patients can visit the rheumatologist quickly (~1-2 weeks), the duration of the delay time, de-
fi ned as the time between the onset of symptoms and the fi rst visit at a rheumatologist, can in 
this case be roughly divided into two parts: it could lie either at the patients’ end, by reluctance 
to seek medical care, or at the end of their general practitioner (GP), by referring a patient in a 
later stage than would be preferred. Although this subject has been studied before and to some 
extent is subject to geographical variation and depending on the organisation of health care in 
a particular nation, our study shows that the main contributor to delay in assessment in the 
Netherlands is the GP delay (chapter 9). An important element in this study was to identify a 
profi le that characterises the patients that have the longest delay. Notably, strikingly similar to 
the classical image of RA,18 among all early arthritis patients the current observations were that 
older age, female sex, gradual symptom onset, involvement of the small joints, lower levels of C-
reactive protein, and the presence of autoantibodies were associated with longer total delay. Th us 
although confi rming the general idea about RA, this indicates the need for active and increased 
awareness to decrease delay time in the future. 
Th e second step in achieving personalized medicine, aft er early recognition of RA, is to obtain 
the ability to predict the long-term outcome of RA. To identify risk factors, to this end, two 
main outcomes used to identify new risk factors for the severity of RA were studied: the rate 
of joint destruction and the achievement of DMARD-free remission. In this thesis we analysed 
longitudinal data using a powerful statistical approach (chapter 2) that takes maximal advantage 
of the presence of serial radiographs observed in studies. Th e ultimate purpose of identifying risk 
factors is to put together a risk profi le for the individual patient, that can lead to the composition 
of an adequate prediction rule.19,20
Although some studies on genetic risk factors for the severity of RA have been performed, fairly 
little is known about this subject. Most importantly, most observations done thus far, are single 
studies which have not been replicated. Years of experience however indicate that the replication 
is in fact needed to prevent false positive fi ndings.21 In addition, false negative fi ndings should be 
avoided. Since the eff ect sizes observed in genetics association studies are in general small, eff ects 
may be lost in case of too much noise. 
In chapter 7, we show that the minor alleles in two loci, rs675520 and rs9376293, located on 
chromosome 6q23 in a region close to the gene encoding for TNFAIP3, associate with a higher 
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rate of joint destruction within ACPA-positive RA. Since this was the fi rst study to show an as-
sociation between SNPs located in the TNFAIP3 region, replication of our fi ndings for the eff ect 
on the severity of RA however is needed to confi rm the validity of our fi ndings. Nonetheless, 
when looking at the role of TNFAIP3 region in RA susceptibility, it can be suggested that the 
region has similar infl uences not only on the risk for development but also for a worse outcome 
of RA, and that the eff ect in both cases is confi ned to the ACPA-positive subset of RA patients. 
For two previously identifi ed susceptibility risk loci in this locus, rs6920220 and rs10499194,22,23 
no eff ect on the rate of joint destruction was observed however. 
A similar observation was done for PTPN22, a genetic region previously identifi ed as a risk 
factor for susceptibility in ACPA-positive RA. As described in chapter 9, no association was 
found between the polymorphism and the rate of joint destruction. Notably, this observation was 
done in two independent cohorts and thereby provides further indication that PTPN22 does not 
aff ect the development of damage to the joints of RA patients, but may primarily have a role in 
predisposing to the emergence of ACPA.24 Other risk factors that also showed similar discrepan-
cies between the risk for susceptibility and severity are KIF5A/PIP4K2C, CDK6, CCL21, PRKCQ, 
and MMEL1/TNFRSF14 (chapter 8). Taken together, these observations might indicate that a 
risk factor for susceptibility is not necessarily always a risk factor for severity of joint damage in 
RA as well. 
Inconsistent eff ects for RA susceptibility and severity were also found in chapter 8, where we 
investigated the eff ect of a SNP in the CD40 gene (rs4810485) on the rate of joint destruction in 
ACPA-positive patients. Our results show that, in two independent cohorts, ACPA-positive RA 
patients homozygous for the minor T allele were characterized by signifi cantly higher rates of 
joint destruction. However, counterintuitive to what one would expect, associating with a less 
severe course of RA, the common (G) allele conferred risk to develop RA.25 As pointed out in 
this chapter, the disease-associated (common) allele marks a haplotype of CD40 that contains a 
polymorphism in the upstream Kozak sequence that results in increased surface expression on B 
cells.26 In addition, it has been reported that CD40 expression is increased on synoviocytes in RA, 
and triggering of CD40 in synovial fi broblasts is associated with the production of proinfl am-
matory cytokines and osteoclastogenesis.27,28 Th e likeliness that the biologic pathways underlying 
susceptibility and severity are distinct, in this case with respect to the triggering of CD40, would 
provide an explanation for the observed discrepancy and in theory could, at least partially, pro-
vide an alternative explanation for the discrepancies that are observed for other polymorphisms. 
A special role in the pathogenesis of RA is fulfi lled by the presence of autoantibodies. Th ese 
autoantibodies characterize the derailment of the autoimmune system, intended to protect 
the human body from allogenic threats, by showing a cross-reaction with autoantigens and a 
subsequent activation of immune responses. Presence of these autoantibodies has fi rmly been 
established as associating factors with increased development and severity of RA.29 
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Various tests (IgM-RF, anti-CCP2, anti-CCP3 and anti-MCV) have been manufactured and 
all have shown to be useful in the process of detecting autoantibodies present during the process 
of RA. Th ese tests have all individually been reported to have adequate characteristics in terms 
of performance in terms of sensitivity and specifi city, but a head-to-head comparison has never 
been performed. Although overall anti-CCP2 tended to have the best performance, we fi nd that, 
evaluating all these tests for a positive or negative test result, no large diff erences were observed 
between either test (chapter 3) for both the development of RA as well as the rate of joint de-
struction and the achievement of DMARD-free remission. Th ese results are not surprising since 
the proportion of patients with presence of more than 1 autoantibody was over 71%, indicating 
a large coexistence of these autoantibodies. Presence of more than one autoantibody however 
was associated with worse outcomes. In addition to the presence of ACPA, IgM-RF did not have 
a signifi cant additive contribution. Th is also suggests that the predictive value of ACPA is larger 
than that of IgM-RF. 
In the updated item serology of the new 2010 criteria now also the use of ACPA was included 
in addition to RF.5 Notably, in addition to the mere presence, the levels of these autoantibodies 
were given weight as well in the process of classifying a patient with RA. Although higher levels 
of autoantibodies have been shown to display a higher specifi city and associate with an increased 
development and a higher severity of RA than autoantibody positivity,30-32 we show that the pres-
ence of ACPA also performs better than raising the used cutoff  for RF-positivity (chapter 4) in 
addition to the presence of RF (chapter 3). In chapter 4, the presence of ACPA performed better 
for predicting the development as well as the outcome of RA. Moreover, performing a RF test in 
ACPA-negative patients did not prove to be valuable, while determining ACPA in RF negative 
patients did contribute. Th erefore, we propose to omit the use of RF from the 2010 criteria.
IgM-RF is frequently observed in other infl ammatory diseases33,34 and is sometimes present in 
healthy older persons,35 suggesting that RF can be a consequence of nonspecifi c immune activa-
tion. In contrast to IgM-RF, antibodies to anti-citrullinated proteins are highly specifi c for RA.36 
It has been suggested that IgM-RF production is a consequence of the rheumatoid infl ammation 
whereas ACPA may have pathophysiological properties. Moreover, it is presumed that the as-
sociation of RF with the presence of RA is primarily explained by its interaction with ACPAs.37 
However, formal proofs that ACPA are causal for RA are lacking.
It has been hypothesized that two diff erent subsets of RA can be characterized by the presence 
or absence of ACPA.38,39 Th is hypothesis is supported by the observed diff erences in risk profi les 
for both genetic factors (references,25,40,41 chapter7 and 8)), environmental factors42 and their 
interactions, as well as a diff erent reaction to methotrexate treatment in both subsets.43 Fully 
understanding the diff erences between ACPA-positive and ACPA-negative RA as separate enti-
ties, especially the underlying molecular pathophysiology, might elucidate the etiology of RA.
Infl ammation of the synovium in a rheumatoid joint is a key process in RA, and the intensity 
and duration of such an infl ammation is largely depending on the interplay between diff erent 
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cell types of the immune system that are localized either in the joints, like fi broblast-like syn-
oviocytes, and cells that roam the human body and are attracted to sites of infl ammation, like 
dendritic cells, macrophages and B- and T-lymphocytes.44,45
In chapter 5, we show that the CXCL13, a cytokine that selectively attracts B cells46, signifi -
cantly associates with the amount of joint damage in terms of erosiveness and the total Sharp/
van der Heijde score. Higher serum CXCL13 levels corresponded with higher rates of joint 
destruction. Th e eff ect was independent of the infl ammatory marker CRP, with which the level 
of CXCL13 on itself is also correlated. Subsequent treatment with anti-TNFα therapy has been 
reported to signifi cantly reduce CXCL13 serum levels.47,48 Evidence for joint localization of 
CXCL13 has been found, both by the detection of mRNA in infl amed synovial tissue49 as well 
as the presence of ectopic lymphoid follicles expressing CXCL13 in the synovium of chronic 
RA patients.50 Importantly, formation of these ectopic lymphoid follicles has been implicated in 
initiating and maintaining the infl ammatory response in RA.51 In addition, they have been sug-
gested to associate with increased disease severity and accelerated breakdown of self-tolerance,52 
have been attributed a role in the priming and antigen presentation, and possibly contribute 
to initiating and maintaining the production of ACPAs, although this latter has not been un-
equivocally established.53 Th e observation that CXCL13 expression takes part in the same chain 
of events leading to the formation of ACPA, together with the data establishing ACPA as one of 
the strongest predictors for joint damage, could explain our observation that CXCL13 only shows 
an association in ACPA-negative RA and that the association is lost in ACPA-positive disease. 
Notably, high levels of CXCR5 (the CXCL13 receptor) were also found on human osteoblasts and 
activation by its ligand CXCL13 induced the release of extracellular matrix degrading enzymes. 
As such, CXCL13 may play a direct role in the process of bone remodeling as well.54
Th e involvement of TNFAIP3 and CD40, genetic regions associated with the rate of joint destruc-
tion in RA (chapters 7 and 8) as well as susceptibility to RA, together with recent discoveries 
of other genetic associations -for RA susceptibility- with several genes relevant to this pathway, 
TRAF1 and REL, especially in autoantibody-positive RA, might point to a central important role 
of the CD40/NF-κB signaling pathway.55 As such, to increase understanding of the pathophysiol-
ogy underlying RA, identifi cation of the cell types that mainly drive this pathway would be of great 
interest and would propose new interesting targets for interrupting the disease process in RA. 
Th e observed expression of CD40 on the surface of multiple immune cells, including the 
B-cells, might implicate that CD40 has a broader role in autoimmune regulation in general.56 
Notably, the risk genotype of CD40 that associates with RA susceptibility but has a protective 
eff ect for RA severity (chapter 8), has been observed to cause enhanced expression of CD40 
on B-cells in Graves’ disease.26 Interestingly, in RA, interaction of CD40 with its ligand, CD40L 
(CD154), potentially leads to various immune reactions. Th ese include B-cell proliferation 
through regulation of CDK6 expression, selective attraction of B-cells by regulating CXCL13, 
germinal center formation, diff erentiation of B-cells into plasma cells that secrete large titers of 
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high-affi  nity antibodies, immunoglobulin class switching, memory B-cell development,57-61 and 
aff ecting osteoclastogenesis by NF-κB/CD40-mediated bone destruction. Th e sustained presence 
of the IgM isoform of anti-CCP during the ACPA response that is observed early in the course of 
ACPA-positive RA, is indicative for ongoing recruitment of new B cells.62
Altogether, these fi ndings are supportive for the notion that especially the recruitment 
and organization of B-cells in the synovium play a critical role in the persistency of arthritis 
in ACPA-positive RA. Th is would support the hypothesis of ACPA-positive RA being a B-cell 
driven disease that was fi rst postulated more than a decade ago.63 Indeed, modern therapies with 
B-lymphocyte-depleting agents have shown to be useful in treating ACPA-positive RA.64,65 
Infl ammation is the hallmark of RA and is regarded as the catalyzer leading to disturbances in 
bone homeostasis by infl uencing the balance between bone formation by osteoblasts and bone 
degradation by osteoclasts. Th is disbalance generally leads to erosions of the joints. Th e recipro-
cal processes lead to the occurrence of repair at these sites. Although the concept of repair is still 
less well accepted, the results from our eff ort to characterize the subphenotype of RA patients 
with repair (chapter 11), support the notion that repair does exist. In 7.2% of RA patients we 
observed radiological repair in one or more joints of the same patient. In addition, our results 
show that despite the absence of aggressive or biological anti-rheumatic treatment, repair occurs 
in part of the general RA population. Notably, the most frequent occurrence of repair was in the 
patients who had the highest degree of radiological damage. As mentioned, one of the explana-
tions could be that, to detect this phenomenon, a relatively high degree of eroded bone lesions 
has to be present (chapter 11). Th is coincides with the observation that in general, the patients 
with repair simultaneously showed an overall progression in total erosion and Sharp/van der 
Heijde scores (reference 66 and chapter 11). 
Th e observations done on erosions and repair support the idea that not only the occurrence 
of erosions but also the repair of joint erosions is based rather on the processes involved in local 
bone homeostasis than on a systemic reaction.66 Indeed, in our study, repair occurred only in 
joints without joint swelling in the two preceding years, a fi nding similar to that done in the 
TEMPO trial.67 Th ese observations imply that infl ammation drives bone damage, a mechanisti-
cal hypothesis that has generally been accepted.45 Notably, it is recently also suggested that the 
presence of cartilage and bone breakdown components can induce infl ammatory processes.68 As 
such a “vicious circle” may be activated. 
Th us, the classic paradigm is that infl ammation leads to damage, and indeed in majority of cases 
infl ammation goes hand-in-hand with joint destruction. Progressing insights however indicate 
that the relation between infl ammation and joint damage might not be that straight forward and 
that infl ammation and joint damage might have diff erent causal pathways.68 Evidence substanti-
ating this notion is provided by the observation that, in reaction to treatment an uncoupling of 
synovitis and joint damage at the individual joint level was observed.69 
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Th orough evaluation of patients with a disconnection between joint infl ammation and de-
struction may yield insight in the processes involved in the link between infl ammation and bone 
destruction. To this end we selected extreme discordant phenotypes (chapter 12). We identifi ed 
patients with persistent joint infl ammation over time but aft er 5 years no erosions (4%), and 
patients with a very low infl ammatory burden but highly progressive joint damage (11%). Th e 
high-infl ammatory, non-erosive patients were less oft en autoantibody positive, showed more 
oft en an acute start of the disease, and had more infl amed joints. Th e low-infl ammatory, high-
erosive patients had a more chronic onset of complaints and were more autoantibody positive. 
In case of the latter group of patients, it cannot be ruled that subclinical infl ammation is present 
which causes deterioration in of joint damage.70 It would be very interesting to study whether ge-
netic (rare) variants are associated with these subphenotypes of RA. Although a small number of 
patients are available, it has been shown in other diseases that studying these extreme discordant 
phenotypes may be the basis to valuable new fi ndings.71,72 
Summarizing the data presented in this thesis, in chapter 14 we provide an overview of the 
implications of these data for the progression from UA to RA, the development of persistent 
disease, and the main scope of this thesis, the prediction of outcome in RA in terms of the rate 
of joint damage. In this study, the risk factors that were observed to associate with progression to 
RA and the development of persistent disease in UA patients showed to be largely the same, with 
a main focus on infl ammatory markers and autoantibodies. When analyzing risk factors for the 
outcome of RA, as measured by the rate of joint destruction, the largest eff ect sizes were observed 
for the presence of autoantibodies. Other risk factors were infl ammatory markers like SJC, CRP 
and ESR, BMI and, also described in chapter 9, the symptom duration (delay) at the fi rst visit to a 
rheumatologist. Comparison of the identifi ed risk factors for outcome of UA as well as RA again 
largely resulted in the same set of risk factors. Some risk factors, like a positive family history 
for RA, acuteness of disease onset, morning stiff ness, BMI and several characteristics of joint 
swelling however were only risk factors for either one of the outcome measures. Th is observed 
discrepancy in risk factors for the outcome of UA and RA however is not surprising. We also 
observed discrepancies between several genetic factors and RA susceptibility and RA severity in 
chapter 8 and chapter 9. 
We show that when combining the individually associating risk factors (chapter 14), the overall 
explained variance for the severity of joint destruction is 32%. During previous attempts to 
derive prediction rules for the rate of joint destruction, still ~50% of the RA patients could not 
be adequately classifi ed.73-75 Although these studies did not include genetics, one can ask the 
question whether the use of genetics does live up to its expectation of being “the holy grail”. For 
predicting the development of RA from UA it has been observed, that a prediction model incor-
porating genetic factors did not show an increased performance compared to a prediction rule 
based on common clinical and serological risk factors alone.76 Nonetheless, it has unequivocally 
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been shown that identifi cation of genetic factors, especially in the light of the related concept of 
heritability, has a substantial infl uence on understanding the pathophysiology underlying the 
development of RA.77,78 Th e general notion is that for genetics only the tip of the iceberg has been 
revealed thus far, indicating the need for identifi cation of more and newer genetic risk factors. 
Moreover, the genetic risk factors identifi ed might not only ultimately allow us to make enhanced 
prediction of RA development and outcome, but may also give us the opportunity to predict the 
response to therapy.79-83 
Our observations might implicate that including genetic factors in predicting the rate of joint 
destruction can in fact contribute to an increased explanation for the rate of joint destruction, 
but that for optimal performance, since these factors are primarily identifi ed in the ACPA-
positive subset, it would be desirable for future studies to determine the explained variance in the 
ACPA-positive and ACPA-negative subgroups separately. Next to the inclusion of genetics, also 
the evaluation of other markers might increase the explained variance of 32% that we observed 
in chapter 14. For example, including CXCL13 (chapter 5) will increase the total variance ex-
plained, since at the individual level, this factor could explain ~7% of the rate of joint destruction.
In conclusion, huge advances in the understanding and treatment of RA have been made in 
the last few decades, resulting in dramatically improved perspectives of RA patients nowadays. 
Nonetheless, the ultimate goal of personalized medicine however has not yet been reached. Al-
though limited in the complete picture of RA, the results described in this thesis may present one 
step further in the process of achieving individualized treatment decision making. Especially the 
identifi cation of genetic and serological factors are useful for this purpose. Future studies, dedi-
cated to the identifi cation of more and newer risk factors might help in completing the picture. 
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Reumatoïde artritis
Reumatoïde artritis (RA) is een chronische en progressieve ziekte die bij ongeveer 1% van de 
wereldbevolking voorkomt en wordt gekenmerkt door symmetrische ontsteking van met name 
de kleine hand en voet gewrichten. Het is een complexe, multifactoriële ziekte en wordt be-
schouwd als een auto-immuun ziekte door de aanwezigheid van autoantilichamen, zoals tegen 
gecitrullineerde eiwitten (ACPA), die reageren met het lichaamseigen weefsel. Karakteristiek 
voor RA is het sluipend ontstaan van de gewrichtsontsteking die kan leiden tot lokale gewrichts-
schade (boterosie). Klinisch uit RA zich meestal in progressieve klachten van ochtendstijfh eid 
en functionele beperkingen met mogelijk zelfs invaliditeit tot gevolg indien RA niet tijdig 
behandeld wordt. Een vroege herkenning gevolgd door een snelle en adequate behandeling zou 
derhalve kunnen helpen het ontwikkelen alsmede het ernstig verlopen van RA te beperken en 
mogelijk zelfs te voorkomen. Daarnaast zou de mogelijkheid het verloop van de ziekte te kunnen 
voorspellen, kunnen leiden tot het opstellen van een persoonlijk risicoprofi el met een daarop 
afgestemde behandeling voor de individuele patiënt. In dit proefschrift  wordt gekeken naar deze 
voorspellende factoren met als doel het identifi ceren van nieuwe factoren die kunnen worden 
gebruikt voor het voorspellen van het verloop van RA.
Vroege herkenning
Om RA te kunnen classifi ceren werd tot recentelijk gebruik gemaakt van een set criteria uit 
1987, bestaande uit aanwezigheid van ochtendstijfh eid (>1 uur), symmetrische artritis in >3 ge-
wrichtsgebieden met in ieder geval >1 gezwollen handgewricht, aanwezigheid van reumanoduli, 
een positieve reumafactor test (autoantilichaam) en erosieve afwijkingen op een röntgenfoto. 
Voor de classifi catie van artritis als RA moest worden voldaan aan 4/7 criteria en moesten enkele 
criteria langere tijd (>6 weken) aanwezig zijn. Voortschrijdend inzicht heeft  recentelijk geleid tot 
de ontwikkeling van de ‘2010 revised ACR/EULAR criteria for RA’, een nieuwe set criteria met 
als oogmerk een vroege classifi catie van RA in vergelijking met de oude criteriaset. Een directe 
vergelijking in hoofdstuk 13 met de criteria uit 1987 laat zien dat volgens de 2010 criteria de 
ziekte inderdaad in een vroeger stadium als RA kan worden geclassifi ceerd. 
Ondanks een toegenomen bewustwording van de noodzaak tot vroege behandeling door een 
reumatoloog was over de oorzaken en het eff ect op de uitkomst van RA die wordt veroorzaakt 
door een vertraging in het bezoeken van een reumatoloog na het optreden van gewrichtsklachten 
weinig bekend. Zoals is te zien in hoofdstuk 9 wordt slechts 31% van de patiënten binnen 12 
weken door een reumatoloog gezien en is een langere vertraging in het bezoeken van de reuma-
toloog geassocieerd met een slechtere uitkomst van RA, onafh ankelijk van de behandeling die 
de patiënt uiteindelijk kreeg. De vertraging is op te delen in twee onderdelen, namelijk de tijd 
van het begin van de klachten tot het bezoek van de patiënt aan de huisarts en de tijd tussen het 
bezoek aan de huisarts en het bezoek aan de reumatoloog. Het blijkt dat in Nederland de patiënt 
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redelijk snel hulp zoekt (~2-3 weken) maar dat de grootste vertraging zit bij het doorsturen 
van de patiënt door de huisarts (~8 weken). Enkele belangrijke factoren die samenhangen met 
het laat doorsturen zijn een oudere leeft ijd, vrouwelijk geslacht, het langzaam ontstaan van 
gewrichtklachten en aanwezigheid van antilichamen; de laatste twee factoren refl ecteren het 
typische beeld van RA. Dit wijst op een noodzaak voor betere herkenning van de kenmerken 
van RA door de huisarts met als beoogd doel een snellere doorverwijzing van de patiënt bij een 
klinische verdenking op RA.
Voorspellende factoren
Met het oog op het opstellen van een risicoprofi el en het kunnen voorspellen van de ziekte zijn 
met name in het afgelopen decennium meerdere risicofactoren geïdentifi ceerd voor het ontwik-
kelen van RA. Naast omgevingsgerelateerde factoren zoals roken en alcoholgebruik kunnen ook 
genetische factoren en aanwezigheid van stoff en die kunnen worden gemeten in het bloed van 
patiënten (serologie), in het bijzonder autoantilichamen, samenhangen met een verhoogd risico. 
Over de invloed van zulke factoren op de uitkomst op lange termijn en met name het optreden 
van gewrichtsschade is echter tot nu toe echter minder bekend. 
Een van de vragen in dit proefschrift  is wat de invloed is van genetische variatie in gebieden 
die recent zijn geïdentifi ceerd als risicofactoren voor het ontwikkelen van autoantilichaam posi-
tieve (ACPA-positieve) RA op de progressie van gewrichtsschade. Onze analyses laten zien dat 
mutaties in TNFAIP3 (hoofdstuk 6) en CD40 (hoofdstuk 7) zijn geassocieerd met een slechtere 
uitkomst van ACPA-positive RA; de onderzochte genetische variatie in PTPN22 (hoofdstuk 8) 
heeft  echter geen invloed op de progressiesnelheid van gewrichtsschade. Deze resultaten zijn een 
indicatie dat risicofactoren voor het ontwikkelen van RA niet perse ook een hoger risico geven 
op een ernstiger beloop. 
De aanwezigheid van autoantilichamen vervult een zeer prominente rol bij de pathogenese 
van RA. Zo is bekend dat aanwezigheid van reumafactor (RF) en de meer recent ontdekte anti-
gecitrullineerde antilichamen (ACPA) een zeer sterke associatie hebben met een verhoogd risico 
op het ontwikkelen van RA en het ontstaan van gewrichtsschade. In hoofdstuk 3 zijn verschil-
lende autoantilichaam testen, namelijk een RF test en drie ACPA testen (anti-gecitrullineerd 
cyclisch peptide (anti-CCP2&3) en anti-gecitrullineerd vimentine (anti-MCV)) naast elkaar 
gezet en hun voorspellende eigenschappen vergeleken. Zowel voor het risico op het krijgen van 
RA als de mate van het ontwikkelen van gewrichtsschade lijkt de aanwezigheid van ACPA, en 
dan met name de aanwezigheid van anti-CCP2, het meest voorspellend te zijn. Een vergelijking 
van ACPA met RF laat bovendien zien dat RF op zichzelf weinig lijkt bij te dragen aanvullend op 
ACPA, een bevinding die wordt ondersteund door de resultaten uit hoofdstuk 4.  
Ontsteking vormt een weerspiegeling van een complex samenspel tussen verschillende 
ontstekingscellen, zoals B en T cellen. Van de stoff en die zij produceren kunnen naast (auto)
antilichamen ook andere serologische factoren zoals cytokines mogelijk worden gebruikt bij 
het voorspellen van het ziekteverloop van RA. In hoofdstuk 5 identifi ceren we een cytokine die 
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selectief B cellen aantrekt, CXCL13, als een nieuwe risicofactor voor RA, waarbij een hogere 
concentratie CXCL13 samenhangt met het ontwikkelen van meer gewrichtsschade. 
Ontsteking en schade
Het optreden van gewrichtsontsteking is een van de karakteristieke kenmerken van RA en het 
optreden ervan wordt gezien als katalysator voor het verstoren van de balans tussen botaanmaak 
en botafb raak (bothomeostase), die uiteindelijk kan leiden tot het optreden van gewrichtsschade 
in de vorm van boterosies. Van oudsher is de algemeen geaccepteerde gedachte dat deze vorm 
van gewrichtsschade irreversibel is en herstel (‘repair’) niet kan optreden. De recente gedachten-
verandering dat ‘repair’ wel kan optreden, maar slechts infrequent optreedt wordt ondersteund 
door data in hoofdstuk 11, waar ‘repair’ wordt gezien bij 7.2% van de bestudeerde RA patiënten. 
Een van de observaties in de studie was dat deze patiënten ‘repair’ vertoonden in individuele 
gewrichten maar tegelijkertijd in de andere gewrichten ook toename van erosies lieten zien, met 
als gevolg meer progressie in totale schade in vergelijking tot patiënten zonder ‘repair’. Dit en het 
afwezig zijn van zwelling in de gewrichten in de twee jaar voorafgaand aan het optreden van de 
‘repair’ illustreren het lokale karakter van de balans tussen botaanmaak en afb raak.
Het klassieke dogma is dat gewrichtsontsteking de directe oorzaak is van het optreden van de 
gewrichtsschade. Ondanks dat ontsteking en schade meestal tegelijk worden gezien zijn er echter 
steeds meer aanwijzingen dat zij niet onlosmakelijk met elkaar verbonden zijn, zogenaamde 
‘ontkoppeling’, en er verschillende oorzakelijke mechanismen aan ten grondslag liggen. In 
hoofdstuk 12 hebben we patiënten geïdentifi ceerd die voldoen aan de criteria voor ontkoppe-
ling, te weten patiënten met continu veel gewrichtsontsteking maar na 5 jaar nauwelijks erosies 
(4%) en patiënten met zeer weinig ontsteking maar veel gewrichtsschade (11%). In vergelijking 
met de hoog erosieve patiënten kenmerken de laag erosieve patiënten zich door een meer acuut 
ontstaan van klachten en een verminderde aanwezigheid van autoantilichamen. Het bestuderen 
van bijvoorbeeld verschillen in genetische factoren bij deze patiënten zou meer inzicht kunnen 
geven in de relatie tussen ontsteking en schade.
De stand van zaken
In hoofdstuk 14 wordt een samenvatting gegeven van een groot gedeelte van de resultaten die bij 
de totstandkoming van dit proefschrift  zijn verkregen en de implicaties die zij hebben voor het 
kunnen voorspellen van zowel het ontwikkelen van RA als de uitkomst op langere termijn. Het 
blijkt dat de risicofactoren voor beide groepen grotendeels overeenkomen, waarvan de aanwezig-
heid van autoantilichamen het grootste eff ect heeft  op een slechte uitkomst. Daarnaast dragen 
ook o.a. ontstekingsgerelateerde factoren, zoals gewrichtszwelling en CRP, maar ook het te laat 
bezoeken van een reumatoloog, zoals beschreven in hoofdstuk 9, bij aan zowel een verhoogd 
risico voor het ontwikkelen van RA als een ernstig verloop. Combineren we al deze individuele 
risicofactoren, dan kan ongeveer 32% van de variantie in progressie van gewrichtsschade worden 
verklaard.
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Conclusie 
De enorme vooruitgang in het begrip en de behandeling van RA in de laatste decennia heeft  
geresulteerd in sterk verbeterde perspectieven voor patiënten met RA. Het uiteindelijke doel 
van op maat gemaakte, persoonlijke geneeskunde is echter nog niet gerealiseerd. Alhoewel in dit 
proefschrift  maar een klein deel van RA als ziektebeeld is belicht zijn de resultaten die worden 
beschreven wel een stap in de goede richting voor bereiken van geïndividualiseerde behandeling. 
Toekomstige studies, gewijd aan de identifi catie van meer en nieuwere risicofactoren zouden aan 
het bereiken van het uiteindelijke doel kunnen bijdragen.
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